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ABSTRACT
The developing world is desperate for new, safe, effective and affordable 
antimalarial drugs and has been since the demise of chloroquine (CQ) due to PfCRT- 
mediated parasite resistance, which emerged in the 1960s. Regarded as one of the most 
important chemotherapeutic agents in history, CQ is now largely ineffective in many 
areas of the world prompting studies into alternative treatments for malaria.
Using the related amodiaquine (AQ) as our template, we have developed simple 
routes to novel rationally designed analogues that are highly effective against CQ- 
resistant and CQ-sensitive parasites.
This thesis explores the metabolism and dispositional fate in rats of three such 
novel compounds; N-tert butyl isoquine (NTBISQ), N-tert butyl fluoro amodiaquine 
(FAQ-4) and N-tert butyl chloro amodiaquine (C1AQ-4), making comparisons with CQ, 
AQ and isoquine (ISQ).
Interchange of the 4 ’hydroxyl and 3’Mannich side-chain function of AQ has 
been found to block toxic quinone imine formation in vivo and replacement of the 
diethylamino side-chain with a tert butyl group has prevented P450 dealkylation. In 
addition to this, it has also been found that replacement of the 4’hydroxyl group of AQ 
with a halogen atom such as chlorine or fluorine can also inhibit metabolic activation to 
toxic quinone imine metabolites. After administration of [3H]-NTBISQ to rats, the 
compound underwent direct glucuronidation to form the phenolic glucuronide (89.88 ± 
2.31 %), this was in stark contrast to AQ which undergoes phase II gluthathione 
conjugation. [3H]-ClAQ-4 was observed to undergo extensive metabolism to a side- 
chain carboxylic acid analogue (60.76 ± 2.34 %), whilst the main metabolite of [3H]- 
FAQ-4 remains unresolved.
All three compounds were found to have excellent in vitro activity against a 
number o f strains o f P. falciparum. In vivo studies showed NTBISQ to have activity 
similar to that of AQ, with an ED5o value of 2.6 mg/kg. C1AQ-4 however, had 
surprisingly low in vivo activity (25 mg/kg) which was attributed to it undergoing rapid 
first-pass metabolism, due to its increased lipophilicity (LogP = 5.50 ± 0.59).
The results of this work have provided us with three compounds with potential 
for use in the treatment of malaria; NTBISQ in particular has been shown to be the 
stand-out candidate. Concerns over accumulation-based toxicity of these compounds 
still remain. The ability of this class of compounds to cause effects such as 
phospholipidosis and cardiotoxicity still hasn’t been fully dissociated from efficacy. 
However we are confident that with its excellent pharmacokinetic and metabolic profile 
that NTBISQ is comparable, if not superior to piperaquine and pyronaridine, two drugs 
in phase III clinical trials at present. Indeed, NTBISQ is now due to enter phase I 
clinical trials in man.
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1.1 INTRODUCTION TO MALARIA
1.1.1 Epidemiology
Malaria remains one of the most important disease problems in the world. 
Despite the greatest efforts to eradicate the disease in the 1950s and 1960s, malaria 
has not only prevailed but has made a dramatic resurgence within the past two 
decades. Morbidity and mortality rates are at almost unprecedented levels, with 
more than 90 countries affected. Malaria is responsible for approximately 515 
million clinical episodes and 2 million deaths a year (Bell et al, 2004; Olliaro et al., 
1996; Snow et al., 2005).
Malaria is thought to be both a disease of poverty and a cause of poverty. It 
is largely a disease of the tropics, with the majority of cases occurring in sub-Saharan 
Africa, however, it also occurs in many sub-tropical locations. The effects of the 
disease mean that a substantial proportion of the population of sub-Saharan Africa is 
ill for a large part of the year. This makes sustained economic development very 
difficult to achieve and thus the global effects of the disease are a threat to public 
health and productivity, impeding the progress of many countries toward democracy 
and prosperity (www.rbm.who.int, 2001-2010).
Even with the important advances in our understanding of the disease, 
malaria continues to be one of the greatest causes of serious illness and death. The 
majority of deaths tend to be pregnant woman and children, with a child dying from 
the disease every 10 seconds (Oaks et al, 1991; Rosenthal, 2001).
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Figure 1.1 Geographical distribution of malaria. (Map from Roll back 
Malaria partnership, WHO).
1.1.2 The Malarial Pathogen
Humans become infected with malaria after a bite from the female anopheline 
mosquito harbouring plasmodial sporozoites. Four sub-species of Plasmodium exist 
causing human disease. Plasmodium falciparum is, by far, the most important 
species, often causing death through coma or anaemia; it uniquely infects 
erythrocytes of all ages. Infection by this species produces malignant tertian malaria 
-  ‘tertian’ because the fever is said to recur every third day, ‘malignant’ because it is 
the most severe form of malaria and can be fatal. P. falciparum has demonstrated the 
ability to develop resistance to most available antimalarial drugs. P. vivax, also very 
common, is one of the most important causes of morbidity among parasite infections 
but rarely kills (Bell et al., 2004; Rang et al., 1999). Drug resistance to this species 
of malaria has only recently been recognised but it is increasing, with cases resistant 
to chloroquine (CQ) and other antimalarials noted in Southeast Asia, Oceania, India
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and South America (Olliaro et al., 2003). P. malariae and P. ovale infections are 
relatively uncommon causes of human malaria.
1.1.2.1 The Parasite Lifecycle
The lifecycle consists of a sexual stage, which takes place within the 
mosquito, and an asexual stage, which occurs in man (Figure 1.2) (Rang et al., 1999; 
Rosenthal, 2001). During a blood meal the mosquito injects a relatively small 
number of sporozoites into the bloodstream. Within 30 minutes the immature 
parasites are cleared from the blood and enter the parenchymal cells of the liver. It is 
here, over the next 1 0 - 1 4  days that an asymptomatic pre-erythrocytic stage of 
parasite multiplication and development occurs. At the end of this stage the 
parasitised liver cells rupture and merozoites are released into the systemic 
circulation. These merozoites can then bind to and enter the erythrocytes whereby 
the parasites undergo asexual multiplication. This phase is responsible for the 
clinical manifestations of malaria. As the parasite matures it remodels the host cell 
by inserting parasitic proteins and phospholipids into the red cell membrane. 
Haemoglobin is digested by the parasite, using a system of proteases, and is 
transported into the parasite digestive vacuole (DV) (Pagola et al., 2000). Here it is 
converted into monomeric haem and an amino acid source essential for further 
parasite growth (Figure 1.3 ) (Francis et al., 1997; Olliaro et al., 1995). Free haem is 
toxic to the parasite (Orjih et al., 1981) and can cause enzyme inhibition, 
peroxidation of membranes, production of oxygen free-radicals and impaired 
leukocyte function. All Plasmodium species have a unique capability to render the 
haem harmless within the parasite DV by a process of biomineralization resulting in 
a crystalline structure known as haemazoin, or malarial pigment (Figure 1.3) (Ridley
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et al., 1997). The structure of this non-toxic pigment has remained speculative, 
despite the numerous spectroscopic tools used in attempts at characterisation (Bohle 
et al., 1997; Fitch et al., 1987). It is now believed to consist of haem subunits paired 
together as dimers by two reciprocal iron-oxygen bonds (Pagola et al., 2000)
At the end of the parasite multiplication the red blood cell ruptures and 
merozoites are released into the bloodstream which can then bind to, and enter fresh 
red cells, thus beginning the cell cycle again.
In certain forms of malaria, some of the sporozoites entering the liver cells 
can form hypnozoites, a resting form of the parasite. These hypnozoites can remain 
dormant for months or even years, but can be reactivated to continue an 
exoerythrocytic cycle of multiplication leading to relapses of malaria.
Some merozoites can differentiate into male and female gametocytes, which 
can subsequently infect mosquitoes that suck on the blood of an infected host, 
allowing completion of the sexual stage of the life cycle.
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Figure 1.2 The life cycle of the malarial parasite (Jones et al., 2006).
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Figure 1.3 Schematic showing the degradation of human haemoglobin by the 
malaria parasite to form free haem, followed by polymerisation to the non-toxic 
malarial pigment, haemazoin.
1.1.3 Failure to Eradicate Malaria
In 1955, the World Health Organisation launched a programme to eradicate 
malaria using powerful ‘residual’ insecticides and highly effective antimalarial
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agents which had become available (Mabaso et al., 2004). The effort initially 
appeared to be a success owing to the incidence of malaria declining dramatically by 
the end of the 1950s. However, over more recent decades, morbidity and mortality 
caused by malaria have increased in many parts of the world and now 40% of the 
world’s population remains at risk of contracting the disease.
Numerous factors contribute to the persistence of this severe, worldwide 
problem of malaria. Firstly, efforts to control mosquito vectors, which were quite 
successful in some areas many years ago, have been limited by financial constraints 
and insecticide resistance. Secondly, programmes to treat and control malaria have 
been severely limited by poverty in most endemic regions. Thirdly, despite 
significant efforts, an effective malaria vaccine is not yet available. Fourthly, people 
with no natural immunity to the disease are now exposed due to migration, climatic 
change and creation of new habitats. Finally, and from a medicinal chemist’s point 
of view, more importantly, the malaria parasites have consistently demonstrated the 
ability to develop resistance to available drugs. The pace of this developing 
resistance is grossly imbalanced by the development of new compounds, thus the 
efficacy of current compounds in the field has been reduced (Morgan et al., 2005; 
Olliaro et al., 2003; White, 1992; White, 1998). This is best exemplified with 
chloroquine (CQ), a member of the 4-aminoquinoline class of antimalarials (Figure 
1.4) (discussed Chapter 1 Section 1.2.2).
Figure 1.4 Chemical structure of Chloroquine
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1.2 THE 4-AMINO QUIN OLINE CLASS OF ANTIMAL ARIALS
1.2.1 Introduction
Quinoline-containing antimalarial drugs, such as CQ, quinine and mefloquine 
(Figure 1.5) have been used for years as key tools in the fight against malaria (Foley 
et al., 1998). The synthetic 4-aminoquinoline, CQ was introduced during World War 
II for the treatment of malaria (Loeb et al., 1946). Due to its low toxicity and for 
many years, effectiveness as an antimalarial, CQ became a mainstay in the 
chemotherapeutic armoury against malaria. The appearance of CQ resistance 
prompted the initiation of massive screening programmes in the USA, resulting in 
the production of three new drugs; the 4-aminoquinoline, amodiaquine (AQ); the 
quinolinemethanol, mefloquine, and the phenathrene methanol, halofantrine (Figure 
1.5). Unfortunately, problems such as resistance and toxicity have limited the use of 
these drugs and for the first time in 300 years, we are in danger of having no 
effective quinolines in the fight against malaria.
Quinine Chloroquine
CF3
Mefloquine
Amodiaquine Halofantrine
Figure 1.5 Structures of some quinoline-based antimalarial drugs
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1.2.2 Mechanism of Action
CQ is active against only the erythrocytic stages of malaria parasites. It is not 
active against pre-erythrocytic parasites, hypnozoite-stage parasites in the liver, or 
against gametocytes. It is thought that the antimalarial activities of CQ and other 
quinoline-type compounds are a function of both the ability of the drug to interfere 
with the crystallisation process of haemazoin and the ability of the drug to 
accumulate to pharmacologically relevant concentrations at the site of drug action 
(Hawley et al., 1998). This is supported by ultrastructural studies, which showed the 
first observable changes in malarial parasites treated with pharmacologically relevant 
concentrations of CQ to be swelling of the DV and accumulation of undigested 
haemoglobin in endocytic vesicles (Rosenthal, 2001). Thus, the ability of the 4- 
aminoquinolines to target such a parasite-specific process explains the selectivity of 
these drugs.
1.2.2.1 Accumulation o f CQ in the Parasite DV
A major hypothesis for CQ accumulation suggests that it is driven by an “ion 
trapping” mechanism. CQ is taken up only to a very limited extent (to 
concentrations about two-fold those in plasma) by uninfected erythrocytes (Graph
1.1) (Macomber et al., 1966). However, in contrast, the drug is concentrated several 
thousand-fold inside the parasitised erythrocyte.
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Graph 1.1 Correlation between parasitemia and uptake of chloroquine by 
erthyrocytes. Mice, 2-4 days after inoculation with CQ-sensitive P. berghei and 
uninfected mice treated i.p. with [14C]-CQ (40 mg/kg) (Macomber et al., 1966)
CQ is a diprotic weak base (pKa] = 10.2, pK^ = 8.1) and according to the 
weak base model, an unprotonated form can readily cross the membranes of the 
parasitised red cell and move along the pH gradient to accumulate within the acidic 
DV (pH 5-5.2) (Saliba et al., 1998; Yayon et al., 1984). As the drug moves down 
this pH gradient it becomes protonated, rendering it membrane impermeable and 
trapped within the acidic compartment of the DV. The level of accumulation has 
been reported to be higher within the DVs of malaria-infected red blood cells than in 
acidic compartments of mammalian cells, suggesting that there may be additional 
mechanisms for uptake of quinolines in parasite-infected erythrocytes, such as 
receptor binding (Saliba et al., 1998).
1.2.2.2 The Binding o f CQ to Free Haem
The mature human erythrocyte is perceived by the parasite, essentially as a 
“sack” of haemoglobin, providing it with a ready supply of amino acids and other 
nutrients (Francis et al., 1997). However, as haemoglobin is degraded by the
parasite, free haem (ferriprotoporphyrin IX, FP) is generated via haem auto-
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oxidation. FP is fairly innocuous in the ferrous form within haemoglobin but 
becomes toxic upon release from globin. The parasite lacks the machinery for 
enzymatic degradation of the potentially lytic FP and is faced with a significant 
toxic-waste problem. As mentioned earlier, the parasite has a unique ability to 
crystallise the free haem to form the malarial pigment haemazoin, the process of 
which is essential for the survival of the malaria parasite (Ridley et al., 1997).
The issue of haem disposal represents an “Achilles heel” for the parasite, 
leaving it susceptible to attack from chemotherapeutic agents, such as the 4- 
aminoquinolines. CQ has been shown to interact with FP by formation of a co-facial 
7C-7C stacking-type complex (Chou et al., 1980) (Figure 1.6). It has been proposed 
that the quinoline moiety of CQ effectively intercalates two p-oxo dimers of FP and 
also that the haem-quinoline complex is clearly non-covalent, as it can be diminished 
by extensive washing (O'Neill et al., 1998; Sullivan et al., 1996). This model 
predicts that the porphyrin plane can accommodate wide structural variations of the 
interacting species, leading to a weak specificity, consistent with the large variety of 
quinolines able to inhibit parasite growth. By binding to FP, CQ and the 4- 
aminoquinolines can inhibit the parasites method of crystallisation, resulting in 
higher concentrations of free haem, leading to parasite death (Slater et al., 1992).
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Complex with Haematin
Figure 1.6 A-C Molecular representation of the complexation of chloroquine 
analogue, F2BU with FP and D Formation of haemozoin crystals
1.2.3 CQ Resistance of the Malaria Parasite
Resistance to CQ appeared in malaria parasites in the 1960s and since then 
has slowly but inexorably spread from South America and South East Asia and 
throughout Africa, the global heartland of malaria mortality and morbidity (Young et 
al., 1961). The emergence of this resistance after so many years of widespread CQ 
use suggests that multiple mutations are required to produce the CQ resistance 
phenotype (O'Neill et a l, 1998). From a biochemical point of view, CQ-resistant 
isolates of P. falciparum accumulate less drug than their sensitive counterparts (Bray 
et al., 1992; Bray et al., 1998; Verdier et al., 1985).
There are a number of possible theories for reduced CQ uptake including; 
altered pH gradients across the DV membrane or between the parasite cytosol and
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the erythrocyte cytosol or altered membrane permeability or specificity of a 
permease or other transporter (Ridley, 1998).
Importantly, by making only very minor changes to the CQ structure, such as 
varying the amino-alkyl chain length by one carbon atom, compounds with good 
activity against the CQ-resistant strain of malaria can be produced (Bray et al., 
1998). This implies a high degree of structural specificity in the factors responsible 
for reduced CQ uptake. The major CQ resistance determinant has been found to be 
due to a membrane transporter known as Plasmodium falciparum chloroquine 
resistance transporter (PfCRT) (Wellems et al., 1990). More recently it has been 
discovered that mutations in the gene coding for PfCRT are believed to confer CQ 
resistance by reducing the amount of CQ accumulated by the parasite (Bray et al., 
2005; Lakshmanan et al., 2005).
1.2.4 The Development of Amodiaquine
Amodiaquine (AQ), a second member of the 4-aminoquinoline class of 
antimalarials, was initially synthesised by Burckhalter and co-workers in 1948 during 
a programme aimed at the discovery of effective 4-aminoquinoline compounds 
(Burckhalter et al., 1948). At that time AQ was deemed to have an excellent 
activity/toxicity profile. AQ is closely related to CQ, differing only in the presence 
of a jo-hydroxy-anilino aromatic ring in its side chain (Figure 1.5). Interestingly 
during in vitro tests, AQ was shown to be more active at inhibiting the growth of P. 
falciparum than CQ and has also been shown to be superior against CQ-resistant 
strains of P. falciparum (Hawley et al., 1996b; Watkins et al., 1984) (Table 1.2).
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IC50 (nM)
Drug 3D7 HB3 K1
CQ 19.4 ± 1.9 14.9 ±3.9 183.2 ± 11.1
AQ 11.2 ±2.8 9.6 ±3.7 15.5 ±9.4
Table 1.2. In vitro antimalarial activity of CQ and AQ. P. falciparum strains 
3D7 and HB3 are CQ-sensitive, K1 is CQ-resistant. IC50 values are expressed in nM.
AQ is accumulated within the parasite DV more efficiently than CQ which is 
unexpected on the basis of ion trapping as, despite being a diprotic weak base like 
CQ, its pKa values are lower (pKai = 8.1, pK^ = 7.1) (Hawley et al., 1996a). This 
increased uptake of AQ may be due to an enhanced affinity for an intra-parasitic 
binding site leading to a subsequent increase in drug accumulation and therefore 
greater activity against the malaria parasite (Hawley et al., 1996b).
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1.3 DRUG METABOLISM AND TOXICITY
1.3.1 Introduction to Drug Metabolism
Metabolism is a drug clearance process and knowledge of the metabolic 
pathways of a drug can help us understand the processes of elimination of that 
compound from the body. Humans and animals have evolved complex systems that 
detoxify foreign chemicals entering the body. Most of the substances entering the 
body are lipophilic and can be reabsorbed from the kidney tubule back into the 
bloodstream where they can go on to accumulate within tissues (Gram, 1980). In 
order for these chemicals to be efficiently eliminated they must undergo the process 
of biotransformation.
Metabolic processes are divided into phase I and phase II reactions which can 
occur sequentially. Phase I is the alteration of the original foreign molecule so as to 
add on a functional group which can then be conjugated during Phase II metabolism 
in order to undergo elimination (Timbrell, 2000).
1.3.1.1 Phase I  Metabolism
Phase I reactions modify the structure of a xenobiotic so as to introduce a 
functional group which will increase the hydrophilicity of the molecule. The three 
main chemical reactions involved in this process are oxidation, reduction and 
hydrolysis (Table 1.3).
A series of enzymes, located in the endoplasmic reticulum, known as the 
cytochrome P450 microsomal mixed function oxidase (MFO) system, are 
particularly important in oxidation reactions (Gibson et al., 1994).
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Phase I Phase II
Oxidation involving cytochrome P450 Glucuronidation/glucsidation
Oxidation - others Sulfation
Reduction Methylation
Hydrolysis Acetylation
Hydration Amino acid conjugation
Isomerisation Glutathione conjugation 
Fatty acid conjugation 
Condensation
Table 1.3 Reactions classed as phase I or phase II metabolism
1.3.1.2 Phase IIMetabolism
The conjugation reactions tabulated above, involve a diverse group of 
enzymes. They involve the addition of endogenous co-factors to the reactive moiety, 
leading to a progressive increase in polarity of the molecule. This increase in polarity 
means the compound will become more soluble in bile or urine and will 
consequently be excreted from the body, thus reducing the potential for toxicity 
(Pirmohamed et al., 1996).
Glucuronidation is the most widespread, and the most important of the 
conjugation reactions, possibly due to the relative abundance of UDP-glucuronic 
acid, the co-factor required for the reaction which is present in all tissues of the body 
(Dutton, 1980) (Figure 1.7). Conjugation can occur with alcohols, phenols, 
hydroxylamines, carboxylic acids, amines, sulfonamides and thiols. The process 
involves nucleophilic attack of an oxygen, sulfur or nitrogen atom at C-l of the 
glucuronic acid moiety. Drug-glucuronide conjugates are often excreted in bile and 
once in the intestine they have two possible fates. The first is that the drug will be 
excreted in faeces and the second is that it can be hydrolysed back to the parent 
compound by (3-glucuronidase (present in gut bacteria). The free drug can then be 
absorbed through the gut wall and re-enter the liver via the hepatic portal vein and
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the cyclic process can begin again. This re-circulation, known as enterohepatic 
circulation can occur for several cycles leading to retention and a substantially 
increased half-life of a drug (Dutton, 1980).
Glucuronvl
transferase
OH
Ether glucuronide
Figure 1.7 Formation of an ether glucuronide in the p-conformation.
Glutathione conjugation is recognised as a major defence system in 
deactivating toxic materials within the body (Gibson et al., 1994). Glutathione exists 
as a tripeptide, composed of gluatamic acid, cysteine and glycine. Located in the 
cytosol of many cells, but primarily the liver, it can react with a vast range of 
structurally diverse electrophilic substrates such as epoxides, haloalkanes, 
nitroalkanes, alkenes, and aromatic compounds (Smith et al., 2001; Timbrell, 2000). 
The presence of the cysteine residue provides a nucleophilic sulfydryl group and so 
the glutathione molecule is likely to react as the thiolate ion, GS'. An important 
example of glutathione conjugation is the detoxification of the reactive metabolite 
formed from paracetamol, vV-acetyl-p-benzoquinone imine (NAPQI) (Kitteringham 
et al., 2003) (Figure 1.8). Paracetamol largely undergoes detoxification by the phase 
II processes glucuronidation and sulfation to form stable metabolites. Approximately 
5-10 % of the dose undergoes P450 metabolism to form the toxic quinone imine 
metabolite, NAPQI, which can subsequently react with glutathione to form a 
conjugate (Newton et al., 1986; Williams et al., 2004). At overdose, the formation 
of toxic metabolites overloads the capacity of the conjugating system to inactivate
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them. Toxicity occurs as a greater proportion of the drug undergoes bioactivation 
and binds covalently to proteins (Timbrell, 2000). This is an important process as it 
can be directly related to the metabolism of the antimalarial AQ (Chapter 1; Section 
1.3.7).
Glucuronide
/ concugation (inactive)
0=O " ' NCOCH3
9
hs- ch2chcnhch2cooh
NH^CH2CH2CH<j:OOH 
O NH2
Glutathione
Paracetamol (active) 
\
'  Sulfate 
conjugation 
(inactive)
NAPQI (active)
Covalent binding to liver protein
Necrosis
HO— 7—NHCOCH3
GS
Paracetamol- 
glutathione conjugate 
(inactive)
Figure 1.8 Proposed metabolic activation of paracetamol to a toxic, reactive 
intermediate (NAPQI). NAPQI can react with glutathione to form a conjugate. In 
the absence of GSH, such as paracetamol overdose, NAPQI can react with 
nucleophilic residues on proteins (e.g. SH of cysteine).
1.3.2 Metabolism of CQ
CQ has excellent oral bioavailability with almost complete absorption from 
the gastrointestinal tract (Gustafsson et al., 1983). In man, CQ is found in the plasma 
and tissues mostly as the parent compound. It is metabolised mainly by the hepatic 
microsomal system by degradation of the alkyl side chain to form 
desethylchloroquine (desCQ) and also bisdesethylchloroquine (bisdesCQ) (Kim et 
al., 2003) (Figure 1.9).
Excretion of CQ is slow, taking approximately 3-4 weeks for equilibrium to 
be reached between the tissue and plasma levels. Particularly high binding of CQ 
occurs within the tissues, especially those containing the pigment melanin (for
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example the eyes and skin). Retinopathy is the most serious form of toxicity 
associated with long-term CQ usage in humans (Peters et al., 1984).
Figure 1.9 Chloroquine (CQ) and desethylchloroquine (desCQ) N- 
dealkylation pathways in humans (Projean et al, 2003)
1.3.3 Drug Metabolism: Bioactivation versus Detoxication
On average, some 10,000 compounds undergo testing before one is found that 
can be marketed as a drug. Many compounds are dropped from the drug-discovery 
pipeline at different steps along the way, often due to toxicity. Therefore toxicity is a 
major barrier to drug development.
The toxicity profiles of some compounds can be related to chemical 
structures, and more specifically, to particular substructures, known as toxicophores 
(Hakimelahi et al., 2005; Wang et al., 1999).
By identifying chemical functionalities and acknowledging the conditions 
under which these functionalities could be changed, it may be possible to develop 
novel, more marketable drugs which carry less risk of causing adverse drug reactions 
(Guengerich, 2006).
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A drug entering the systemic circulation may take one of three pathways, two 
of which can lead to various forms of toxicity.
Cellular accumulation of a drug can lead to direct toxicity. Accumulation is a 
major concern and can occur after administration of large doses of drug causing the 
excretion or metabolism processes to become saturated, hence decreasing the rate of 
elimination (Timbrell, 2000). It can also occur simply due to inefficient metabolism 
and excretion due to some property of the drug; for example the retinal toxicity 
observed with the long-term use of CQ. In some cases, cofactors or protective agents 
may be required and their concentration may become limited e.g. glutathione in 
paracetamol detoxification. Accumulation results in levels of drug higher than those 
required for therapeutic effect and thus the tissue cells experience chemical stress 
which can lead ultimately to cell death.
A drug may undergo bioactivation to give chemically more reactive 
metabolites. These reactive metabolites can bind to or interact with nucleic acids, 
protein receptors or enzyme transporter signalling pathways, to cause 
carcinogenicity, necrosis, apoptosis or hypersensitivity reactions.
Alternatively, the drug may undergo metabolism via phase I and II pathways, 
forming stable metabolites which can then be excreted.
It is an improved understanding of these processes that can allow us to better 
predict and therefore prevent adverse drug reactions.
1.3.4 Adverse Drug Reactions
Adverse drug reactions (ADRs) are significant drug toxicity problems that 
contribute to the morbidity and mortality of patients. An ADR has been defined as 
any noxious or unintended reaction to a drug that occurs when administered in 
standard doses by the appropriate route for the purpose of prophylaxis, diagnosis or
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treatment (Vervloet et al., 1998). ADRs can be classified into three types, A, B and 
C.
Type A (pharmacological) reactions encompass all those that are predictable 
from the known pharmacology of the drug (Davies, 1996). They account for over 80 
% of all reactions and often represent an exaggeration of the pharmacological effect 
of the drug.
Type B (idiosyncratic) reactions are ones that are not predictable from 
knowledge of the basic pharmacology of a drug and exhibit marked inter-individual 
variation. The classic example of an idiosyncratic reaction is the toxicity of 
paracetamol (Figure 1.8). Whilst it cannot be classed as an adverse reaction per se, 
(the hepatoxicity is caused by inappropriate use of the drug), the hepatic injury 
resulting from paracetamol is a function of various host factors and not only dose. 
As with AQ toxicity, the quinone imine can bind to cellular macromolecules and 
initiate an idiosyncratic response. This explains why many drugs, that are not toxic 
in therapeutic doses, become toxic when higher doses are ingested or conjugation is 
impaired by depletion of cofactors.
Type C (chemical) reactions have biological characteristics which can either 
be predicted or rationalised in terms of chemical structure (Park et al., 1998).
Tebuquine and halofantrine are two notable antimalarial drugs that have 
caused serious adverse reactions (Figure 1.10). Tebuquine reached pre-clinical 
toxicological trials on the basis of its antimalarial activity, however failed to reach 
man due to the presence of neutrophil toxicity in animals (Naisbitt et al., 1998; 
Werbel etal., 1986). In contrast, halofantrine is still in clinical use, however cases of 
cardiotoxicity have been reported and it is no longer used in patients with known
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cardiac impairment (Bouchard et al., 2002; Ker Keule et al., 1993; Wesche et al. 
2000).
Tebuquine Halofantrine
Figure 1.10 Chemical structures of tebuquine and halofantrine.
1.3.5 Structural Alerts and the Prediction of Toxic Metabolites
It is important to know which chemical features, or toxicophores, of a drug 
are likely to cause an adverse reaction. An extensive list of structural alerts exist, 
these include (Kalgutkar et al., 2005):
aniline • furan
epoxide • thiophene
quinone • allylic alcohol
quinone imine • acyl glucuronide
acyl halide • 4-aminophenol
hydroxylamine
It is unfortunate that this list also encompasses a large number of 
pharmacophores, e.g. anilines and aromatic amines -  which are particularly relevant 
to anti-infective agents (Figure 1.11). As highlighted with paracetamol, the presence 
of a structural alert does not guarantee toxicity.
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OH
Paracetamol Pyronaridine
Figure 1.11 Structural alerts in anti-infective agents. Groups highlighted in 
red, such as the amine, methoxy and acetamido groups indicate the presence of 
structural alerts.
1.3.5.1 Computational Approaches to Predict Drug Toxicity
A new approach in the evaluation of drug toxicity, absorbtion, distribution, 
metabolism and excretion (ADME) and pharmacokinetics is the use of computational 
prediction. Many software packages are now available such as Meteor (Lhasa); 
(Boobis et al., 2002) and MetaDrug™ (Genego); (Ekins et al., 2000; Elkins et al., 
2006). These systems assess compounds for potential therapeutic indications and 
side effects by examining the compound’s structure and making comparisons to large 
compound libraries and databases. MetaDrug™ in particular, will take a novel 
compound and split it into metabolites before running them through QSAR models 
and visualising them in the context of pathways, cell processes and toxic and disease 
networks disturbed by the compound’s action. Although these programs have not yet 
been adequately validated and still require improvements, the emerging consensus is
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that the predictions may provide an advantage to in vitro testing, as less investment 
in technology, resources and time are required. It is possible that in the future, these 
programs may provide a useful tool in the expedition of drug discovery.
1.3.6 CQ Toxicity
CQ toxicity is relatively uncommon, yet can be very serious, and is usually 
associated with long term usage and accumulation of the drug. Retinopathy and 
cardiac toxicity appear to be the main forms of toxicity related to the drug. CQ has 
been shown to have strong affinity for melanin granules and has been demonstrated 
to have a very high affinity for the retina in rhesus monkeys (Peters et al., 1984). 
This retinal toxicity is likely to be due to non-specific accumulation owing to its long 
half-life and its weakly basic nature, resulting in its ability to enter any acidic cell 
type within the body via ion-trapping.
In patients undergoing CQ treatment for rheumatic diseases, several cases of 
cardiac damage, such as cardiomyopathy and conduction system disturbances, have 
been reported (Don Michael et al, 1970). CQ is able to inhibit phospholipase activity 
and induce cytoplasmic inclusion body formation. It can also be accumulated within 
lysosomes, due to its basicity and can inhibit enzyme activity, increase lysosomal pH 
and cause inactivation of proteins (Teixeira et al., 2002). It is these properties that 
have led to the described atrial and ventricular antiarrhythmic effects described.
1.3.7 The Metabolism and Toxicity of AQ
After oral dosing, in man, AQ is rapidly cleared from the plasma with a half- 
life of 5.2 ±1.7 hours (Winstanley et al., 1987). This is in contrast to CQ which has 
a half-life of 7-14 days, a factor which may contribute towards the increasing
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resistance of malaria to CQ as the parasites may be seeing sub-therapeutic 
concentrations of drug for long periods of time (Watkins et al., 1993).
In vivo, AQ is rapidly metabolised via the cytochrome P450 enzyme, 
CYP2C8 to form its equipotent desethyl analogue, desAQ which is responsible for 
most of the antimalarial activity. DesAQ achieves much higher concentrations than 
its parent drug meaning AQ can be regarded as a pro-drug (Figure 1.12) (Li et al., 
2002; Winstanley et al., 1987; Winstanley et al., 2004). The formation of desAQ is 
also seen in animal models (Winstanley, 1988) (Chapter 3).
However, due to cases of agranulocytosis and hepatoxicity, the clinical use of 
AQ has become severely limited (Neftel et al., 1986). The prevalence of these 
adverse effects has been estimated to be in the order of 1:2000 (Hatton et al., 1986). 
AQ has a structural metabolic alert, as with paracetamol (Figure 1.11), and the toxic 
effects observed can be attributed to the formation of a toxic quinone ¡mine 
metabolite (AQQI), which is also thought to be catalysed by myeloperoxidase 
(MPO) as well as cytochrome P450 (Figures 1.8 and 1.13) (Jewell et al., 1995; 
Maggs et al., 1987). This metabolite is thought to be of too low a molecular weight 
to be immunogenic itself, but when covalently bound to the thiol groups of a 
macromolecular carrier it could act as an antigen, as the detection of antidrug IgG 
antibodies suggests (Clarke et al., 1991; Harrison et al., 1992; Pirmohamed et al., 
1996).
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Cl
Figure 1.12 The cytochrome P450 mediated A-dealkylation of AQ to desAQ.
GSH
k k
Figure 1.13 Possible mechanisms of AQ bioactivation and GSH conjugation.
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1.4 RATIONAL APPROACHES TO DRUG DESIGN
1.4.1 Introduction
Chemical modification has long been used to dissociate the pharmacological 
activity of a drug from unwanted side effects. A lead compound with a desired 
pharmacological activity may have associated undesirable side effects, characteristics 
that limit its bioavailability or structural features which adversely influence its 
metabolism and excretion from the body.
The widespread application of the concept of isosterism to modify biological 
activity has given rise to the term bioisosterism (Patani et al, 1996). Bioisosterism 
represents one approach that medicinal chemists use for the rational modification of 
old compounds towards the development of new, more effective drug molecules A 
number of classic bioisosteres exist such as fluorine, hydroxyl, amino and methyl 
group interchanges. In the case of AQ, two approaches have been used in order to 
attempt to prevent the occurrence of metabolic bioactivation:
i. Isomerisation of the 4’-hydroxyl group and the amino side chain leading 
to the production of isoquine (ISQ), a compound which does not 
undergo bioactivation to form the toxic quinone imine metabolite 
(O'Neill et a l, 2003).
ii. Halogen substitution of the 4’-hydroxyl group using fluorine or chlorine 
to increase the oxidation potential in comparison to AQ, thus preventing 
in vivo oxidation.
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1.4.2 Interchange of the Amino and 4’-Hydroxyl Group of AQ
ISQ, the original lead compound, was prepared as part of a study to prepare a 
second generation of 4-aminoquinoline antimalarials (Figure 1.15). It was proposed 
that interchanging the 4' hydroxyl and the 3' Mannich side-chain of AQ would 
provide a new series of analogues unable to form toxic quinone imine metabolites via 
cytochrome P450-mediated metabolism (O'Neill et al., 2003). The potent in vitro 
antimalarial activity of ISQ was translated into excellent oral in vivo ED5o activity of
1.6 and 3.7 mg/kg against the rodent malaria P. yoelii NS strain, compared to 7.9 and
7.4 mg/kg for AQ. Subsequent metabolism studies in the rat model demonstrated that 
ISQ does not undergo in vivo bioactivation, as evidenced by the complete lack of 
glutathione metabolites in bile. In sharp contrast to AQ, ISQ undergoes clearance by 
direct glucuronidation.
Figure 1.15 Isoquine, the isomeric analogue of AQ and its desethyl metabolite.
1.4.3 The Effect of Fluorine Substitution on AQ
The strategic substitution of fluorine into therapeutic agents can have a 
profound effect on the chemical properties, disposition and biological activity of 
drugs (Park et al., 2001).
30
The inclusion of a fluorine atom into a drug molecule can influence both the 
disposition of the drug and interaction of the drug with its pharmacological target 
(Figure 1.16).
FLUORINE
SUBSTITUTION
PHYSIOCHEMICAL PROPERTIES
Bond Strength 
Lipophilicity 
Conformation 
Electrostatic Potential 
Dipole 
pKa
PHARMACOKINETIC PROPERTIES
< Tissue Distribution \Clearance \  Route of Metabolism /  Rate of Metabolism /
PHARMACOLOGICAL CONSEQUENCES
Pharmacodynamics^ 
Toxicologyy
Figure 1.16 Flow diagram illustrating the effect of fluorine substitution on 
drug response. (Park et al., 2001)
Fluorine substitution can also have a huge effect on drug disposition, in terms 
of distribution, drug clearance and drug metabolism. Such changes can be used 
constructively to improve both the safety and efficacy of a drug.
The isosteric replacement of a hydroxyl group is a commonly used strategy in 
medicinal chemistry. This substitution is based on the premise that fluorine is a
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comparable hydrogen bond acceptor to a hydroxyl oxygen atom. Also, the higher 
electronegativity and lower polarizability of fluorine over oxygen has a major 
influence on the ability of fluorine to mimic a hydroxyl group (Dixon et al., 1991).
The presence of fluorine can alter the oxidation potential of an aromatic 
system, and thus alter the rate of auto-oxidation and formation of quiñones and 
quinone ¡mines. This was demonstrated when the sequential introduction of fluorine 
atoms into the nucleus of paracetamol produced an increase in the oxidation potential 
of the molecule, as measured by cyclic voltammetry (Barnard et al., 1993).
AQ and its desethyl analogue both have very low oxidation potentials, in 
comparison to paracetamol. This means that they can undergo facile chemical 
oxidation to their respective quinone imines. Studies have shown that by substituting 
the hydroxyl functionality with fluorine, the oxidation potential of AQ can be 
increased resulting in a more favourable balance between drug activation and 
detoxification whilst retaining antimalarial activity (Harrison, 1994; O'Neill et al., 
1994). On the basis of these findings it may be possible to design a novel and potent 
antimalarial which does not undergo bioactivation in the manner of AQ and is 
metabolically more stable than ISQ.
1.5 AIMS OF THESIS
The work presented in this thesis is aimed at determining whether it is 
possible to utilise rational drug design for the production of a novel, inexpensive 
antimalarial compound. The desired compound will exhibit similar efficacy to AQ 
against CQ-sensitive and CQ-resistant parasites, lack the ability to undergo 
bioactivation resulting in reactive metabolites and be unable to undergo non-specific 
accumulation within the body.
A safe and effective 4-aminoquinoline must have the following features:
• The correct structural features, which permit high-affinity binding in the 
parasite.
• No functional groups which allow metabolic conversion to products that have 
lower activity against resistant strains.
• No functionalities that can undergo bioactivation and subsequent binding to 
protein reactive nucleophiles.
• A functionality that allows metabolic clearance by conjugation, for example, 
glucuronidation, in order to prevent accumulation within the tissues leading 
to potential toxicity.
The strategies to be employed in order to achieve these specific requirements 
involve a combination of the following:
• Interchange of the 4’-hydroxyl group of AQ with the 3’-amino side chain to 
produce a compound that does not undergo oxidation to a quinone imine 
metabolite.
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• Replacement of the diethyl amino side chain with a tert butyl group to 
increase the metabolic stability of the compound.
• Insertion of a fluorine or chlorine atom in place of the hydroxyl group to 
increase the oxidation potential of the drug.
Candidate compounds will undergo extensive dispositional and in vivo metabolic 
studies to determine the pathways of metabolism and clearance in rats. From these 
experiments we will determine the biodistribution of the drug in the body. Further 
analysis will reveal the possibility of retention and whether there is any accumulation 
or retention in the tissues over time. In addition, preliminary toxicity studies shall be 
performed and the results from these experiments will be compared to those from CQ 
and AQ.
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2.1 INTRODUCTION
The main introduction to this thesis highlighted some of the key issues 
concerning the treatment of modern malaria and revealed how rational drug design 
involving structural change of current drugs can be used to design novel antimalarial 
agents. It is clear that a new 4-aminoquinoline drug is required to supersede 
amodiaquine (AQ) due to its ability to cause adverse reactions; this has prompted 
chemists to design a range of structural analogues.
This chapter is primarily concerned with the chemical syntheses of isoquine 
(ISQ) (2c), its desethyl and tert-butyl analogues (3c and 4c respectively) and also AQ 
(6c) and its tert-butyl fluoro and chloro derivatives (8d and l id  respectively) (Figure
2.1). The optimisation and eventual scale-up of these syntheses will then enable 
pharmacological evaluation leading to the selection of a suitable candidate for pre- 
clinical studies.
6c 8d lid
Figure 2.1 Compounds to be synthesised. Isoquine (ISQ) 2c, desethyl 
isoquine (desISQ) 3c, A-tert-butyl isoquine (NTBISQ) 4c, amodiaquine (AQ) 6c, 
A'-ferf-butyl fluoro amodiaquine (FAQ-4) 8d and N -tert butyl chloro 
amodiaquine (C1AQ-4) lid .
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2.1.1 Drug-Design Rationale
Previous structure-activity-relationship (SAR) work suggested that the 
presence of the 4’hydroxyl group within the aromatic ring imparted greater inherent 
antimalarial activity against CQ-resistant parasites than the corresponding deoxy 
analogues (O'Neill et al., 1998; O'Neill et al., 1997). However, as mentioned in 
chapter 1 (Section 1.4.2), interchange of the hydroxyl group with the amino side- 
chain of AQ provides a means of preventing oxidation to toxic metabolites whilst 
retaining the possible important bonding interactions of aromatic hydroxyl function 
(ISQ). ISQ has been noted to have poor oral bioavailability and undergoes extensive 
yV-dealkylation to its desethyl form, desISQ (O'Neill et al., 2003). It was postulated 
that incorporation of a tert butyl group as the amine side chain instead of a diethyl 
group would hopefully lend to the stability of the molecule (NTBISQ). The 
sterically hindered group is metabolically less labile than the A-ethyl group of AQ 
and ISQ and is not thought to be a substrate for CYP2C8 dealkylation. It was 
therefore proposed that we would not observe any major side chain loss in 
metabolism experiments.
An alternative method for avoiding the toxicity observed in vivo with AQ 
involves the substitution of the hydroxyl function with fluorine or chlorine. The 
introduction of a halogen atom can have a profound effect on the biological activity 
and the physiochemical parameters of some aromatic compounds. It has previously 
been shown with paracetamol that providing the oxidation potential of the fluoro 
derivative is sufficiently greater than that of the parent compound; fluorine 
substitution can block in vivo oxidation. Thus preventing formation of its quinone 
imine metabolite (Barnard et al., 1993).
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Previous studies on fluorinated analogues of AQ have shown that the critical 
balance between drug activation and the process of oxidative bioactivation can be 
altered, without any significant loss of activity against CQ-sensitive and CQ-resistant 
parasites (Madrid et al., 2005). Studies within the group showed that interchange of 
the hydroxyl group of AQ with fluorine gave rise to a compound which did not 
undergo bioactivation to a reactive metabolite in vivo but had similar antimalarial 
activity to AQ (O'Neill et al., 1994). Coupling this idea with the concept of a tert 
butyl group in place of the diethyl group will hopefully lead to two promising 
candidates for animal studies [FAQ-4 (8d) and C1AQ-4 (lid)]. FAQ-4 and C1AQ-4 
should have greater in vivo stability than AQ and will be unable to form a toxic 
quinone imine metabolite.
Therefore, the aim of the work presented in this chapter was to develop a 
simple and efficient synthesis of three rationally designed lead compounds, NTBISQ, 
FAQ-4 and C1AQ-4, along side ISQ, desISQ and AQ. The compounds were to be 
synthesised in quantities sufficient enough to permit pharmacodynamic and 
pharmacokinetic analysis using standard methods.
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2.2 MATERIALS AND METHODS
2.2.1 Materials
Unless otherwise noted, all solvents and reagents were obtained from 
commercial suppliers and were used without further purification. 3- 
Hydroxyacetanilide, 4-hydroxyacetanilide, and 2-fluoro, 5-nitrotoluene were 
purchased from Sigma Aldrich Chemical Co. (Poole, United Kingdom). [3H]-4, 7 
Dichloroquinoline (20 Ci/mmol; radiochemical purity by HPLC 99.9 %) was 
purchased from Morovek Biochemicals, Inc. (California, USA). C1AQ-4 (lid ) was 
prepared by D. Stanford of the Department of Chemistry, University of Liverpool.
All compounds were purified by flash column chromatography, performed 
using a Merck 9385 Kieselgel 60 (230-400 mesh) silica gel, using hand bellows to 
apply pressure.
Analytical thin layer chromatography (TLC) was performed on aluminum 
backed sheets, pre-coated with a 0.25 mm layer of silica gel obtained from Merck. 
After elution, the plates were visualized using ultra-violet (254 nm).
Infrared (IR) spectra were recorded in the range of 4000-600 cm'1 using a 
Perkin-Elmer 298 infrared spectrometer. Solid samples were run as nujol mulls and 
liquids neat on sodium chloride discs.
'H Nuclear Magnetic Resonance spectra were recorded using a Brucker 
instrument (400 MHz). 13C spectra were recorded on a Varian Gemini 2000 
instrument (100 Mhz). All spectra were recorded using deuterated chloroform or 
deuterated methanol as a solvent. Spectra are presented in the form: chemical shift in 
ppm (number of hydrogens, appearance of signal, coupling constant, assignment). 
The following symbols have been used in the description of spectra obtained:
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5 = Chemical shift (in parts per million (ppm))
J=  coupling constant (in Hz)
s = singlet
d = doublet
t = triplet
q = quartet
Mass spectra were performed by A. Mills of the Department of Chemistry, 
University of Liverpool and are given as accurate mass.
Microanalyses were performed in the microanalytical laboratory in the 
Department of Chemistry, University of Liverpool using a Carlo Erba elemental 
analyser.
Melting points (mp) were determined using a Gallemkamp melting point 
apparatus.
2.2.2 Methods -  Chemical Synthesis
2.2.2.1 N-[4-(Diethylamino)methyl-3-hydroxyphenyl]-acetamide (2a)
3-Hydroxyacetonilide 1 (4.00 g, 26.5 mmol) (Scheme 2.1) was dissolved in 
ethanol (20 mL) at room temperature to which aqueous formaldehyde (2.19 g, 2.5 
eq) and diethylamine (2.13g, 1.1 eq) were then added and the solution was heated to
NHCOCH3
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reflux for 16 h. The solvent was then removed under reduced pressure and the crude 
material was purified by silica gel flash column chromatography using 1 0 - 8 0  % 
MeOH/DCM as eluent. The product was afforded as a pale brown oily residue, 2a 
(3.40 g, 54 %) 'H-NMR (400 MHz, MeOD) 5 7.11 (dd, 1H, J=  8.2, 1.9 Hz Ar-//), 
6.98 (d, 1H, J=  8.2 Hz, Ar-//), 6.87 (d, 1H, J=  1.9 Hz, Ar-//), (3.81 (s, 2H, CHi), 
2.72 (q, 4H, J  = 7.2 Hz, NC//2CH3), 2.14 (s, 3H, CH3), 1.09 (t, 6H, J  = 12  Hz, 
NCH2C//5); ,3C-NMR(100 MHz) 5 168.9, 156.2, 138.4, 130.5, 118.5, 113.9, 106.1,
49.1, 22.9, 13.1; IR (neat): 3500-2800 (broad-OH band), 1650, 1612, 1548, 1417, 
1348, 1256, 1152, 1138, 1016, 972, 870, 824, 754, 724 cm'1; MS m/z calcd for 
C13H21N2O2 [M+H]+ 237.16043 found 237.16042; Elemental analysis: C: 66.76, H: 
8.42, N: 11.56 (required values; C: 66.10, H: 8.47, N:11.86).
2.2.2.2 N-[4-((Ethylamino)methyl)-3-hydroxyphenyl]-acetamide (3a)
Compound 3a was prepared in an identical manner to Mannich base 2a but 
using ethylamine (1.89 mL), to afford the product as a brown, oily residue. (3.19 g, 
58 %); 'H-NMR (400 MHz, MeOD) 8 6.93 (d, 1H, J = 2.0 Hz, Ar-//), 6.81 (dd, 1H, J  
= 8.0, 1.9 Hz, Ar-//), 6.67 (d, 1H, J=  8.0 Hz, Ar-//), 3.49 (s, 2H, CH2), 2.55 (q, 2H, 
NHC//2CH3), 1.89 (s, 3H, COCH3), 1.01 (t, 3H, NHCH2C//3); 13C-NMR (100 MHz) 
8 168.9, 155.9, 138.2, 129.6, 119.2, 114.8, 105.4, 44.3, 44.0, 22.6, 15.8; IR (neat) 
3500-2800 (broad-OH band), 1664, 1609, 1535, 1459, 1377, 1270, 1169, 1016, 968, 
859, 722 cm'1; MS m/z calcd for C11H16N2O2 [M+H]+ 209.1291 found 209.1020;
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Elemental analysis: C: 62.98, H: 7.32, N: 12.78 (required values; C: 63.40, H: 7.74, 
N:13.65).
2.2.2.3N-[4-((tert-butylamino)methyl)-3-hydroxyphenyl]-acetamide (4a)
Compound 4a was prepared in an identical manner to Mannich base 2a using 
tert butylamine (2.1 mL) to give the product as an off-white solid (3.62 g, 72 %); 'H- 
NMR (400 MHz, MeOD) 8 6.93 (d, 1H J=  8.2 Hz, Ar-H), 6.78 (dd, 1H, J=  8.2, 2.2 
Hz, Ar-H), 6.53 (d, 1H, J=  2.2 Hz, Ar-H) 3.55 (s, 2H, CH2), 1.59 (s, 3H, CH3), 1.23 
(s, 9H, 'Bu); 13C-NMR (100 MHz) 8 167.3, 154.2, 137.9, 129.6, 121.3, 114.6, 108.3,
54.6, 39.3, 31.0, 24.5; IR (Nujol) 3500-2800 (broad-OH band), 1732, 1682, 1614, 
1548, 1489, 1462, 1377, 1322, 1274, 1213, 1171, 1148, 1114, 936, 866, 818, 790, 
736 cm'1; MS m/z calcd for CI3H2iN20 2 [M+H]+ 237.16031 found 237.16042; 
Elemental analysis: C: 67.33, H: 8.12, N: 11.87 (required values; C: 66.07, H: 8.53, 
N:11.85).
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2 .2 .2 .4 N -[3 -D ie th y la m in o m e th y l-4 -h y d ro x y -p h e n y l]-a c e ta m id e  (6a)
OH
The AQ Mannich intermediate, 6a was prepared in the same manner as the 
ISQ analogue 2a, utilizing 4-hydroxyacetonilide as the precursor, to afford a brown, 
oily residue (4.01 g, 64 %); 'H-NMR (400 MHz, MeOD) 8 7.07 (d, 1H, J = 8.6 Hz, 
Ar-H), 7.03 (dd, 1H, J=  8.6, 2.4 Hz, Ar-H), 6.49 (d, 1H, J=  8.6 Hz, Ar-H), 3.52 (s, 
2H, CH2), 2.50 (q, 4H, J=  7.2 Hz, NC/72CH3), 1.91 (s, 3H, COCH3), 0.99 (t, 6H, J  =
7.2 Hz, NCH2CH3y, 13C-NMR(100 MHz) 5 168.9, 151.6, 128.9, 123.4, 122.7, 121.7, 
114.9, 49.1, 19.8, 13.6; IR (neat); 3500-2800 (broad-OH band), 1732, 1654, 1566, 
1490, 1462, 1377, 1262, 1194, 1167, 1147, 1075, 1041, 982, 897, 859, 832, 768, 725, 
688 cm'1; MS m/z calcd for C,3H2iN20 2 [M+H]+ 237.16038 found 237.16039; 
Elemental analysis: C: 67.23, H: 8.19, N: 11.91 (required values; C: 66.07, H: 8.53, 
N: 11.85).
2.2.2.5 5-(7-Chloroquinolin-4-ylamino)-2-[(diethylamino)methyl]-phenol (2c)
Aqueous HC1 (20 %) (10 mL) was added to the amide, 2a, (1.01 g, 4.2 mmol) 
and the solution heated to reflux for 5 h under an inert atmosphere. The solvent was
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then removed in vacuo to give the resulting amine as its hydrochloric salt. 4, 7 
Dichloroquinoline (0.97 g, 1.1 eq) and EtOH (20 mL) were added and the reaction 
heated to reflux for 16 h until completion (determined by TLC). The solvent was 
removed under reduced pressure and the crude product was purified by flash column 
chromatography using 10 - 80% MeOH/DCM as eluent to yield the product as a 
foamy, yellow solid, 2c (1.02 g, 68 %): mp; 171.0-171.5 °C (decomposed); ’H-NMR 
(400 MHz, MeOD) 5 8.65 (d, 1H, J=  5.2 Hz, quinoline-//), 8.01 (d, 1H, J=  2.2 Hz, 
quinoline-//), 7.72 (d, J  = 8.9 Hz, quinoline-//), 7.43 (dd, 1H, J  = 8.9, 2.2 Hz, 
quinoline-//), 6.75 (d, 1H, J=  5.2 Hz, quinoline-//), 6.49 (d, 1H, J=  8.0 Hz, Ar-H) 
5.91 (dd, 1H, J =  8.0, 2.2 Hz, Ar-//) 5.81 (d, 1H, J=  2.2 Hz, Ar-//), 3.67 (s, 2H, 
C //2), 2.46 (q, 4H, / =  7.1 Hz, NC//2CH3), 1.07 (t, 6H, J=  7.1 Hz, NCH2C//5); 13C- 
NMR (100 MHz) 8 156.8, 151.4, 149.5, 148.2, 136.7, 131.2, 129.3, 127.4, 122.5, 
118.9, 113.0, 112.8, 107.8, 100.7, 49.4, 49.2, 13.4; IR (Nujol) 2931, 2832, 1674, 
1619, 1545, 1514, 1460, 1432, 1372, 1327, 1256, 1190, 1172, 1148, 1112, 1062, 992, 
902, 873, 821, 812, 740 cm'1; MS m/z calcd for C20H23CIN3O [M+H]+ 356.15292 
found 356.15287; Elemental analysis: C: 67.33, H: 6.12, N: 11.87 (required values; 
C: 67.5, H: 6.23, N:11.81).
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2 .2 .2 .6 5 -(7 -ch lo ro q u in o lin -4 -y la m in o )-2 -(e th y la m in o )m e th y lp h en o l (3c)
Compound 3c was prepared in a similar way to ISQ affording a pale, brown 
solid (0.25 g, 16 %). mp 136.0-131.5 °C; 'H-NMR (400 MHz, MeOD) 5 8.61 (d, 1H, 
J =  9.2 Hz, quinoline-//), 8.38 (d, 1H, J=  2.0 Hz, quinoline-//), 7.95 (dd, 1H, J  =
7.1, 2.0 Hz, quinoline-//), 7.78 (d, 1H, J=  7.1 Hz, quinoline-//), 7.54 (d, 1H, J =  8.6 
Hz, Ar-//), 7.41 (d, 1H, J=  9.1 Hz, quinoline-//), 7.14 (dd, 1H, J=  8.6, 2.6 Hz, Ar- 
H), 6.86 (d, 1H, J =  2.6 Hz, Ar-//), 4.25 (s, 2H, C/fe), 3.15 (q, 2H, J =  7.3 Hz, 
NHC//2CH3), 1.46 (t, 3H, J = 7.3 Hz, NHCH2CH3); 13C-NMR (100 MHz) 5 156.8, 
153.4, 148.7, 147.2, 142.8, 134.9, 130.5, 129.7, 127.3, 122.6, 120.1, 113.8, 113.1, 
108.7, 100.6, 44.3, 44.0, 14.8; IR (Nujol) 3274, 1614, 1538, 1504, 1454, 1376, 1208, 
109, 902, 821, 719 cm'1; MS m/z calcd for QgH^ClNaO [M+H]+ 329.63191 found 
329.62969; Elemental analysis: C: 66.43, H: 6.17, N: 10.87 (required values; C: 
65.95, H: 5.53, N:10.82).
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2 .2 .2 .7 2 -[( te r t-b u ty la m in o )m e th y l)-5 -(7 -c h lo ro q u in o lin -4 -y la m in o ]-p h en o l (4c)
Compound 4c was prepared using a similar procedure to 2c providing the 
product as a pale yellow solid (1.17 g, 78 %); mp: 243.2-244.2 °C 'H-NMR (400 
MHz, MeOD) 5 8.26 (d, 1H, J =  5.7 Hz, quinoline-77), 8.16 (d, 1H, J=  9.1 Hz, 
quinoline-77), 7.75 (d, 1H, J=  2.2 Hz, quinoline-77), 7.40 (dd, 1H, J=  9.1, 2.2 Hz, 
quinoline-77), 7.06 (d, 1H, J=  7.9, Ar-77), 6.87 (d, 1H, J=  5.7 Hz, quinoline-77), 6.61 
(d, 1H, J=  1.9 Hz, Ar-77), 6.58 (dd, 1H, J=  7.9, 2.1 Hz, Ar-77), 3.92 (s, 2H, CH2),
1.12 (s, 9H, 'Bu); 13C-NMR (100 MHz, MeOD) 5 155.9, 150.8, 149.4, 147.6, 143.2, 
136.5, 129.9, 129.1, 127.6, 122.6, 117.9, 113.5, 112.9, 105.3, 100.2, 48.7,38.9,31.0; 
IR (Nujol) 3473, 1606, 1587, 1537, 1459, 1377, 1238, 1165, 1125, 970, 908, 819, 
778, 722 cm’1; MS m/z calcd for C20H22CIN3O [M+H]+ 356.15308 found 356.15306; 
Elemental analysis: C: 67.48, H: 6.42, N: 11.78 (required values; C: 67.50, H: 6.51, 
N: 11.81).
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OH
2 .2 .2 .8  4 -[7 -c h lo ro q u in o lin -4 -y la m in o )-2 -((d ie th y la m in o )m e th y l]-p h en o l (6c)
AQ was synthesized using a similar procedure to ISQ, 2c to produce a pale, 
yellow solid, 6c (1.14 g, 76 %). mp; 207.5-208.6 °C (decomposed); 'H-NMR (400 
MHz, MeOD) 5 8.61 (d, 1H, J =  9.2 Hz, quinoline-77), 8.37 (d, 1H, J=  12  Hz, 
quinoline-77), 7.98 (d, J  = 1.9 Hz, quinoline-77), 7.78 (dd, 1H, J  = 9.1, 1.9 Hz, 
quinoline-77), 7.53 (d, 1H, J  = 2.6 Hz, quinoline-77), 7.41 (dd, 1H, J=  8.7, 2.6 Hz, 
Ar-77) 7.18 (d, 1H, J=  8.7 Hz, Ar-77) 6.82 (d, 1H, J=  12  Hz, Ar-77), 3.34 (s, 2H, 
C772), 2.46 (q, 4H, / =  7.1 Hz, NC/72CH3), 1.07 (t, 6H, 7 =  7.1 Hz, NCH2C773); 13C- 
NMR (100 MHz) 5 155.6, 143.4, 149.5, 130.8, 130.6, 129.2, 127.6, 125.4, 119.5,
117.6, 100.6, 49.4, 49.2, 9.4; IR (Nujol) 2891, 2842, 1663, 1619, 1565, 1513, 1460, 
1432, 1384, 1331, 1246, 1197, 1173, 1152, 1109, 1062, 996, 912, 863, 820, 810, 738 
cm'1; MS m/z calcd for C2oH23C1N30  [M+H]+ 356.15292 found 356.15301; 
Elemental analysis: C: 67.43, H: 6.17, N: 11.77 (required values; C: 67.47, H: 6.23,
NH
N: 11.81).
2 .2 .2 .9 2 -(b ro m o m e th y l)- l- f lu o ro -4 -n itro b e n ze n e  (8a)
F
N 0 2
2-Fluoro-5-nitrotoluene, 7, (1.90 g, 12.34 mmol) was dissolved in 
trifluoronitrotoluene (40 mL). To this, AIBN (0.20 g, 1.21 mmol) and NBS (3.00 g, 
17.48 mmol) were added and the solution heated under nitrogen, at reflux for 24 h. 
The solution was cooled to 0°C and solids were filtered off before removal of the 
solvent in vacuo to give the bromo-substituted product, 8a. The crude product was 
purified by flash column chromatography using 10 % EtOAc/Hexane as eluent to 
yield the product as a yellow oil. (1.32 g, 47 %): 'H-NMR (400 MHz, CDCI3) 8 8.78 
(dd, 1H, J=  9.2 Hz (H-F), 2.8 Hz Ar-H), 8.22 (ddd, 1H, J=  16.36 (H-F), 9.1, 1.5 Hz, 
Ar-H), 7.27 (dd, 1H, J=  8.11 Hz (H-F), 1.0 Hz, Ar-H)- 4.52 (s, 2H, CH2); ,3C-NMR 
(100 MHz) 5 165.8, 143.7, 130.8, 127.6, 127.4, 118.7, 28.1; IR (neat): 1627, 1589, 
1530, 1487, 1424,1349, 1325, 1254, 1078, 836, 745 cm'1; MS m/z calcd for 
C7H5N 02F79Br [M+H]+ 234.0225 found 234.0293; Elemental analysis: C: 34.98, H: 
2.14, N: 5.58 (required values; C: 35.93, H: 2.15, N: 5.99).
2.2.2.10 N-(2-fluoro-5-nitrobenzyl)-2-methylpropan-2-amine (8b)
N 0 2
To a solution of 8a (1.00g, 4.27 mmol) in acetonitrile, iert-butylamine (0.34g, 
4.70 mmol) and potassium carbonate (0.65g, 4.70 mmol) were added and the mixture
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was heated to reflux for 24 h. The solution was allowed to cool to room temperature
before diluting with DCM and washing with distilled water. The organic layer was 
dried over MgSCU, filtered and the solvent removed under reduced pressure to give 
the crude product. The crude product was then purified using flash column 
chromatography using 100 % DCM to give the product as an orange oil, 8b. (0.59 g, 
59 %): ‘H-NMR (400 MHz, MeOD) 5 8.57 (dd, 1H, J=  6.17, 3.26 Hz, Ar-H), 8.44 
(ddd, 1H, J =  9.09, 8.91, 3.09 Hz, Ar-H), 7.53 (dd, 1H, J=  18.0, 8.91 Hz, Ar-H),
4.04 (s, 2H, CH2), 1.48 (s, 9H, 'Bu); 13C-NMR (100 MHz) 5 158.7, 142.1, 130.6,
127.6, 127.4, 118.8, 49.8, 40.2, 29.1; IR (neat): cm"1 3390, 2966, 2368, 2324, 1913, 
1649, 1628, 1585, 1519, 1475, 1450, 1388, 1284, 1240, 1062, 812; MS m/z calcd for 
C11H15N20 2F [M+H]+ 227.1195 found 227.1189; Elemental analysis: C: 57.55, H: 
6.39, N: 12.25 (required values; C: 58.40, H: 6.68, N: 12.38).
2.2.2.11 N-[3-((tert-butylamino)methyl)-4-fluorophenyl]-7-chloroquinolin-4-amine 
(8d)
Concentrated HC1 (5 mL) was added to the fluoronitrobenzylamine, 8b, (1.01 
g, 4.45 mmol). Tin granules (0.99 g, 8.32 mmol) were added and the solution was 
heated to reflux for 5 h. The solution was cooled and basified using NaOH solution 
(20 %) to pH 10 before extraction using DCM. After drying over potassium 
carbonate, the solution was filtered and the solvent removed in vacuo to give the
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resulting amine as its hydrochloric salt. 4, 7 Dichloroquinoline (0.91 g, 4.90 mmol) 
and EtOH (20 mL) were added and the reaction heated at reflux for 16 h until 
completion (determined by TLC). The solvent was removed under reduced pressure 
and the crude product was purified by flash column chromatography using 0-20 % 
MeOH/DCM as eluent to yield the product as a light brown solid, 8d (0.99 g, 66 %): 
mp; 181-183 °C (decomposed); 'H-NMR (400 MHz, CDCI3) 8 8.67 (d, 1H, J=  9.11 
Hz, quinoline-//), 8.46 (d, 1H, J=  6.83 Hz, quinoline-//), 8.02 (d, 1H, J =  1.9 Hz, 
quinoline-//), 7.88 (dd, 1H, J=  6.08, 1.90 Hz, Ar-//), 7.82 (dd, 1H, J=  9.11, 1.9 Hz, 
quinoline-//), 7.65 (ddd, 1H, J=  15.75, 4.18, 1.9 Hz, Ar-//), 7.47 (dd, 1H, / =  18.03, 
8.92, Ar-//), 7.02 (d, 1H, J =  6.83 Hz, quinoline-//); 13C-NMR (100 MHz) 6 157.2,
145.6, 141.3, 140.8, 130.9, 130.1, 129.9, 127.6, 122.3, 120.8, 119.6, 117.6, 102.3, 
59.2, 40.1, 26.7; IR (nujol): cm'1 3361, 2967, 2324, 1610, 1585, 1540, 1502, 1475, 
1448, 1378, 1340, 1213, 1101, 1062 MS m/z calcd for C20H21CIFN3 [M+H]+ 
358.14862 found 358.14807.
2.2.2.12 Radiometric Synthesis o f [3HJ-NTBISQ (4c *)
The radiolabelled compound 4c* was prepared in a similar manner to non- 
labelled NTBISQ (4c) (Section 2.2.2.7). To the amine, 4b (15 mg, 77.21 pmol), [3H] 
-  4, 7 dichloroquinoline (lmCi/mL in 1 mL EtOH, 9.9 pg/mL) was carefully added
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ensuring no droplets formed. EtOH (2 mL) was used to wash out the ampoule of 
radioactive material 4, 7 Dichloroquinoline (13 mg, 61.77 pmol) was added to the 
reaction mixture followed by HC1 (2 pL) and the reaction was heated at reflux for 16 
h until completion (determined by TLC). The solvent was allowed to evaporate in 
the fumehood and the crude product was purified by flash column chromatography 
using 10 - 80% MeOH/DCM as eluent to yield the product as a yellow solid, 4c* 
(23.9 mg, 72 %). The radiolabelled product was analysed using LC-MS.
2.2.2.13 Radiometric Synthesis o f f  HJ-FA Q-4 (8d*)
The radiolabeled compound 8d* was prepared using the same method as 4c* 
by addition of 4, 7 dichloroquinoline (8.1 mg, 41.12 pmol) to a solution of the amine 
side chain 8c (10 mg, 51.28 pmol) and [3H]-4, 7 dichloroquinoline (lmCi/mL in 1 
mL EtOH, 9.9 pg/mL). A light brown solid, 8d*, was produced (7.2 mg, 39 %). The 
product was analysed by LC-MS.
F
N H
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2 .2 .2 .1 4  R a d io m e tr ic  S yn th esis  o f  f 3H ]-C IA Q -4  (1 Id * )
Cl
The radiolabeled compound lid*  was prepared using the same method as 
4c* by addition of 4, 7 dichloroquinoline (28 mg, 142.13 pmol) to a solution of the 
chlorinated amine side chain (30 mg, 140.02 pmol) and [3H]-4, 7 dichloroquinoline 
(lmCi/mL in 1 mL EtOH, 9.9 pg/mL). A light brown solid, lid* , was produced 
(13.7 mg, 26 %). The product was analysed by LC-MS.
2.2.3 Methods -  Pharmacological Evaluation
Antimalarial testing of the drugs used in this study was carried out using 
standard protocols at the Liverpool School of Tropical Medicine. The methods used 
are shown below (Berenbaum, 1978; Desjardins et al., 1979; Lambros et al., 1979; 
Trager etal., 1976).
Four strains of P. falciparum were used in this study: The K1 and TM6 
strains, which are known to be chloroquine resistant, and the HB3 and 3D7 strains 
which are sensitive to chloroquine. Parasites were maintained in continuous culture 
using the method of Jensen and Trager (Trager et al., 1976). Cultures were grown in 
flasks containing human erythrocytes (2-5 %) with parasitaemia in the range of 1 % 
to 10 % suspended in RPMI 1640 medium supplemented with HEPES (25 mM), 
NaHCCb (32 mM), and 10 % human serum (complete medium). Cultures were 
gassed with a mixture of 3 % O2, 4 % CO2 and 93 % N2.
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Antimalarial activity was assessed using a sensitivity assay introduced by 
Desjardins, which involved incorporating [3H]-hypoxanthine, the preferred form of 
purine required by the parasite for growth and development, into parasite nucleic 
acid as a marker to measure parasite growth (Asahi et al., 1996; Desjardins et al., 
1979).
All compounds were prepared as the hydrochloride salt so that they were 
more soluble than their equivalent free-base. Stock drug solutions were prepared 
using DMSO (100 %) and diluted to the appropriate concentration using complete 
medium. The final solvent concentration was less than 0.1 % so parasite viability 
was unaffected. Assays were performed using 96-well micro titre plates. Each drug 
was tested in triplicate and parasite growth was compared to control wells (which 
constituted 100 % parasite growth). After 24 h incubation at 37 °C, 0.5 pCi [3H]- 
hypoxanthine was added to each well. Cultures were incubated for a further 24 h 
before they were harvested onto glass filter-mats, dried for 1 h at room temperature, 
and counted using a Wallac 1450 Microbeta Trilux Liquid scintillation and 
luminescence counter. IC 50 values were calculated by interpolation of the probit and 
transformation of the log dose -  response curve.
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2.3 RESULTS AND DISCUSSION
2.3.1 Chemistry
23.1.1 ISQ, DesISQ and NTBISQ
The preparation of ISQ and its analogues involved a three-step synthesis from 
inexpensive, commercially available starting materials based on a method originally 
utilized by Burckhalter and co-workers (Scheme 2.1) (Burckhalter et al., 1948). The 
first step of the procedure involved a Mannich reaction of 3-hydroxyacetanilde, 1 to 
provide the Mannich intermediate in yields ranging from 54 % to 72 % (Table 2.1). 
The Mannich reaction involved condensation of the primary amine with 
formaldehyde to form a stable Schiff base. Electrophillic substitution by the 
imminium ion ortho to the hydroxyl group of 3-hydroxyacetanilide led to the 
formation of the Mannich intermediates in moderate to good yields (2a, 3a and 4a) 
(Scheme 2.2) (Blicke, 1942). The next step involved an acid-catalysed hydrolysis of 
the amide function to give the corresponding Mannich-substituted 3-aminophenol in 
high yield (Table 2.1). The final stage of the synthesis involved coupling with 4, 7- 
dichloroquinoline to provide the target molecules required (2c, 3c and 4c) (Scheme
2.1). The compounds were obtained as their hydrochloride salts which proved to be 
more convenient for dosing in the subsequent animal studies performed (Chapters 3, 
4 and 6).
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(2) R , + R 2 =  (C2H 5)2
(3) R , = C 2H5jR2 = H
(4) R] =  C (CH3)3, R2 = H
Scheme 2.1 Three step chemical syntheses of isoquine, ISQ (2c), desethyl 
isoquine, desISQ (3c) and jV-terf-butyl isoquine, NTBISQ (4c). Reagents and 
conditions: (i) EtOH, formaldehyde (2.5 eq), (a) -NHEt2, (b) -N H 2Et, (c) - NH2‘Bu 
(1.1 eq), 80 °C, 16 h; (ii) cone. HC1, EtOH, 80 °C, 5 h; (iii) 4,7 dichloroquinoline 
(1.1 eq), EtOH, 80 °C, 16 h.
% Yield
Compound (a ) (b) (c )
ISQ, 2 54 88 68
DesISQ, 3 58 86 16
NTBISQ, 4 72 92 78
Table 2.1 Percentage yields for each of the three steps of the synthesis for 
the isoquine analogues, ISQ, (2); desISQ, (3) and NTBISQ, (4).
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Scheme 2.2 Mechanism of the Mannich-type reaction: formation of 
intermediate 4a. Condensation of tert butylamine with formaldehyde forms the 
Schiff base.
2.3.1.2 The "Reverse Route " Synthesis
In an attempt to optimize the synthesis of the 4-aminoquinoline analogues, a 
second pathway for the synthesis of ISQ and its analogues was designed and termed 
the “reverse route”. The reverse route involved only two steps, utilising inexpensive 
and commercially available materials. Direct coupling of 3-hydroxylamine with 4, 
7-dichloroquinoline gave 3-(7-chloroquinolin-4-ylamino) phenol, 9, in very high 
yields (Scheme 2.3). Indeed, it was possible to make 9 in multi-gram quantities and 
from this intermediate a divergent synthesis could be carried out. This was achieved 
by reacting 9 with the appropriate amine in a solution of'PrOH and /»-formaldehyde. 
Unfortunately, the products formed from these reactions were obtained in low yield, 
and purification via flash column chromatography was deemed as unsuitable for 
industrial scale-up.
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O H 2c
NEt2
•OH
N H Q
/ N H E t
/ ^ / O H
N H Q
3c
N H 'B u
N H Q
4c
Scheme 2.3 “Reverse route” for the formation of isoquine analogues.
Reagents and conditions: (i) EtOH, 4,7- dichloroquinoline (1.2 eq), 80 °C, 16 h (90 
%); (ii) (CH20)n (1.1 eq), z'PrOH, (2c) -NHEt2 (39 %), (3c) -N H 2Et (17 %), (4c) - 
NH2'Bu (9.8 eq), 80 °C, 16 h. Yields obtained: (2c) (39 %), (3c) (17 %), (4c) (42 %)
2.3.1.3 Optimisation o f Conditions -  The “Reverse Route ”
NTBISQ was initially prepared at GSK via the three-step “forward route” 
described previously (Chapter 2, section 2.3.1.1) (GlaxoSmithKline, 2006). 
However, the synthesis proved arduous to scale up to an industrial level due to poor 
selectivity of step two, resulting in low yields and poor purity coupled with 
instability of the drug substance under the processing conditions used. Therefore, 
GSK scientists used a computational-design approach in order to optimize the 
conditions used. The parameters chosen to be analysed by the “computational design 
of experiment” (DoE) screening programmes were:
• The number of Schiff base equivalents required
• The Schiff base addition time
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• The reaction time
• The reaction temperature
• The volume of solvent
The factors favouring formation of product (NTBISQ) were first investigated 
by GSK (Figure 2.2).
DESIGN-EXPERT Plot
Logit(Pioduct) 
X = A : Inline 
Y  = B: dilution
Actual Factors 
C: temp = 35.00 
D: Tim e = 4.00 
E: Solvent =  IPA
Figure 2.2 Example of a DoE plot showing the amount of NTBISQ formed 
with different volumes of solvent and different concentrations of imine. (Figure 
obtained from GlaxoSmithKline, Stevenage, UK (GlaxoSmithKline, 2006))
The results showed that product formation was favoured by high dilution, low 
temperature, low reaction time and lower concentrations of imine. Further plots 
were carried out exploring the factors required for maximum consumption of starting 
material and also minimal formation of side products. The overall predicted optimal 
reaction conditions from these experiments were four equivalents of imine, a dilution 
of twenty-four volumes, and a temperature of 35 °C over a time period of six hours. 
The use of /PrOH was found to be the ideal solvent for isolation of NTBISQ as it was 
found that the crystalline mono-Mannich product precipitated of solution whilst the 
bis-Mannich side-product remained in the solvent. This allowed for simple filtration
6 7
to isolate the desired material. The optimized synthesis identified a route similar to 
that of ours (the “reverse route”, Scheme 2.3) (Scheme 2.4). Scientists reacted 
together compound 9 with tert butylamine in a solution of /PrOH and para­
formaldehyde. The aim was to synthesise a large quantity of NTBISQ, however, 
instead of the recovery of NTBISQ; they instead observed the formation of a cyclic 
benzoxazine compound, 10. This was a surprising result; however the target 
molecule was readily isolated by hydrolyis of 10 using HC1 in ‘PrOH. The product 
was then purified by re-crystallisation, rather than flash column chromatography, 
resulting in a yield of 91 % (Scheme 2.4). This chemistry has been scaled up to 15 
kg.
Scheme 2.4 GlaxoSmithKline optimised chemical synthesis of NTBISQ.
Reagents and conditions: (i) (CH20)n (5 eq), NH2'Bu (5 eq), /PrOH (35 vol), 40 °C, 
3 h (55 %); (ii) 20 % HC1, /PrOH (20 vol), RT, 2 h (96 %); (iii) 10 % KOH 
(ethanolic), /PrOH (15 vol), RT (91 %).
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2.3.1.4 AQ andFAQ-4
AQ, 6c was prepared, in good yield following the same synthetic pathway as 
ISQ and its analogues using 4-hydroxyacetanilde, 5 as the precursor (Scheme 2.5). 
Step one involved a Mannich reaction between the Schiff base formed from reaction 
of diethylamine and formaldehyde and the 4-hydroxyacetanilide, 5 to give the 
intermediate 6a. Hydrolysis of 6a using HC1 in EtOH afforded the amine 6b which 
could then be coupled with 4, 7 dichloroquinoline, completing the synthesis of AQ,
6c.
? H o H ?H
S  ( i ) ( | 7  N E t2 ( i i ) i f V ^ N E t , ( i i i )V V
N H C O C H 3 N H C O C H 3 n h 2
5 6 a 6 b
N E t,
Scheme 2.5 Three step chemical syntheses of amodiaquine, AQ (6c). Reagents 
and conditions: (i) EtOH, formaldehyde (2.5 eq), -  NHEt2, (1.1 eq), 80 °C, 16 h (64 
%); (ii) cone. HC1, EtOH, 80 °C, 5 h (89 %); (iii) 4,7 dichloroquinoline (1.1 eq), 
EtOH, 80 °C, 16 h (76 %).
The synthesis of FAQ-4, 8d involved four steps, commencing with a radical 
bromination of 7, employing trifluoronitrotoluene as the solvent (Scheme 2.6).
AIBN was used as a radical initiator and A-bromosuccinamide as a source of 
bromine. Step two involved nucleophilic substitution at the C-Br bond of 8a using 
tert butylamine in acetonitrile, in the presence of potassium carbonate to afford 8b as 
an orange oil. The third step of the synthesis was a Sn/HCl reduction of the nitro 
group to the primary amine 8c, and this was achieved in a good yield of 74 %. The 
final step involved coupling of the 4-aminophenol compound to 4, 7 
dichloroquinoline in the presence of ethanol to yield the product, 8d, in good yield.
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Scheme 2.6 Four step chemical synthesis of N-tert-bxtfy\ fluoro amodiaquine 
(FAQ-4), (8d). Reagents and conditions: (i) trifluoronitrotoluene, NBS (1.4 eq), 
AIBN (0.1 eq), 100 °C, 24 h (47 %); (ii) ACN, -NH2'Bu (1.1 eq), K2C 03 (1.1 eq), 83 
°C, 24 h (59 %); (iii) cone. HC1, Sn (2eq), 100 °C, 5 h (74 %); (iii) 4,7 
dichloroquinoline (1.1 eq), EtOH, 80 °C, 16 h (66 %).
2.1.3.5 Radiometric Syntheses o f [3HJ-NTB1SQ, [^H]-FAQ-4 and [3HJ-CIAQ-4
NTBISQ (4c*), FAQ-4 (8d*) and C1AQ-4 (lid*) were each radiolabelled 
using [3H]-4, 7 dichloroquinoline (Scheme 2.7). The reaction involved the coupling 
of the relevant amino side-chain (4b, 8c or 11c) with tritium-labeled 4, 7 
dichloroquinoline and non-radiolabeled 4, 7 dichloroquinoline. Only one step was 
required for this coupling reaction and so minimal loss of the radiolabel occurred 
during the synthesis. Each compound was analysed by radiometric HPLC and LC- 
MS using a mobile phase of acetonitrile (10-50 %, 30 min) and trifluoroacetic acid 
(TFA) (0.1 %) at a flow rate of 0.9 mL/min (Figure 2.3). NTBISQ was seen to elute 
at retention time (Rt) = 12.6 min, whilst the fluoro analogue eluted at Rt = 13.8 min 
and the chloro at Rt = 13.6 min. Radiochemical purity of each compound was 
observed to be greater than 97 %. LC-MS analysis located co-eluting pairs of 
chlorine isotope peaks in the positive-ion mass chromatograms for m/z 356 ([3H]- 
NTBISQ [M+l]+), m/z 358 ([3H]-FAQ-4 [M+l]+) and m/z 374 ([3H]-ClAQ-4
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[M+l]+) (Figure 2.4). The parent compound was seen together with a fragment 
representing loss of the tert butylamino side-chain (-56 amu).
r 2
NHo
4b, 8c, 11c 4c*,8d*, lid *
4 R] = CH2NH(CH3)3, R2 = OH 
8 Rj = F, R2 = CH2NH(CH3)3 
11 R, = Cl, R2 = CH2NH(CH3)3
• 3Scheme 2.7 General scheme outlining the radiometric synthesis of [ H]- 
NTBISQ, [3H] -FAQ-4 and [3H]-ClAQ-4. Reagents and conditions: 4b (1 eq), 8c 
(1 eq), 11c (1 eq), 4,7 Dichloroquinoline (0.8 eq), [3H] -4 ,  7 dichloroquinoline 
(9.9.pg/mL, 20 Ci/mmol), EtOH, HC1 (20 pL), 80 °C, 16 h.
[JH)-NTBISQ, -NTBFA, -NTBCIA
Hypurity Elite, ACN [10-50 %, 30 min] TFA (0.1 %)
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Figure 2.3 Positive-ion electrospray mass chromatograms corresponding to 
(A) [3H]-ClAQ-4 (B) [3H]-FAQ-4 and (C) [3H]- NTBISQ.
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of (A) [3H]-ClAQ-4 (B) [3H]-FAQ-4 and (C) [3H]-NTBISQ
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2.3.2.1 In Vitro Antimalarial Activity
All of the compounds synthesized were evaluated by The School of Tropical 
Medicine, Liverpool using standard procedures (Berenbaum, 1978; Desjardins et al., 
1979; Lambros et al., 1979; Trager et al., 1976).
It was decided that the in vitro activities of NTBISQ, FAQ-4and C1AQ-4 
should be evaluated along side the related 4-aminoquinolines CQ, AQ, ISQ and 
desISQ in order to define the activity range of an isoquine family. Four strains of P. 
falciparum were used; the CQ-resistant un-cloned K1 and CQ-resistant TM6 strains, 
and the CQ-sensitive HB3 and 3D7 strains (Table 1.4).
2.3.2 Pharmacodynamics of the 4-Aminoquinoline Series
IC 50 nM
Drug K1 HB3 3D7 TM6
CQ 183.2 ±11.1 14.9 ±3.9 19.4 ± 1.9 75 ±22.1
AQ 15.1 ±9.4 9.6 ±3.7 11.2 ± 1.4 7.2 ±3.3
ISQ 17.6 ±7.0 12.6 ±4.7 11.6 ± 2.3 ND
DesISQ 6.0 ±8.0 9.0 ±4.1 9.2 ±3.1 ND
NTBISQ 13.2 ± 3.2 12.6 ±5.3 11.2 ±2.2 ND
FAQ-4 20.2 ±4.6 13.2 ±3.4 11.2 ± 2.5 ND
C1AQ-4 ND 10.1 ±3.2 ND 3.0 ±2.2
Table 1.4 In vitro antimalarial activities of CQ, AQ, ISQ, DesISQ, NTBISQ, 
FAQ-4 and C1AQ-4. Data obtained from The School of Tropical Medicine, 
Liverpool. Values expressed as IC50 (nM) against four strains of the malaria parasite, 
P. falciparum: the CQ-resistant strains K1 and TM6 and the CQ-sensitive strains 
HB3 and 3D7. ND = No data.
All compounds showed good antimalarial activity against all three strains of 
P. falciparum tested. NTBISQ showed potent growth inhibition of both CQ- 
sensitive and CQ-resistant parasite strains, with IC 50 values ranging between 11.2 
and 13.2 nM respectively. NTBISQ exhibited similar activity to AQ against all three 
strains tested
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It was anticipated that FAQ-4 and C1AQ-4 might be less active against 
malaria than their non-halogenated analogues due to the fact they are less basic. This 
reasoning was based on the fact that the 4-aminoquinolines cross the wall of the 
human red blood cell at pH 7.4 and enter the acidic compartment of the parasite 
along a concentration gradient. As the molecule passes along the gradient it becomes 
protonated and can no longer pass back through the wall of the erythrocyte, 
becoming “ion trapped”. In doing so it accumulates inside the parasite DV to levels 
much higher than those in the circulating blood where it can then bind to free heme, 
preventing polymerisation to hematin (Chou et al., 1980; Ferrari et al., 1990; 
Sullivan et a l, 1996). Based on the mechanism of action of these compounds, the 
less basic the molecule, the less accumulation within the parasite DV might be 
expected (Ginsburg et al., 1992). However, data obtained so far, clearly suggests 
that FAQ-4 and C1AQ-4 are as active as their non-halogenated counterparts.
Cross resistance is the subsequent resistance of the parasite to related 
antimalarials. The results in this section demonstrate a lack of cross-resistance 
between NTBISQ and CQ, as indicated by the similar IC50 values, in the nanomolar 
range, obtained across the three strains of malaria tested. This was in stark contrast 
to those obtained for CQ whereby it could be seen there was a marked difference 
between the IC50 values for the K1 strain versus the 3D7 and HB3 strains. The IC50 
value for K1 was more than 9-fold higher than the values obtained against the 3D7 
and HB3 strains. The lack of cross-resistance was found to be consistent for the other 
ISQ and AQ derivatives tested.
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2.3.1.2 In Vitro Therapeutic Index
The compounds synthesized were subjected to a standard battery of in vitro 
cytotoxicity assays at GSK, Tres Cantos. The in vitro selectivity ratio was studied in 
terms of whole cell inhibition, comparing activity against P falciparum versus 
cytotoxicity in various mammalian cell lines such as hamster ovary cells, monkey 
kidney cells, human leukemia cells, human lung cells, mouse glial cells, rat liver 
cells and human hepatocytes (Table 1.5).
The potential cytotoxicity of NTBISQ was studied in immortalised cell lines 
derived from target organs for in vivo toxicity (Table 1.5). Mammalian cells were 
» incubated with the compounds for twenty-four hours, and cell damage was
determined using an oxidation-reduction marker as an indication of cell energy 
metabolism. Results were compared to the 4-aminoquinoline series as before. At 
present no data has been received for FAQ-4 or C1AQ-4.
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Cell Line CQ AQ
Tox50 ; 
ISQ
jM
desISQ NTBISQ
Therapeutic
Index
NTBISQ
CHO (ovary, 
hamster) >96.9 >70.2 113.2 71.1 84.3 7527
Cos-1 (kidney, 
monkey) >96.9 >70.2 68.5 65.6 81.5 7276
HL-60
(promyelocytic
leukemia,
human) >96.9 >70.2 61.8 48.8 50.7 4527
MRC5 (lung, 
human) >96.9 >70.2 96.9 45.8 42.1 3759
Neuro 2 A 
(glial, mouse) >96.9 >70.2 60.1 47.6 59 5268
MH1C1 (liver, 
rat) >96.9 >70.2 45.2 <18.3 <16.9 <1509
Hep G2 (liver, 
human) >96.9 >70.2 60.8 45.8 42.1 3759
Table 1.5 In vitro cytotoxicity of NTBISQ and the 4-aminoquinoline series.
Data obtained from a pre-clinical, pharmacokinetics study at GlaxoSmithKline, Tres 
Cantos. Data are expressed as mean ± SD (n = 3). Maximum solubility in the assay 
conditions: AQ 70.2 pM, CQ 96.9 pM, ISQ 14.1 pM, desISQ >30.5 pM and 
NTBISQ 28.9 pM.
It can be seen immediately that the cytotoxicity values obtained for NTBISQ 
against the mammalian cell lines employed were at least 1500 times greater than 
values required to kill the malarial parasite (Table 5). NTBISQ was shown to have 
Tox5o values ranging from 1.1 - 5.7-fold lower than CQ. However, the fact remains 
that the in vitro therapeutic window for NTBISQ was still very high across all cell 
lines tested. These results illustrate that the concentration of NTBISQ required to 
kill the parasite is much higher than that required to kill each of the mammalian cell 
lines. This shows that not only is NTBISQ an extremely effective antimalarial in 
vitro, but it is also highly selective for the malaria parasite.
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2.3.1 Pharmacokinetic Data
2.3.1.1 Oral Bioavailability
The term bioavailability is defined as the fraction of an ingested dose of a 
drug that gains access to the systemic circulation. It may be low if absorption is 
incomplete, or if the drug is metabolised in the gut wall or liver before reaching the 
systemic circulation (Rang et al., 1999).
The oral bioavailabilities F (%) of ISQ, desISQ, NTBISQ and FAQ-4 were 
determined in a study, evaluating four species of animal, by GlaxoSmithKline. The 
data received indicated that less than 21 % of ISQ reached the systemic circulation 
after oral dosing (Table 1.6).
Species ISQ F (%) desISQ F (%) NTBISQ F (%) FAQ-4 F (%)
Mouse 21 100 100 37
Rat 17.0 ±4.0 60 ±26 89 ± 12 100
Dog NQ NE 92 ± 13 ND
Monkey ND 40 ± 14 100 25 ±5
Table 1.6 Oral bioavailability of ISQ, desISQ, NTBISQ, FAQ-4 in animals.
Data obtained from a pre-clinical, pharmacokinetics study at GlaxoSmithKline, Tres 
Cantos, Spain. Data are expressed as mean ± SD (n=3). NE = Not estimated (emesis 
observed in oral leg may have resulted in decreased oral exposure). NQ = Not 
quantifiable. ND = no data.
As previously discussed (Chapter 1, section 1.5.2), ISQ is in fact, a pro-drug 
of desISQ, undergoing extensive P450-mediated dealkylation via the CYP2C8 
enzyme (O'Neill et al., 2003). DesISQ has been shown to have excellent 
bioavailability in the mouse and more moderate bioavailability across other species. 
Emesis in the dog study precluded an estimate of the oral bioavailability of this 
species.
The stand out candidate based on these sets of data was NTBISQ. The oral 
bioavailability of NTBISQ across all four species was greater than 89 % suggesting
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that almost all of the drug would reach the systemic circulation after oral dosing. 
The implications of these tests revealed NTBISQ as the more favourable candidate to 
go forth into further clinical testing.
2.3.1.2 Blood Clearance
The levels of drug in blood are important in giving a composite picture of the 
disposition of a compound. A high clearance value may equate to a faster rate of 
metabolic degradation due to clearance being an expression of the amount of drug, in 
a volume of plasma that has been metabolised in unit time (Rang et al., 1999).
The blood clearance values of ISQ, desISQ, NTBISQ and FAQ-4 are shown 
below (Table 1.7).
Species Blood
Clearance of 
ISQ
(mL/min/kg)
Blood
Clearance of 
desISQ 
(mL/min/kg)
Blood
Clearance of 
NTBISQ 
(mL/min/kg)
Blood
Clearance of 
FAQ-4 
(mL/min/kg)
Mouse 21.9 43.5 17.2 40.4
Rat 89.2 ±4.3 61.5 ± 21.6 25.9 ±4.9 35 ±4.2
Dog 151.4 ± 23.6 11.5 ± 2.6 6.39 ± 1.57 ND
Monkey ND 49.4 ±2.6 14.5 ±0.7 17.9 ±7.8
Table 1.7 Blood clearance of ISQ, desISQ, NTBISQ and FAQ-4 in animals.
Data obtained from a pre-clinical, pharmacokinetics study at GlaxoSmithKline, Tres 
Cantos, Spain. Data are expressed as mean ± SD (n=3). For composite mouse 
studies, variability of parameters has not been estimated. ND = No data.
Clearance values of desISQ, NTBISQ and FAQ-4 were shown to be moderate 
across all four species. ISQ appeared to be cleared from the blood at a very high rate 
(exceeding that of blood flow in the liver) in the rat and dog with values close to that 
of CQ (140 mL/min/kg) (Augustijins et al., 1992). This is consistent with the fact 
that ISQ is rapidly metabolised to desISQ in vivo.
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DesISQ had substantially lower blood clearance compared to ISQ in the 
mouse and the rat. In the dog, blood clearance was about 2-fold higher than that of 
NTBISQ, the clearance of which was approximately 40 % of liver blood flow in all 
species.
2.3.1.3 Plasma Half-Life o f NTBISQ
The plasma half-life of a drug can be defined as the time taken for the 
concentration of a drug in plasma to decrease by half from a given point. It reflects 
the rates at which the various dynamic processes, distribution, excretion and 
metabolism are taking place in vivo (Timbrell, 2000).
The half-life of NTBISQ was studied in mouse, rat and monkey (Table 1.8). 
The values obtained across all four species are moderate and it can be estimated that 
the half-life in humans may be approximately 9 hours.
Species NTBISQ T,/2(h)
Mouse 3.3 ± 1.2
Rat 7.9 ±4.3
Dog 14.2 ± 3.1
Monkey 9.0 ±4.2
Human N/A
Table 1.8 Half-life of NTBISQ in four different species of animals. Data 
obtained from a pre-clinical, pharmacokinetics study at GlaxoSmithKline, Tres 
Cantos, Spain. Data are expressed as mean ± SD (n=3).
The literature half-life values of AQ and CQ in humans are 5.2 ±1.7 hours 
and 275.7 ± 110.8 hours respectively (Gustafsson et al., 1983; Winstanley et al., 
1987). The long half-life of CQ must be noted as it has been suggested that a long 
terminal half-life is a considerable factor in drug-resistance. A long half-life means 
that the drug may be present in the body at sub-therapeutic concentrations for long
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periods of time, allowing for the increase in selection pressure for resistant mutants 
(Watkins et al., 1993).
2.3.2 Conclusions
This chapter clearly demonstrates the highly efficient chemical and 
radiochemical syntheses of a number of ISQ and AQ analogues. The pathways used 
were inexpensive, facile and led to generally good yields of product. In the case of 
the ISQ analogues, in particular NTBISQ, a second route was investigated, and was 
further optimized by our industrial partners GlaxoSmithKline. This resulted in the 
ultimate large-scale formation of 15 kg of NTBISQ.
The efficient synthesis of these compounds has led to a preliminary 
comparison of four promising antimalarial drugs and their possibility for further 
development. Each compound was assessed for antimalarial activity against both 
CQ-sensitive and CQ-resistant parasites. All showed excellent activity against all 
three strains of malaria, notably against the CQ-resistant strain, K1 with no signs of 
cross-resistance, as with CQ.
The 4-aminoquinoline compounds were analysed against various mammalian 
cell lines for toxicity. Whilst the Tox50 values for NTBISQ were lower than that of 
CQ, the in vitro therapeutic index remained greater than 1500 showing that NTBISQ 
was selective for the malaria parasite over mammalian cell lines.
The oral bioavailability of NTBISQ was shown to be highly impressive 
across all four species, with an average value of 95 %. FAQ-4 showed 100 % 
bioavailability in the rat; however the results were lower in the mouse and monkey.
These studies have generated vital data that validated the selection of 
NTBISQ as a lead compound for progression into rigorous metabolism and definitive
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safety assessment studies. FAQ-4 and C1AQ-4 were selected as back-up compounds, 
and investigation into their metabolism has also been carried out.
The forthcoming chapters of this thesis will present an in depth study of the 
in vivo metabolic fate of NTBISQ, FAQ-4 and C1AQ-4, with comparisons made to 
CQ, AQ and ISQ.
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CHAPTER 3
THE IN  VIVO  METABOLISM AND DISTRIBUTION OF CHLOROQUINE 
AND AMODIAQUINE IN RATS
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3.1 INTRODUCTION
Chloroquine (CQ) has been used in the treatment of malaria for over 50 years 
and its disposition in man has been well documented. As discussed in the 
introduction to this thesis, there is increasing resistance to CQ by malaria parasites, 
and this is driving an ever increasing urgency to find new antimalarials.
In man, CQ is rapidly and completely absorbed from the gastrointestinal tract 
after oral administration with peak plasma levels being attained 1 -  3 hours after a 
single oral dose (Gustafsson et al., 1983). CQ is found mainly as the parent 
compound in the tissues and plasma of humans, but the major route of metabolism is 
cleavage of the alkyl groups to its desethyl (desCQ) and bisdesethyl (bisCQ) 
analogues (Figure 3.1) (Ademowo et al., 2000; Gustafsson et al., 1983; Hellgren et 
al., 1989; McChesney et al., 1967; Projean et al., 2003). This dealkylation process 
does not result in loss of antimalarial activity as the main metabolite, desCQ, has 
appreciable antimalarial activity against CQ-sensitive strains and has been shown to 
have an additive effect on the antimalarial action of CQ (Aderounmu, 1984).
BisDesethylCQ
Figure 3.1 Chloroquine (CQ) and desethyl chloroquine iV-dealkylation 
pathways in humans (Minzi et al., 2003).
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Although CQ is thought to be relatively well tolerated in the treatment of 
malaria; several cases of ocular toxicity and have been noted with the long-term 
usage of the drug, for example in patients being treated for rheumatism (Santaella et 
al., 2007). The basis for this toxicity lies with CQ having a distinct affinity for 
melanin-containing tissues in pigmented animals such as the iris, skin and hair which 
can lead to accumulation (Kasuya et al., 1976; Lindquist et al., 1972; Tanaka et al., 
2004).
In addition to the ocular toxicity linked to the long-term use of CQ, 
phospholipidosis is also a concern. Phospholipidosis is a generalised condition in 
humans and animals that is characterised by the intracellular accumulation of 
phospholipids and the concurrent development of concentric lamellar bodies (Reasor 
et al., 2001). There are an abundance of data providing mechanisms for the 
induction of phospholipidosis; however, the process is likely to be complex and may 
differ from one drug to another (Hostetler, 1984; Martin et al., 1989; Reasor et al., 
2006). Many drugs containing a cationic lipophilic structure are capable of inducing 
phopholipidosis in cells during in vivo administration (Figure 3.2). Drugs with this 
kind of structure typically contain a hydrophobic moiety, such as an aromatic and/or 
aliphatic ring structure, which may be halogen substituted and a hydrophilic domain 
comprising of an amine group (Figure 3.2). CQ and the other 4-aminoquinolines in 
this study can clearly be seen to have a structural alert, common to that of the drugs 
shown which are known to induce phospholipidosis, and therefore have potential to 
cause the disorder (Figure 3.2) (Figure 3.3). Indeed, evidence for of CQ-induced 
phospholipidosis in the liver has previously been reported in the literature (Harder et 
al., 1980; Shaikh etal., 1987).
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The functional consequences of this biochemical disorder for cellular and 
tissue function are not yet fully understood and the general consensus is that the 
condition is an adaptive response rather than a toxicological manifestation; however 
additional studies are needed. Until this is issue is resolved, concerns about 
phospholipidosis will continue to exist at regulatory agencies (Reasor et al., 2006).
Figure 3.2 Structures of representative drugs that can induce 
phospholipidosis in vivo. The hydrophilic moiety of each molecule has been 
highlighted in red.
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Figure 3.3 Structures of chloroquine (CQ), amodiaquine (AQ), N-tert butyl 
isoquine (NTBISQ), N-tert butyl fluoro amodiaquine (FAQ-4) and N-tert butyl 
chloro amodiaquine (C1AQ-4). Structural analogues of chloroquine share the same 
metabolic alert for potential induction of phospholipidosis.
There has been a great deal of work regarding the in vivo metabolic fate of 
CQ in humans, however relatively little work in rats has been published. We wished 
to make a direct comparison of the chemical aspects of the metabolism and 
distribution of AQ and CQ. Therefore the work presented in this chapter is an 
investigation of the metabolism and distribution of [l4C]-CQ in the rat. The results 
could then be related directly to previous work on the metabolism of [3H]-AQ in rats 
using exactly the same experimental model (Randle, 2001). In addition it is of 
interest to compare the metabolic pathways in the rat and man. The rat and human 
models can then be compared directly in order to assess the validity of the rat model 
for in vivo studies. This work also shows a comparative study of the cytotoxicity of 
CQ and AQ in rat hepatocytes.
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3.2 MATERIALS AND METHODS
3.2.1 Materials
[14C] -  CQ (54 mCi/mmol; radiochemical purity by HPLC 98.9 %) was a gift, 
generously donated by GlaxoSmithkline, (Stevenage, UK). Tissue solubilizer-450 
(0.5 N quaternary ammonium hydroxide in toluene) was purchased from Beckmann 
Chemicals, (Bremen, Germany). Ultima Flo and Ultima Gold scintillant were from 
Packard Bioscience BV, (Groningen, Netherlands). HPLC grade solvents were 
products of Fisher Scientific, (Loughborough, Leicestershire, UK). All other 
chemicals were purchased from Sigma Aldrich Co. (Poole, United Kingdom).
Adult male Wistar rats (200-400 g) were obtained from Charles River 
(Margate, UK). The protocols described were undertaken in accordance with criteria 
outlined in a licence granted under the Animals (Scientific Procedures) Act 1986 and 
approved by the University of Liverpool Animal Ethics Committee.
3.2.2 Methods
3.2.2.1 In Vivo Metabolism o f [UCJ-CQ in the Rat (.5 h)
Adult male Wistar rats (250 -400 g n = 4) were anaesthetised with urethane 
(1.4 g/mL in isotonic saline; 1 mL/kg, i.p.). Polyethylene cannulae were inserted 
into the trachea, femoral vein and common bile duct and the penis was ligated. 
Drug-blank bile was collected for approximately 20 minutes before treatment. [14C]- 
CQ (54 pmol/kg; 20 pCi/rat) was dissolved in saline (0.5-1 mL depending on animal 
weight) and was injected over 10 min (z'.v.). Bile was collected hourly for a time 
period of 5 h into pre-weighed eppendorfs. Samples were weighed after collection to 
determine the extent of biliary secretion and stored at -30 °C until analysis by LC- 
MS.
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After 5 h, urine was aspirated from the bladder and transferred to a pre­
weighed eppendorf tube and a cardiac puncture was performed. The blood was 
centrifuged (1000 g, 6 min) and the plasma transferred to a separate tube. The 
plasma from each experiment was pooled together and then proteins were removed 
via the exhaustive addition of MeOH (5 eq vv) followed by centrifugation (1200 g, 
10 min). The supernatant was removed and concentrated by evaporation before re­
dissolving it in MeOH (200 pL). The plasma and urine samples were stored at -30 
°C until analysis by LC-MS.
Aliquots of bile and urine (30 pL) were mixed with scintillant (4 mL) for 
determination of radioactivity.
3.2.2.2 LC-MS Analysis o f Bile, Urine and Plasma Samples
Aliquots of bile, urine and plasma (100 pL) were analysed at room 
temperature on a Hypersil 5-pm HyPurity Elite C-18 column (150 x 4.6 mm; 
Thermo Hypersi 1-Keystone, Runcorn, Cheshire, UK) with a gradient of acetonitrile 
(5-40 % over 30 min) in trifluoroacetic acid (0.1 %, v/v). The LC system consisted of 
two Jasco PU980 pumps (Jasco UK, Great Dunmow, Essex, UK) and a Jasco HG- 
980-30 mixing module. The flow rate was 0.9 mL/min. Eluate split-flow to the LC- 
MS interface was ca. 40 pL/min. A Quattro II mass spectrometer (Micromass MS 
Technologies, Manchester, UK) fitted with the standard co-axial electrospray source 
was used in the positive-ion mode. Nitrogen was used as the nebulizing and drying 
gas. The interface temperature was 80 °C; the capillary voltage, 3.9 kV. Spectra 
were acquired between m/z 100-1050 over a scan duration of 5 s. Fragmentation of 
analyte ions was achieved at a cone voltage of 50-70 V. Data were processed with 
MassLynx 3.5 software (Micromass). Radiolabelled analytes in the remainder of the
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eluate were detected with a Radiomatic A250 flow detector (Packard, Pangbourne, 
Berkshire, UK). Eluate was mixed with Ultima-Flo AP scintillant (Packard 
Bioscience BV, Groningen, Netherlands) at 1 mL/min.
3.2.2.3 In Vivo Retention Studies o f [UC]-CQ in the Rat (24 h)
Adult male Wistar rats (200-400 g, n=4) were administered a solution of 
[14C]-CQ (54 mol/kg; 20 pCi/rat) dissolved in saline (0.5-1 mL; i.p). The animals 
were then transferred to individual metabolism cages equipped with a well for 
collecting urine and faeces. The rats were allowed full access to food and drink for a 
24 h period before administration of a lethal dose of pentabarbitone.
Aliquots of urine (30 pL) were collected and mixed with scintillant for 
determination of radioactivity. The collected faeces were weighed and dissolved in 
distilled water for a period of 16 h before determination of radioactivity using the 
same method as described earlier (Chapter 3, Section 3.2.2.6). The major organs 
were then removed and assessed for radioactivity.
3.2.2.4 In Vivo Retention Studies o f [I4C]-CQ in the Rat (48 h)
Adult male Wistar rats (n = 4) were administered a solution of [14C]-CQ (54 
mol/kg; 20 pCi/rat) dissolved in saline (0.5 -  1 mL; i.p.). The animals were kept in a 
normal animal cage for a period of 24 h before they were transferred to individual 
metabolism cages equipped with a well for collecting urine and faeces. The rats 
remained in the metabolism cages for a further 24 h, with full access to food and 
drink, before administration of a lethal dose of pentabarbitone.
Aliquots of urine (30 pL) were collected and mixed with scintillant for 
determination of radioactivity. The collected faeces were weighed and dissolved in
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distilled water for a period of 16 h before determination of radioactivity using the 
same method as described (Chapter 3, Section 3.2.2.6). The major organs were then 
removed and assessed for radioactivity.
3.2.2.5 In Vivo Retention Studies o f [UC]-CQ in the Rat (168 h)
Adult male Wistar rats (n = 4) were administered a solution of [14C]-CQ (54 
mol/kg; 20 pCi/rat) dissolved in saline (0.5 -  1 mL; i.p). The animals were kept in a 
normal animal cage for a period of 168 h with full access to food and drink before 
administration of a lethal dose of pentabarbitone. The major organs were then 
removed and assessed for radioactivity.
3.2.2.6 Tissue Distribution o f [I4C]-CQ in the Rat
At the end of the relevant time-point (5 h, 24 h, 48 h or 168 h) the animals 
were sacrificed by a lethal dose of pentabarbitone and the major organs were excised 
(brain, eyes, heart, lungs, liver, kidneys, spleen, testes and skin) and stored at -30 °C.
Duplicate portions (50-100 mg) of the tissues were weighed and solubilized 
in tissue solubilizer (0.75 mL) at 50 °C for 16 h. The solutions were decolourised 
with hydrogen peroxide (200 pL) over 1 h and then neutralised using glacial acetic 
acid (30 pL) before leaving in the darkness for 16 h to prevent chemoluminescence. 
Ultima Gold scintillant (10 mL) was added before the radioactivity was determined 
by scintillation counting.
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3.2.2.7 Cytotoxicity o f [,4C]-CQ in Isolated Rat Hepatocytes
Male Wistar rats (200 - 250g) (n = 3) were terminally anaesthetised with 
pentobarbitone sodium (90mg/kg in isotonic saline i.p.). Hepatocytes were isolated 
using a two-step collagenase perfusion method adapted from that of Guguen- 
Guillouzo et al (Guguen-Guillouzo et al., 1986). The abdomen was opened and the 
liver cannulated through the portal vein using a gauge catheter. Before perfusion, the 
heart was removed to allow free loss of perfusion buffers. The liver was washed 
with calcium-free HEPES buffer for 10 mins at a flow rate of 40ml/min. The liver 
was then perfused with digestion buffer, a mixture of wash buffer with 5 % CaCk 
solution, for 6 -  10 mins. The digested tissue was then excised and placed in a Petri 
dish containing wash buffer and DNAase (0.1 % w/v). The tissue was anchored and 
the Glison’s capsule was disrupted and disturbed to release the cells. The cell 
suspension was filtered through gauze to eliminate cell debris, blood and sinusoidal 
cells. The cells were washed three times in DNAase wash buffer before re­
suspending in incubation buffer (HEPES buffer and MgS04.7H2Û (0.25 % w/v)). 
Cell viability was then assessed microscopically using the trypan blue exclusion test.
The cells were then incubated with various concentrations of either CQ or 
AQ for a period of 6 hours before determining cell viability in the presence of test 
compound using the trypan blue exclusion test.
3.2.2.8 Statistical Analysis
All results are expressed as mean ± standard error of the mean (SEM). 
Values to be compared were analysed for non-normality using a Shapiro-Wilk test. 
Student t-tests were used when normality was indicated. A Mann-Whitney U test 
was used for non-parametric data. For analysis of sets of data with variance, a 1-way
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analysis of variance (ANOVA) test was used for parametric data and a Kruskell- 
Wallis test was used for non-parametric data. All calculations were performed using 
StatsDirect statistical software, results were considered to be significant when P < 
0.05.
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3.3 RESULTS AND DISCUSSION
3.3.1. LC-MS Analysis of In Vivo Metabolites of [14C]-CQ in the Rat
Following i.v. administration of [14C]-CQ (54 pmol/kg, 20 pCi), the recovery 
over 0 -  5 h in bile was 1.84 ± 0.26 % and in urine 6.99 ± 1.43 % of the dose.
[14C]-CQ was excreted mainly as the parent compound, II, in urine [retention 
time (Rt) 14.14 min] and comprised 74.63 ± 1.33 % of the total radioactive 
metabolites produced during urinary excretion (Figure 3.4).
Two other urinary metabolites were identified by LC-MS analysis, which 
located co-eluting pairs of chlorine isotope peaks in the positive-ion mass 
1 chromatograms for m/z 292 and 336 [metabolites I (Rt 12.52 min) and III (Rt 16.77
min) respectively] (Figures 3.5 and 3.6). It was deduced that metabolite I was the 
desethyl analogue of CQ comprising 5.97 ± 2.67 % of the metabolites eliminated 
(Figure 3.5A). Metabolite III was found to be an oxygenated version of the parent 
compound ([M+l+16]+) comprising 19.40 ± 3.29 % of the total metabolites 
eliminated. Inspection of the fragmentation pattern of III revealed that oxygenation 
had occurred within the quinoline ring, rather than the amine side chain, leading to 
the assumption that the N-oxide had been formed (Figure 3.6B) (Figure 3.11).
A common fragment seen in all spectra was loss of the amine side-chain, 
represented by loss of 73 atomic mass units (amu) (Figure 3.6).
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Figure 3.4 HPLC radiochromatogram of the urinary metabolites of [14C]-CQ
(54 pmol/kg, 20 pCi; 1 h collection) where I represents an unknown minor 
metabolite, possibly desethylCQ, the shaded peak, II represents the parent compound 
and III represents CQ A-oxide.
(14C]-CQ Urine Rat A
H> purity Elite, ACN (5 - 40 % ,  30 min] (0.1 %  TFA)
A  MES95 Scan ES+
Figure 3.5 Positive-ion electrospray mass chromatograms corresponding to
(A) m/z 320[14C]-CQ (parent compound) m/z 292, (B) m/z 336, [l4C]-CQ-iV-oxide 
and (C) [14C]-desethylCQ excreted in the urine of male Wistar rats 5 h after dosing 
i.v. with [14C]-CQ (54 pmol/kg, 20 pCi).
9 7
[14C1-CQ Urine, RatA
Figure 3.6 Positive-ion electrospray mass spectra showing the fragmentation
of (A) [UC]-CQ eluted as parent compound and (B) [,4C]-CQ as its jV-oxide excreted 
in the urine of male, Wistar rats 5 h after dosing i.v. with [14CJ-CQ (54 pmol/kg, 20 
pCi).
In the bile, two major metabolites and one minor metabolite were resolved by 
HPLC (Figure 3.7). The major metabolites were determined by LC-MS analysis. 
Co-eluting pairs of chlorine isotope peaks in the positive-ion mass chromatograms 
for m/z 320 and m/z 336 were identified. The peak of m/z 320, metabolite II was 
identified as parent compound (CQ, Rt 17.62 min) (Figure 3.8B). This was seen 
together with the fragment m/z 247 which represented loss of the diethylamino side-
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chain (Figure 3.9A). Metabolite III (Rt 19.41 min) was found to be common to both 
bile and urine and was an oxygenated metabolite of CQ of m/z 336 (Figure 3.8A). 
The fragmentation pattern of the oxygenated species III indicated that the vV-oxide 
had been formed as loss of the amino side-chain did not result in the tandem loss of 
oxygen (Figure 3.8B). The minor metabolite IV could not be identified as it was not 
sufficiently abundant to yield diagnostic fragments by cone-voltage fragmentation in 
the source of the mass spectrometer. The main route of elimination in bile was N- 
oxidation with metabolite III being observed to make up 67.94 ± 10.56 % of the total 
radioactive products. The parent compound II was found to comprise 30.33 ± 6.23 
% of the total metabolites formed whilst the unknown, IV, comprised less than 2 % 
of the dose eliminated (Table 3.1).
Figure 3.7 HPLC radiochromatogram of the biliary metabolites of [14C]-CQ
(54 pmol/kg, 20 pCi; 1 h collection) where II represents the parent compound, 
III represents CQ iV-oxide and IV represents an unknown minor metabolite.
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[14C]-CQ Bile Rat A, lh
Hypurity Elite, ACN [5-40 °-o, 30 mm] (0.1 % TFA)
AES96 Scan ES+
Figure 3.8 Positive-ion electrospray mass chromatograms corresponding to 
(A) m /z 336, [14C]-CQ-iV-oxide metabolite and (B) m /z 320 [14C]-CQ (parent 
compound) excreted in the bile of male Wistar rats dosed Lv. with [14C]-CQ (54 
pmol/kg, 20 p.Ci).
1 0 0
Scan ES«- 
5 i?e3
Hvpuritv Elite ACN [5-40 %, 50 min] (0.1 % TFA)
[M + irAES96 206 (17 535) 320
[14CJ-CQ Bile RaJ A, 1 h
jiCi, 1 h).
A notable feature of the chromatograms of the metabolites produced in bile 
was the later retention times in relation to analogous peaks eluted in urine and also 
that of the chromatogram produced for the [14C]-CQ standard (Figures 3.10A-C) 
(Table 3.1). For example, CQ eluted at around 14 minutes in urine, however in bile 
it eluted at a retention time of almost 18 minutes. This shift in retention time could
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not be explained and it was assumed that some form of interaction between the 
metabolites of CQ and the endogenous components of bile had occurred
[14C1-CQ Bit. R* A, 1 b Eke ACN (5 ■ 40 H. *0 me] OTA 0 1
(I4C) C Q lm c , R aA  
[14CJ-CQ Sttndatd
Figure 3.10 Positive-ion electrospray mass chromatograms showing the total 
ion current for (A) peak-shifted metabolites in bile, (B) metabolites in urine 
excreted by the male, Wistar rats dosed i.v. with [14C]-CQ (54 pmol/kg, 20 pCi) 
and (C) parent compound eluting at 15.67 minutes. The red colour represents 
[ 4C]-CQ, blue represents [14C]-CQ Y-oxide, whilst yellow represents desethylCQ.
As previously described (Section 3.1), CQ is metabolised in humans by the 
Y-dealkylation pathway, to desethyl CQ and bisdesethyl CQ by cytochrome P450. 
The major constitutive P450 isoforms involved in the dealkylation process are 
CYP2C8, CYP3A4/5 and CYP2D6 (Kim et al., 2003; Li et al., 2003; Projean et al., 
2003). Rats, however, do not share all of these same isoforms. For example, in rats 
six isoforms of CYP2D have been identified by genomic analysis CYP2D1, 
CYP2D2, CYP2D3, CYP2D4, CYP2D5,CYP2D18 but not CYP2D6 (Gonzalez, 
1996; Nelson et al., 1996). This may explain why we tend to see Y-oxidation rather 
than dealkylation as the major metabolic pathway in rats.
1 0 2
Metabolite
proportion (% of
Retention Time Metabolite radiolabeled
Peak (min) m/z Identity metabolites, 0-1 h)
I 12.52 292 desethylCQ 5.97 ±2.67%
14.14 (urine), 74.63 ± 1.33 %,
II 17.62 (bile) 320 CQ 30.33 ± 6.23 %
16.77 (urine), 19.40 ±3.21 %,
III 19.41 (bile) 336 CQ-W-oxide 67.94 ± 10.96%
IV 9.75 ND ND 1.73 ±0.26%
Table 3.1 Peak numbers of metabolites correspond to the M
radiochromatographic analysis of bile and urine from rats dosed Lv. with [ C]- 
CQ (54 pmol/kg, 20 pCi). Metabolites were characterised by LC-MS. ND = No
data.
Cl
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I DesethylCQ 
MW 291 
Rt= 12.51 min 
Urine only
III C Q -N -oxide 
MW 335 
Rt= 19.41 min 
Bile and Urine
Figure 3.11 Urinary and biliary metabolites excreted by the male, Wistar rat 
after dosing with [14C]-CQ (54 pmol/kg, 20 jiCi).
Similarly to CQ, AQ is metabolised mainly to its desethyl analogue in 
humans. However, in contrast it also undergoes bioactivation to a quinone imine 
metabolite which is detoxified via glutathione conjugation (Harrison et al., 1992;
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Ruscoe et al., 1994). Previous studies in the group, using an identical experimental 
protocol to that used here, have generated data on the metabolism of AQ in rats 
(Randle, 2001).
After dosing male, Wistar rats with [3H]-AQ (54 pmol/kg, 5 pCi/rat) over 5 
hours, four peaks could be seen in the radiochromatogram representing the metabolic 
composition of urine. These peaks represented the formation of four metabolites 
(Figure 3.12). The major metabolite present in urine was the parent compound (m/z 
356) (78.05 ± 12.01 % of the radioactive metabolites) which was seen together with 
the fragment m/z 283 representing loss of the side-chain. A small amount of 
desethylAQ (m/z 328) was also recovered in urine (6.34 ±2.11 %) as well as a 
benzoic acid analogue {m/z 317; 14.63 ± 2.31 % of metabolites excreted in urine). 
Finally, a small amount of a mercapturate analogue of desthylAQ was found (m/z 
489, 0.98 ± 0.11 %).
In bile, only one metabolite could be resolved, the glutathione conjugate of 
AQ (jm/z 661) (Figure 3.12).
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Figure 3.12 Metabolic Scheme for AQ, 5 h after dosing rats with [3H]-AQ (54 
pmol/kg, 5 pCi/rat), with suggested metabolites as proposed by a study 
performed at the University of Liverpool (Randle, 2001).
3.3.1.1 Conclusions
The metabolic profile of [14C]-CQ in rats was deduced. The route of 
metabolism proved to be fairly simple, with CQ being excreted mainly as the parent 
compound in the urine. The main route of metabolism of [14C]-CQ was been found 
to be A-oxidation, as recovered in both bile and urine. There was a small amount of 
dealkylated metabolite in the urine, and potentially in the bile also, however, the 
spectrum proved to be too poorly resolved in order to determine the accuracy of this 
statement. Not only was the resolution of the biliary spectrum extremely poor, the
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retention times of the peaks representing the metabolites were shifted to higher time- 
points. We can only assume that the endogenous components of bile were causing 
this change in retention time.
Introduction of a phenyl ring system into the CQ structure, (AQ), led to a 
more complex metabolic profile in rats. A small amount of desethylAQ was 
recovered in the urine; however this was not the major route of metabolism as in 
humans. The major metabolite after dosing with AQ was a glutathione conjugate, 
which is thought to be the detoxified adduct of AQ quinone imine in humans 
(Naisbitt et a l, 1996). It appeared that the phenyl ring of AQ leads to a compound 
much more susceptible to undergo chemical reactions inside the body. Rather than 
simple dealkylation or oxidation as with CQ, we have also seen conjugation reactions 
involving glutathione and mercapturic acid.
CQ is mainly excreted as the parent compound in humans; this was mirrored 
in our studies in the rat. However, in man, the main route of metabolism of CQ is 
dealkylation (as mentioned Section 4.1), whereas in rat we saw mainly A-oxidation 
and only a small amount of de-ethylation.
3.3.2 Tissue Distribution of [14C]-CQ and [3H]-AQ in the Rat
Five hours after administration of a single dose of [14C]-CQ to cannulated rats 
46.99 ± 4.45 % of the dose could be accounted for in the organs, bile and urine 
(Figure 3.13). Of this, 35.64 ± 2.47 % was found in the organs alone. The largest 
proportion of this dose was found to be in the liver (19.25 ± 1.27 %), followed by the 
skin (9.03 ± 0.84 %) and the kidneys (4.42 ±1.31 %). Minor levels of radioactivity 
were detected in the brain, heart, lungs, spleen and testis (less than 1.54 %). More 
than 50 % of the radioactive dose was unaccounted for after 5 h. Under acidic
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conditions, CQ can become protonated to its membrane-impermeable form and is 
then unable to cross the gut wall. This lends to the possibility that the majority of the 
unaccounted dose remained in the gastro-intestinal tract due to accumulation.
On comparison with the results generated 5 hours after dosing with [3H]-AQ, 
a similar pattern of distribution in the tissues was observed (Figure 3.14). The 
amount of radioactivity retained in the kidneys was significantly greater in rats dosed 
with [3H]-AQ than in those dosed with [14C]-CQ (4.42 ±1.31 % versus 9.45 ±1.31 
% respectively) (p = 0.046). This was also true when comparing the excretion of 
drug in bile, whereby significantly more drug was excreted 5 hours after 
administration after dosing with [3H]-AQ than [14C]-CQ (16.13 ± 1.97 % versus 1.87 
± 0.26 % respectively) (p = 0.017).
Figure 3.13 Percentage of radioactive dose recovered in tissues 5 h, after 
administration of [14C]-CQ (54 jamol/kg, 20 pCi/rat) to male Wistar rats (n = 4).
Results are expressed as mean percentage of dose ± SEM.
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Figure 3.14 Percentage of radioactive dose recovered in tissues 5 h, after 
administration of [14C]-CQ and [3H]-AQ (54 pmol/kg, 20 jaCi/rat) to male 
Wistar rats (n = 4). Results are expressed as mean percentage of dose ± SEM. 
Statistics were performed using a one way ANOVA test for parametric data and 
Kruskal Wallis test for non-parametric data. *P<0.05, **P<0.01, ***P<0.001
In order to investigate the possibility of accumulation of [14C]-CQ in the rat 
after a single dose, the experimental time-point was increase to 24 h and beyond 
(Figures 3.15 and 3.16).
Twenty-four hours after dosing with [14C]-CQ the total dose accounted for 
was 61.46 ± 6.71 % with very little retention of radioactivity detected in any of the 
major organs (Figure 3.15). There still remained a typical pattern of distribution, 
with the largest proportion of radioactivity located in the liver (5.45 ± 0.71 %), 
however excretion of radiolabelled material by both biliary and urinary routes 
increased significantly (p = 0.0286 and p = 0.0105 respectively). In all, excretion by 
these routes was greater than 56 % of the total dose (biliary 34.40 ± 9.05 %; urinary 
22.45 ± 3.97 %). The distribution in tissues after dosing with [3H]-AQ was highly 
comparative with that after dosing with [14C]-CQ (Figure 3.15). The only significant 
difference lay with the percentage of radioactivity retained in the skin, whereby 1.81
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± 0.21 % of the dose remained in the skin of rats dosed with [14C]-CQ and 6.34 ± 
1.40 % remained in rats dosed with [3H]-AQ (p = 0.0464).
Forty-eight hours after administration of [14C]-CQ to rats, the radioactivity in 
all major organs was negligible aside from the liver and skin which retained only 
2.95 ±0.11 % and 1.39 ± 0.22 % of the dose respectively (Figure 3.16). The total 
amount of radioactivity retained in the organs was 5.16 ± 0.42 % of the dose. More 
than 45 % of the dose was eliminated in the faeces (47.55 ± 0.53 %) with renal 
elimination containing 27.33 ± 0.52 % of the total administrated dose.
After seven days, the amount of [14C]-CQ remaining in the tissues was 
negligible and there were no signs of retention of the drug.
Figure 3.15 The percentage of radioactive dose recovered in tissues 24 h, after 
administration of [14C]-CQ and [3H]-AQ (54 pmol/kg, 20 pCi/rat) to male 
Wistar rats (n = 4). Results are expressed as mean percentage of dose ± SEM. 
Unpaired t-test for parametric data and Mann-Whitney test for non-parametric data 
*P<0.05, **P<0.01, ***P<0.001
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Figure 3.16 The percentage of radioactive dose recovered in tissues, 5 h, 24 h, 
48 h and 168 h, after administration of [14C] -  CQ (54 pmol/kg, 20 pCi/rat) to 
male Wistar rats (n = 4). Results are expressed as mean percentage of dose ± SEM. 
Unpaired t-test for parametric data and Mann-Whitney test for non-parametric data. 
*P<0.05, **P<0.01, ***P<0.001
3.3.2.1 Conclusions
After dosing with [l4C]-CQ (54 pmol/kg, 20 pCi) the majority of drug was 
found to be in liver and skin of rats. This was not an unexpected result solely on the 
basis of tissue size and the role of the liver in drug metabolism. There appeared to be 
relatively little excretion in urine and bile after 5 hours, although this increased to 
almost 75 % of the dose after 48 h. After 7 days less than 2.5 % remained in the 
body.
The results showed that the incorporation of a phenyl ring into the CQ side- 
chain made little difference to the pattern of distribution of the drug in the rat after 
administration of an identical dose. In general, the pattern of distribution tended to 
be identical in animals dosed with CQ and AQ, despite the fact they had radically 
different routes of metabolic clearance. It appeared that the two compounds enter the 
same tissues of the body regardless of any structural differences. The rate of 
clearance of total products was also seen to be similar for both CQ and AQ. There
110
was, however, significantly more radioactivity distributed in the kidneys after dosing 
with AQ and also a significant difference in the amount of biliary excretion (more 
than 8 times the amount of radioactivity was excreted in the bile of rats dosed with 
AQ than those dosed with CQ).
3.3.3 Cytotoxicity of CQ and AQ in Isolated Rat Hepatocytes
Rat hepatocytes, isolated using a two-step collagen digestion method (Section
32.2.1) were incubated with CQ or AQ at concentrations of 0, 20, 50, 100, 200 and 
500 pM (Figure 3.17) Results were expressed as the percentage of viable cells, 
measured microscopically, using a trypan blue exclusion test (as a percentage of the 
control). After incubation with CQ, it can clearly be seen that there was no effect on 
cell viability until the concentration of drug reached 200 pM, whereby there was a 30 
% decrease in cell viability. This was in contrast to the results shown with AQ, a 
drug known to cause hepatoxicity in humans. After incubation with AQ the results 
showed a marked decrease in cell viability at 100 pM (30.72 ±21.49 %) and saw that 
at 200 pM only 12.77 ± 10.75 % of the cells remained viable. The results for CQ and 
AQ, at 200 pM, were shown to be significant (p =0.0046). After incubation with 500 
pM of CQ and AQ, there was a highly significant difference between the effect of the 
two drugs on the liver cells (p = 0.0002). Of the cells treated with CQ, 40.57 ±0.18 
% of the cells remained viable, compared with complete cell death after incubation 
with AQ.
I l l
Figure 3.17 Viability of male, Wistar rat hepatocytes, incubated for 6 h with 
various concentrations of CQ and AQ, and stained with Trypan blue dye as an 
indicator for cell death. Results are expressed as mean percentage of dose ± SEM. 
Statistics were performed using a one way ANOVA test. *P<0.05, **P<0.01,
***p<0 ooi
3.3.3.1 Conclusions
This study showed unequivocally that CQ was less toxic in rat hepatocytes 
than AQ, a known causative agent of hepatoxicity in man, at concentrations ranging 
from 0 -  500 pM. The 4-aminophenol structure of AQ has led to decrease of Tox50 
from greater than 300 pM with CQ to 70 pM. Combined with the knowledge of the 
presence of a glutathione conjugate excreted in bile, it is possible that this toxicity, as 
in man, is due to the electrophilic AQ quinone ¡mine.
These findings suggest that this could be a useful study to compare the 
relative toxicities of novel compounds in the 4-aminoquinoline series (Chapters 4 
and 5).
3.3.4 Conclusion
The full metabolic and distributional profile of [14C]-CQ in rats has been 
defined, with the main route of metabolism being identified as V-oxidation and the 
main areas of accumulation being the liver and skin.
1 1 2
The results of this work have provided data that can be used to begin to build 
an overall structure metabolism relationship profile for the 4-aminoquinolines 
antimalarials.
In addition to this, we will now be able to directly compare the information 
generated in this chapter with that from N-tert butyl isoquine (NTBISQ), N-tertiary 
butyl fluoro amodiaquine (FAQ-4) and N-tert butyl chloro amodiaquine (C1AQ-4) in 
the forthcoming chapters (Chapters 4 and 5). This will lead to a full investigation on 
how structural alteration of these molecules affects the pathway of metabolism inside 
the rat and also the distribution and rate of clearance.
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4.1 INTRODUCTION
This chapter describes a formal study on the metabolism and distribution of 
N-tert butyl isoquine (NTBISQ), a rationally designed novel 4- aminoquinoline.
As discussed in Chapter 1, the universal utility of the 4-aminoquinoline drugs 
chloroquine (CQ) and amodiaquine (AQ) has been eroded to the point of therapeutic 
uselessness due to resistance and toxicity (Hatton et a l, 1986; Macomber et al., 
1966; Nefteleio/., 1986).
Drug-design studies have led to the formation of regioisomers of AQ, e.g. 
isoquine (ISQ), where interchange of the amino side-chain and the hydroxyl group 
have created a more stable amino phenol template (O'Neill et al., 2003). Substitution 
of the diethyl group of ISQ with a tert butyl gives the potentially, metabolically more 
stable analogue, NTBISQ. NTBISQ has been selected as the lead candidate to go 
forward for further pre-clinical studies. This selection was based on the cost- 
effective and facile chemical synthesis of the compound, as well as its potent 
antimalarial properties (IC50 13.2 ± 3.2 nM against the K1 CQ—resistant strain of P. 
falciparum) and promising pharmacokinetic data (Table 4.1) (Chapter 2). NTBISQ 
was noted to have excellent activity against all strains of malaria tested with no 
evidence of cross-resistance between sub-species of parasite. Its half-life (T1/2) was 
found to be less than 15 h across all four species tested. This compared favourably to 
that of CQ, the half-life of which has been noted to be approximately 275 hours, 
which could be a contributing factor to the development of resistance by malaria 
parasites (Gustafsson et a l, 1983). This shorter half-life may offer a significant 
advantage in terms of the opportunity to combine with an artemisinin-based drug. 
The oral bioavailability (F %) of NTBISQ across all species tested was greater than 
89 % indicating that almost all of the drug can enter the systemic circulation after
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oral dosing. Blood clearance levels of NTBISQ were found to be moderate across all
species.
Species T ,/2 (h) F (%)
Blood Clearance 
(mL/min/kg)
Mouse 3.3 ± 1.2 100 17.2
Rat 7.9 ±4.3 89 ± 12 25.9 ±4.9
Dog 14.2 ±3.1 92 ± 13 6.39 ± 1.57
Monkey 9.0 ±4.2 100 14.5 ±0.7
Table 4.1 Summary of pharmacokinetic data of NTBISQ in animals. Data 
was obtained from pre-clinical, pharmacokinetic studies at GlaxoSmithKline, Tres 
Cantos, Spain. Data are expressed as mean ± SD (n = 3).
The original lead compound ISQ was shown to be excreted mainly as the 
parent compound in the urine of rats. In bile, the main metabolite was found to be a 
glucuronide of the carboxylic acid (Scheme 4.2). In a similar way to AQ, ISQ was 
observed to undergo dealkylation, however; it is incapable of forming the toxic 
quinone imine adduct (Scheme 4.1). ISQ also undergoes glucuronidation and 
oxidation to its carboxylic acid in vivo, in rats. The absence of an ISQ-glutathione 
conjugate indicates that the bioactivation seen with AQ has been blocked (O'Neill et 
al., 2003).
It was proposed that the N-tert butyl analogue, NTBISQ will share this 
enhanced metabolic stability of ISQ and will not undergo bioactivation to form the 
toxic quinone imine metabolite seen with AQ. The aim of this work was to explore 
the metabolism and distribution of NTBISQ and to compare the results with ISQ and 
AQ. Of particular interest was the potential impact of the N-tert butyl group on 
simplifying the metabolic profile of the original lead compound, ISQ. Previous work 
has demonstrated that this molecule undergoes multiple routes of metabolism as 
depicted in scheme 4.2. The susceptibility of the A-diethylamino group to metabolic 
cleavage is partly responsible for the poor bioavailability of ISQ (Chapter 1).
1 2 0
This chapter examines the metabolic fate of chemically synthesised [3H]- 
NTBISQ in vivo, in the rat (chemical and radiochemical syntheses described in 
Chapter 2). In addition to this, the distribution of [3H]-NTBISQ in the rat was 
investigated, and the effects of time and dose were explored. The results of this work 
were compared to those of [3H]-ISQ from a previous study which utilised exactly the 
same experimental model (Randle, 2001)).
AQ quinoneimine Glutathione conjugate
Scheme 4.1 AQ ^-dealkylation pathways and the P450 oxidation of AQ to the 
toxic quinone imine, followed by conjugation to glutathione in humans.
(Hombhanje et al., 2004; O'Neill et al., 1998)
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4.2 MATERIALS AND METHODS
4.2.1 Materials
[3H]-NTBISQ (4.6 pCi/mmol; radiochemical purity by HPLC greater than 98 
%) was prepared via a 1-step synthesis described previously, (Chapter 2, Section 
2.2.2.12). Tissue solubilizer-^150 (0.5 N quaternary ammonium hydroxide in 
toluene) was purchased from Beckmann Chemicals, (Bremen, Germany). Ultima Flo 
and Ultima Gold scintillant were from Packard Bioscience BV, (Groningen, 
Netherlands). HPLC grade solvents were products of Fisher Scientific, 
(Loughborough, Leicestershire, UK). All other chemicals were purchased from 
Sigma Aldrich Co. (Poole, United Kingdom).
All data for ISQ was taken from a study by LE Randle, (Department of 
Pharmacology, The University of Liverpool) (Randle, 2001) (O'Neill et al, 2003).
Adult male Wistar rats (200-400 g) were obtained from Charles River 
(Margate, U.K.). The protocols described were undertaken in accordance with 
criteria outlined in a licence granted under the Animals (Scientific Procedures) Act 
1986 and approved by the University of Liverpool Animal Ethics Committee.
4.2.2 Methods
4.2.2.1 In Vivo Metabolism o f [3H]-NTBISQ in the Rat (5 h)
Adult male Wistar rats (250 - 400 g n = 4) were anaesthetised with urethane 
(1.4 g/mL in isotonic saline; 1 mL/kg, i.p.). Polyethylene cannulae were inserted 
into the trachea, femoral vein and common bile duct and the penis was ligated. 
Drug-blank bile was collected for approximately 20 minutes before treatment. [3H]- 
NTBISQ (54 pmol/kg; 20 pCi/rat or 216 pmol/kg; 20 pCi/rat) was dissolved in saline 
(0.5-1 mL depending on animal weight and dose) and was injected over 10 min
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(z.v.). Bile was collected hourly for a time period of 5 h into pre-weighed Eppendorf 
tubes. Samples were weighed after collection to determine the extent of biliary 
secretion and stored at -30 °C until analysis by LC-MS.
After 5 h, urine was aspirated from the bladder and transferred to a pre­
weighed Eppendorf tube and a cardiac puncture was performed. The blood was 
centrifuged (1000 g, 6 min) and the plasma transferred to a separate tube. The 
plasma from each experiment was pooled together and then blood proteins were 
removed by the exhaustive addition of MeOH (5 eq vv) followed by centrifugation 
(1200 g, 10 min). The supernatant was removed and concentrated by evaporation 
before re-dissolving it in MeOH (200 pL). The plasma and urine samples were 
stored at -30 °C until analysis by LC-MS.
Aliquots of bile and urine (30 pL) were mixed with scintillant (4 mL) for 
determination of radioactivity.
4.2.2.2 LC-MS Analysis o f Bile, Urine and Plasma Samples
Aliquots of bile, urine and plasma (100 pL) were analysed at room 
temperature on a Hypersil 5-pm HyPurity Elite C-18 column (150 x 4.6 mm; 
Thermo Hypersil-Keystone, Runcorn, Cheshire, UK) with a gradient of acetonitrile 
(10-50 % over 30 min) in trifluoroacetic acid (0.1 %, v/v). The LC system consisted 
of two Jasco PU980 pumps (Jasco UK, Great Dunmow, Essex, UK) and a Jasco HG- 
980-30 mixing module. The flow rate was 0.9 mL/min. Eluate split-flow to the LC- 
MS interface was ca. 40 pL/min. A Quattro II mass spectrometer (Micromass MS 
Technologies, Manchester, UK) fitted with the standard co-axial electrospray source 
was used in the positive-ion mode. Nitrogen was used as the nebulizing and drying 
gas. The interface temperature was 80 °C; the capillary voltage, 3.9 kV. Spectra
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were acquired between m/z 100 - 1050 over a scan duration of 5 s. Fragmentation of 
analyte ions was achieved at a cone voltage of 50-70 V. Data were processed with 
MassLynx 3.5 software (Micromass). Radiolabelled analytes in the remainder of the 
eluate were detected with a Radiomatic A250 flow detector (Packard, Pangbourne, 
Berkshire, UK). Eluate was mixed with Ultima-Flo AP scintillant (Packard 
Bioscience BV, Groningen, Netherlands) at 1 mL/min.
4.2.2.3 Tissue Distribution o f [3 HJ-NTBISQ in the Rat
At the end of the relevant time-point (5 h, 24 h, 48 h, 168 h or 240 h) the 
animals were killed by a lethal dose of pentabarbitone and the major organs were 
excised (brain, eyes, heart, lungs, liver, kidneys, spleen, testes and skin) and stored at 
-30 °C.
Duplicate portions (50 -  100 mg) of the tissues were weighed and solubilized 
in tissue solubilizer (0.75 mL) at 50 °C for 16 h. The solutions were decolourised 
with hydrogen peroxide (200 pL) over 1 h and then neutralised using glacial acetic 
acid (30 pL) before leaving in the darkness for 16 h to prevent chemoluminescence. 
Ultima Gold scintillant (10 mL) was added before the radioactivity was determined 
by scintillation counting.
4.2.2.4 In Vivo Retention Studies o f [3HJ-NTBISQ in the Rat (24 h)
Adult male Wistar rats (200 - 400 g, n = 4) were administered a solution of 
[3H]-NTBISQ (54 pmol/kg; 20 pCi/rat) dissolved in saline (0 .5 -1  mL; iIp.). The 
animals were then transferred to individual metabolism cages equipped with a well 
for collecting urine and faeces. The rats were allowed food and drink ad libitum for 
a 24 h period before administration of a lethal dose of pentabarbitone.
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Aliquots of urine (30 pL) were collected and mixed with scintillant for 
determination of radioactivity. The collected faeces were weighed and dissolved in 
distilled water for a period of 16 h before determination of radioactivity using the 
same method as described earlier (Chapter 4, Section 4.2.2.3). The major organs 
were then removed and assessed for radioactivity.
4.2.2.5 In Vivo Retention Studies o f [3HJ-NTBISQ in the Rat (48 h)
Adult male Wistar rats (n = 4) were administered a solution of [3H]-NTBISQ 
(54 pmol/kg; 20 pCi/rat) dissolved in saline (0.5 -  1 mL; i.p.). The animals were 
kept in a normal animal cage for a period of 24 h before they were transferred to 
individual metabolism cages equipped with a well for collecting urine and faeces. 
The rats remained in the metabolism cages for a further 24 h, with full access to food 
and drink, before overdose using pentabarbitone.
Aliquots of urine (30 pL) were collected and mixed with scintillant for 
determination of radioactivity. The collected faeces were weighed and dissolved in 
distilled water for a period of 16 h before determination of radioactivity using the 
same method as described earlier (Chapter 4, Section 4.2.2.3). The major organs 
were then removed and assessed for radioactivity.
4.2.2.6 In Vivo Retention Studies o f [3HJ-NTBISQ in the Rat (168 h and 240 h)
Adult male Wistar rats (n = 4) were administered a solution of [3H]-NTBISQ
(54 pmol/kg; 20 pCi/rat) dissolved in saline (0.5 -  1 mL; i.p). The animals were 
kept in a normal animal cage for a period of 168 h or 240 h with full access to food 
and drink before administration of a lethal dose of pentabarbitone. The major organs 
were then removed and assessed for radioactivity.
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4.2.2.7 Cytotoxicity ofNTBISQ and ISQ in Isolated Rat Hepatocytes
Male Wistar rats (200 - 250g) (n = 3) were terminally anaesthetised with 
pentobarbitone sodium (90mg/kg in isotonic saline i.p.). Hepatocytes were isolated 
using a two-step collagenase perfusion method adapted from that of Guguen- 
Guillouzo et al (Guguen-Guillouzo et al., 1986). The abdomen was opened and the 
liver cannulated through the portal vein using a gauge catheter. Before perfusion, the 
heart was removed to allow free loss of perfusion buffers. The liver was washed 
with calcium-free HEPES buffer for 10 mins at a flow rate of 40ml/min. The liver 
was then perfused with digestion buffer, a mixture of wash buffer with 5 % CaCl2 
solution, for 6 -  10 mins. The digested tissue was then excised and placed in a Petri 
dish containing wash buffer and DNAase (0.1 % w/v). The tissue was anchored and 
the Glison’s capsule was disrupted and disturbed to release the cells. The cell 
suspension was filtered through gauze to eliminate cell debris, blood and sinusoidal 
cells. The cells were washed three times in DNAase wash buffer before re­
suspending in incubation buffer (HEPES buffer and MgSO4.7H20 (0.25 % w/v)). 
Cell viability was then assessed microscopically using the trypan blue exclusion test.
The cells were then incubated with various concentrations of either NTBISQ 
or ISQ for a period of 6 hours before determining cell viability in the presence of test 
compound using the trypan blue exclusion test.
4.2.2.8 Statistical Analysis
All results are expressed as mean ± standard error of the mean (SEM). 
Values to be compared were analysed for non-normality using a Shapiro-Wilk test. 
Student t-tests were used when normality was indicated. A Mann-Whitney U test 
was used for non-parametric data. For analysis of sets of data with variance, a 1-way
127
analysis of variance (ANOVA) test was used for parametric data and a Kruskell- 
Wallis test was used for non-parametric data. All calculations were performed using 
StatsDirect statistical software, results were considered to be significant when P < 
0.05.
1 2 8
4.3 RESULTS AND DISCUSSION
4.3.1. LC-MS Analysis of In  Vivo Metabolites of [3H]-NTBISQ in the Rat
Following i.v. administration of [3H]-NTBISQ (54 pmol/kg, 20 pCi) to rats 
the total recovery of radioactivity in urine was 2.77 ± 0.32 % of the dose 
administered. Only one peak was resolved by HPLC (Figure 4.1). This was 
identified by LC-MS analysis, which located co-eluting pairs of chlorine isotope 
peaks in the positive-ion mass chromatogram for m/z 356 (I, parent compound) 
(Figure 4.2B). The parent compound eluted at Rt = 13.03 mins, viewed together 
with m/z 300 (loss of the tert butyl group) and appeared to be the only detectable 
metabolite in urine (Figures 4.2A and 4.3).
shaded peak I represents the parent compound.
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Figure 4.2 Positive-ion electrospray mass chromatograms corresponding to 
[3H]-NTBISQ. (A) representation of the fragmentation of the tert butyl side-chain 
(m/z 300), (B) m/z 356 (parent compound) excreted in the urine of male Wistar rats 5 
h after dosing i.v. with [3H]-NTBISQ (54 pmol/kg, 20 pCi).
(3HJ-.NTBISQ Urine R at D
HyPurity Elite, AC'N [10-50 % , 30 mins] TFA (0.1 %)
A£S19 153(13.030) ScanES*-
Figure 4.3 Positive-ion electrospray mass spectrum showing the 
fragmentation of [3H]-NTBISQ excreted in the urine of male, Wistar rats, as 
parent compound, 5 h after dosing ¿v. with [3H]-NTBISQ (54 pmol/kg, 20 pCi).
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In bile, one peak was observed by HPLC following i.v. administration of 
[3H]-NTBISQ (54 pmol/kg, 20 pCi) (Figure 4.4). The O-glucuronide of NTBISQ 
was identified by LC-MS analysis which located co-eluting pairs of chlorine isotopes 
in the positive-ion mass chromatogram for m/z 532 (II) (Figure 4.5). The metabolite 
recognized as [M+l+176]"1" (Figure 4.6) eluted at Rt = 10.74 mins. The metabolite 
comprised 89.88 ± 2.31 % of the metabolites formed and it was thought that 
conjugation of glucuronic acid had occurred with the phenolic group of NTBISQ 
(Scheme 4.3). The glucuronide metabolite was not present in drug-free bile.
A small peak eluting at Rt = 13.03 mins was also observed in the HPLC trace 
for rat bile. This was in too small quantities to be located in the LC-MS trace; 
however it was thought to be representative of the parent compound.
Figure 4.4 HPLC radiochromatogram of the biliary metabolite found in 
male Wistar rats, after dosing with [3H]-NTBISQ (54 pmol/kg, 20 pCi, 2 h 
collection). II represents a phenolic glucuronide of the parent compound.
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Figure 4.5 Positive-ion electrospray mass chromatogram corresponding to 
[3H]-NTBISQ-0-glucuronide (m/z 532) excreted in the bile of male Wistar rats 
after dosing z'.v. with [3H]-NTBISQ (54 pmol/kg, 20 pCi, 2 h collection).
|3H]-NTBISQ Bile Rat D, 2 b
HyPurity Elite, ACN [10-50 %, 30 mios] TFA (0.1 %)
AES23 m i (12.010) ScanESt
Figure 4.6 Positive-ion electrospray mass spectrum showing the 
fragmentation of [3H]-NTBISQ-0-glucuronide excreted in the bile (2 h 
collection) of male, Wistar rats, 5 h after dosing /.v. with [3H]-NTBISQ (54 
pmol/kg, 20 pCi).
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Scheme 4.3 Metabolites found in urine and bile of male, Wistar rats after 
dosing with [3H]-NTBISQ (54 junol/kg, 20 fiCi).
In sharp contrast to AQ, which undergoes phase II conjugation with 
glutathione in vivo, NTBISQ was observed to undergo direct glucuronidation in rats. 
In order to investigate the chemical basis of why one molecule form is more likely to 
undergo direct glucuronidation over the other, a molecular modelling study was 
carried out by an associate of the group, Dr. Nick Greeves. This study investigated 
the various energy conformations of the 3’hydroxy /er/-butyl substituted compound 
versus the 4’hydroxy tert-butyl substituted compound (N-tert butyl isoquine versus 
N- tert butyl amodiaquine) at neutral and acidic pH.
The results of this study showed that at neutral pH, the 3’hydroxy derivative 
was more nucleophilic than the 4’hydroxy compound implying that the nucleophilic 
attack that occurs between the hydroxyl group and glucuronic acid was more liable to 
occur with NTBISQ than the AQ analogue.
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4.3.2 In Vitro Drug Metabolic Profile of NTBISQ
The in vitro disposition of NTBISQ was investigated at GlaxoSmithKline 
using animal and human hepatocytes and liver microsomes. GSK scientists 
incubated NTBISQ with liver microsomes and hepatocytes from mouse, rat, dog, 
monkey and human and in plasma, blood and urine samples of mouse and rat 
following i.v. and oral administration of NTBISQ. NTBISQ was observed to 
undergo metabolism in microsomes and hepatocytes by multiple, common pathways 
in vitro, including mono-oxygenation, ketone formation, oxidative deamination to 
the aldehyde and also glucuronidation (Figure 4.7). These metabolites were also 
detected in mouse plasma and urine and rat plasma and blood. Loss of the tert butyl 
side chain was observed in mouse urine and to a small extent in mouse plasma. The 
rate of in vitro metabolism was found to be low to moderate for NTBISQ in liver 
microsomes and isolated hepatocytes from pre-clinical species and human.
It was deduced that incorporation of the tert-butyl group on the nitrogen, a 
part of the molecule susceptible to oxidative metabolism, significantly reduced 
metabolism at this site in both in vitro and in vivo models as compared with ISQ.
Further more, there was no evidence for glutathione conjugation or reactive 
metabolism via the quinone imine pathway associated with AQ.
These results indicated that the pathway of metabolism of NTBISQ could 
involve more than just simple glucuronidation, however they fully supported our 
own findings at The University of Liverpool.
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Mouse, Rat, Dog, Monkey, Human microsomes Mouse, Rat, Dog, Monkey, Human microsomes Mouse, Rat, Dog, Monkey, Human microsomes 
Mouse, Rat, Dog, Monkey, Human heptaocytes Mouse, Rat, Dog, Monkey, Human heptaocytes Mouse, Rat, Dog, Monkey, Human heptaocytes 
[M+14+H]+ = 370 Mouse plasma and urine (trace) Mouse plasma and urine
[M+ 16+H]+ = 372 Rat plasma and blood
[M+16+H]+ = 372
jCO
jV-Desbutylation
Mouse urine and plasma (trace) 
[M-56+H]+ = 300
[M+H]+ = 356
Oxidative Deamination
Mouse, Rat, Dog, Monkey, Human 
microsomes
Mouse, Rat, Dog, Monkey, Human 
heptaocytes
Mouse plasma (trace) and urine 
[M-57+H]+ = 299
Oxidation
Mouse, Rat, Dog, Monkey, Human 
microsomes
Mouse, Rat, Dog, Monkey, Human 
heptaocytes
Mouse plasma and urine 
Rat plasma and blood 
[M-41+H]+ = 315 I
Glucuronidation Glucuronidation Glucuronidation
Mouse, Rat, Dog, Monkey, Human microsomes Mouse, Rat, Dog, Monkey, Human microsomes Mouse, Rat, Human microsomes
Mouse, Rat, Dog, Monkey, Human heptaocytes Mouse, Rat, Dog, Monkey, Human heptaocytes Mouse, Rat, Dog, Monkey, Human heptaocytes
Mouse urine (trace) Mouse urine Mouse urine
[M+l 76+H]+ = 532 [M+119+H]+ = 475 [M+135+H]+ = 491
Figure 4.7 Metabolic pathway for NTBISQ in mouse, rat, dog, monkey in 
human liver microsomes and hepatocytes as proposed by GlaxoSmithKline 
(Bates, 2005)
4.3.2.1 Conclusions
After 5 h, NTBISQ was excreted solely as the parent compound in urine and 
underwent direct glucuronidation in bile from rats given an i.v. dose of 54 pmol/kg, 
20 pCi. With the absence of any form of glutathione conjugate in the metabolic 
profile (c.f. AQ), it is clear that, as with ISQ, we have created a means of metabolic
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escape by isomerisation of the phenol moiety with the amino side-chain. 
Furthermore, incorporation of the tert butylamine group in place of the diethylamine 
group of ISQ has simplified the metabolic profile and a distinct lack of dealkylation 
has been observed, resulting in a metabolically more stable compound.
The potential of the ISQ derivatives to undergo P450 hydroxylation to the 
aromatic ring still remains. Such hydroxylation could lead to the formation of a 
quinone imine. In all studies carried out no such hydroxylation was observed. These 
findings were further corroborated by an in vitro study carried out at 
GlaxoSmithKline where they too saw glucuronidation as a major pathway of 
metabolism of NTBISQ, along with mono-oxygenation and deamination. No 
evidence of bioactivation was observed in any of the studies conducted at either 
Liverpool or GlaxoSmithKline.
4.3.3 Tissue Distribution of [3H]-NTBISQ and [3H]-ISQ in the Rat
Five hours after administration of a single dose of [3H]-NTBISQ (54 
pmol/kg, 20 pCi) to cannulated rats, 51.78 ± 5.52 % of the dose was accounted for in 
the organs, bile and urine (Figure 4.8). Of this, 41.34 ± 4.90 % was found in the 
organs alone. Similarly to CQ and AQ, (Chapter 3), the largest proportion of the 
dose could be found in the liver (25.84 ± 2.25 %) and also the skin (8.87 ±1.15 %). 
LC-MS investigation of homogenised liver samples deduced that the drug was 
present in this organ as the parent compound.
The brain and heart retained very minor amounts of radioactivity after 5 h, 
reducing any fears of cardiotoxicity or neurotoxicity as a consequence of drug 
accumulation. Biliary and urinary excretion was minimal with only 3.65 ± 0.30 % of 
the dose found in bile and 2.77 ± 0.32 % found in urine after 5 h. Again, as with CQ
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and AQ, the full radioactive dose could not be accounted for, suggesting that there 
was another area of accumulation within the rat. A strong possibility remains that 
this radioactivity could be within the gastrointestinal tract.
Plasma radioactivity fell below background-activity within 0.5 h of 
completion of the injection, making meaningful comparisons of drug levels in 
plasma and tissues impossible. Issues of extraction of NTBISQ from blood were 
also encountered at GlaxoSmithKline, possibly due to extensive haem-binding.
On comparison with the tissue distribution of [3H]-ISQ in rats (54 pmol/kg, 
20 pCi) it can be seen that a similar pattern of distribution of drug existed. The 
majority of the radioactivity also was found in the liver (32.93 ± 2.95 %) followed by 
the skin (21.45 ± 1.90 %) (Figure 4.9). The total amount of radioactivity accounted 
for was 70.92 ± 8.02 %). The amount of radioactivity found in the skin 5 h after 
dosing was almost 2.5-fold higher than that after dosing with [3H]-NTBISQ, this was 
found to be statistically significant with p = 0.011. The distribution of radioactivity in 
the kidneys also showed high statistical significance with almost twice the amount of 
radiolabeled compound retained after dosing with [3H]-ISQ than [3H]-NTBISQ (p = 
0.0006). In addition to this, excretion in bile after dosing with [3H]-ISQ was 
significantly higher than that in the bile of rats dosed with [3H]-NTBISQ (12.73 ± 
0.47 % versus 3.65 ± 0.30 %) (p = 0.0061). These significant changes in distribution 
and routes of clearance could be attributed to the structural differences between the 
two molecules, i.e. the diethylamino side-chain of ISQ versus the tert butylamino 
side-chain of NTBISQ.
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Figure 4.8 Percentage of radioactive dose recovered in tissues 5 h, after 
administration of [3H]-NTBISQ (54 pmol/kg, 20 pCi/rat) to male Wistar rats (n
= 4). Results are expressed as mean percentage of dose ± SEM.
Figure 4.9 The percentage of radioactive dose recovered in tissues 5 h, after 
administration of [3H]-NTBISQ and [3H]-ISQ (54 pmol/kg, 20 pCi/rat) to male 
Wistar rats (n = 4). Results are expressed as mean percentage of dose ± SEM. 
Statistics were performed using a one way ANOVA test for parametric data and 
Kruskal Wallis test for non-parametric data. *P<0.05, **P<0.01, ***P<0.001
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In order to obtain a more clearly resolved mass spectrum for bile and urine 
analysis, a higher dose was used (216 pmol/kg, 20 pCi). A dose comparison study 
was set up to investigate the effects increased dose on the distribution of [3H]- 
NTBISQ in the rat (Figure 4.10). The pattern of distribution and also the levels of 
radioactivity remained similar between both high dose and low dose rats and no 
statistical significance were found between sets of data, indicating that accumulation 
of [3H]-NTBISQ in the rat was not dose-dependent.
Figure 4.10 The percentage of radioactive dose recovered in tissues, 5 h after 
administration of [ H] -  NTBISQ (54 pmol/kg, 20 pCi/rat or 216 pmol/kg, 20 
pCi/rat) to male Wistar rats (n = 4). Results are expressed as mean percentage of 
dose ± SEM. Statistics were performed using the unpaired t-test for parametric data 
and Mann-Whitney test for non-parametric data *P<0.05, **P<0.01, ***P<0.001
Following on from the retention/accumulation studies carried out with [l4C]- 
CQ; experiments were set up using longer time-points from 24 h to 240 h (Figures 
4.11 and 4.12). The aim of these experiments was to assess how long [3H]-NTBISQ
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remained inside the rat and to investigate whether the compound underwent retention 
which could potentially lead to toxicity.
Twenty-four hours after dosing with [3H]-NTBISQ, the total dose accounted 
for was 39.17 ± 5.57 %. The data obtained from [3H]-ISQ was incomplete, with 
missing data of the amount of radioactivity excreted in urine and faeces over a 24 h 
period. Only one experiment was carried out and so statistics could not be performed 
and direct comparisons must be treated with caution.
The distribution of radioactivity appeared to be very similar after dosing with 
[3H]-NTBISQ and [3H]-ISQ, with the highest proportion of dose, again, being 
retained in the liver and skin. In the case of rats dosed with [3H]-NTBISQ, biliary 
output rose significantly from 5 h to 24 h from 3.65 ± 0.30 % to 13.70 ± 1.96 % (p = 
0.0068), and even more so from 5 h to 48 h (p = 0.0002)) (3.65 ± 0.30 % to 23.30 ± 
0.54 % indicating the effective excretion of the drug. Elimination of [3H]-NTBISQ 
was noted to be mainly biliary, in the form of the 0-glucuronide, from 24 h onwards.
After 48 h, the amount of biliary and urinary excretion totalled 35.80 ± 1.32 
%, much less than that of [14C]-CQ (74.88 ± 1.05 %) (Chapter 3) implying there may 
be a greater degree of retention of [3H]-NTBISQ within the tissues.
After 168 h, 3.64 ± 1.15% of the radioactive dose still remained in the tissues 
of the rat, mainly in the liver and skin (Figure 4.12). This prompted us to increase 
the experimental time-point to 10 days (240 h). After this time less than 2 % of the 
dose remained in the rat, 0.90 ± 0.45 % in the liver and 0.70 ± 0.25 % in the skin.
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Figure 4.11 Percentage of radioactive dose recovered in tissues 24 h, after 
administration of [3H]-NTBISQ (n = 4).or [3H]-ISQ (n = 1) (54 pmol/kg, 20 
pCi/rat) to male Wistar rats. Results for [3H]-NTBISQ are expressed as mean 
percentage of dose ± SEM. Statistics could not be performed.
Figure 4.12 Percentage of radioactive dose recovered in tissues, 5 h, 24 h, 48 h, 
168 h and 240 h after administration of [3H]-NTBISQ (54 pmol/kg, 20 pCi/rat) 
to male Wistar rats (n = 4). Results are expressed as mean percentage of dose ± 
SEM. Unpaired t-test for parametric data and Mann-Whitney test for non-parametric 
data. *P<0.05, **P<0.01, ***P<0.001
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4 .3 .3 .1  C o n c lu sio n s
Administration of [3H]-NTBISQ and [3H]-ISQ to rats led to the majority of 
the dose being retained in the liver and skin. As with [14C]-CQ, this was not entirely 
unexpected due to these organs being, by far, the largest in size in the body and also 
the liver is residence to the greatest number of metabolizing enzymes.
After examining two different doses of [3H]-NTBISQ in the rat, (54 pmol/kg 
versus 216 pmol/kg), no significant differences in distribution of compound could be 
seen, suggesting that any accumulation observed was not likely to be dose- 
dependant.
Previous work has shown that [3H]-ISQ has a far more complex metabolic 
pathway than [3H]-NTBISQ (Schemes 4.2 and 4.3), and yet the pattern of 
distribution remained very similar (Figure 4.9). The only areas in the rat showing 
significantly altered accumulation between the two compounds were the kidneys and 
skin, whereby [3H]-ISQ was observed to accumulate to a greater extent than [3H]- 
NTBISQ.
Further investigation into the clearance of NTBISQ by measurement of blood 
levels proved impossible due to the inextractability of NTBISQ from blood. 
Radioactivity in plasma was observed to be much lower than that of background 
level.
Due to the poor total recovery of [3H]-NTBISQ after 5 h, it seemed highly 
probable that there was another area of accumulation within the rat and a strong 
possibility remains that this was the gastrointestinal tract.
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4.3.4.1 Cytotoxicity o f NTBISQ in Isolated Rat Hepatocytes
Rat hepatocytes, isolated using a two-step collagen digestion method (Section 
4.2.2.8) were incubated with CQ, AQ or NTBISQ at concentrations of 0, 20, 50, 100, 
200 and 500 pM for 6 hours (Figure 4.13) Results were expressed as the percentage 
of viable cells, measured microscopically, using a trypan blue exclusion test (as a 
percentage of the control).
NTBISQ was shown to exhibit similar levels of toxicity in rat hepatocytes as 
AQ (Tox5o (NTBISQ) 40 ± 10 pM, Tox5o (AQ) 65 ± 15 pM). When comparing the 
Tox50 value of NTBISQ in rat hepatocytes with the IC50 value of NTBISQ against 
the 3D7 CQ-sensitive strain of malaria (11.2 ± 2.2 nM), the therapeutic index can be 
calculated as 3571. Therefore, the amount of drug required to damage the cells is 
more than 3500-fold that required to kill the parasite.
4.3.4 Toxicology of NTBISQ
Figure 4.13 Viability of male, Wistar rat hepatocytes, incubated for 6 h with 
various concentrations of CQ and AQ, and stained with Trypan blue dye as an 
indicator for cell death. Results are expressed as mean percentage of dose ± SEM. 
Statistics were performed using a one way ANOVA test. *P<0.05, **P<0.01, 
***P<0.001
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A complementary toxicological study of NTBISQ was carried out at the 
Worldwide Development division of GlaxoSmithKline, Tres Cantos, Spain. The 
systemic toxicity of NTBISQ was evaluated in mice, rats, dogs and monkeys in order 
to assess its safety as a drug (GlaxoSmithKline, 2005).
4.3.4.2 Central Nervous System
Central nervous system (CNS) effects were observed in acute and short-term 
dosing studies in all species tested. Single doses of 100 mg/kg or more resulted in 
severe adverse reactions in dogs, such as laboured breathing, tremors and 
convulsions. In monkeys, doses above 180 mg/kg led to multiple episodes of emesis 
along with slight tremors and decreased activity.
In repeat dose studies in rats, CNS effects were evident after four daily doses 
of 150 mg/kg/day. These effects were presented as reduced activity, partially closed 
eyelids, hunched posture, abnormal gait and pilo-erection. Similar adverse signs 
were seen in mice also, after four days of receiving a dose of 300 mg/kg/day.
In a 14 day study in monkeys, using a dose of 75 mg/kg/day, persistent and 
non-tolerable adverse side effects were observed, but on reducing the dose to 35 
mg/kg/day these effects became tolerable and recoverable. These findings were 
consistent across the 4-aminoquinoline class with CQ and AQ.
4.3.4.3 Phospholipidosis
Chapter 3 of this thesis began a brief introduction to phospholipidosis. As 
described, phospholipidosis is a well documented class effect of the 4- 
aminoquinoline family of antimalarials (Glaumann et al., 1992; Halliwell, 1997; 
Shaikh et al., 1987).
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After dosing with NTBISQ, in almost all of the tissues evaluated, foamy 
macrophages were present, consistent with the occurrence of phospholipidosis. 
However, after a four week period without drug, there was a complete recovery in all 
tissues tested. In comparative studies both CQ and AQ showed a similar profile of 
phospholipidosis.
4.3.4.4 Primary Target Organs
A fourteen-day toxicology study in rats showed that the primary targets of 
NTBISQ were the heart, skeletal muscle and the liver.
After dosing male rats with NTBISQ (10 mg/kg/day) an increase in the 
incidence of focal myocardial degeneration/necrosis occurred. In addition to this, 
focal myofibre degeneration was observed in skeletal muscle of both male and 
female rats. Again, after four weeks without dose there was complete recovery of 
skeletal muscle damage and evidence of repair of the cardiac lesion.
Secondary to the hepatic phospholipidosis, hepatocyte apoptosis was also 
observed and transaminase levels in the blood were noted to be elevated after dosing 
with NTBISQ (50 mg/kg/day) indicating damage to the cells of the liver. This 
finding may explain our results, which showed higher levels of cytotoxicity of 
NTBISQ in rat hepatocytes (when compared to CQ) (Section 4.3.3).
These findings were all replicated in comparison studies with CQ and AQ. 
Not only this, but reports in the literature describe a similar pathology in rat skeletal 
muscle after dosing with CQ (Kumamoto et al., 1989).
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4 .3 .4 .5  C o n c lu sio n s
The findings from these toxicology studies showed that NTBISQ was 
consistent with and comparable to CQ and AQ, except for the additional adverse 
hepatic effects AQ is known to cause.
The heart, skeletal muscle and liver were all primary targets after dosing with 
NTBISQ in rats. Importantly, all effects observed were at a dose much higher than 
that of the targeted therapeutic dose. All of the unwanted effects observed were 
deemed to be reversible and could be clinically monitored.
4.3.5 Conclusion
In a recent study by Lin and co-workers they described the potential for ISQ 
and its derivatives to undergo a similar oxidation reaction as AQ in vivo to form an 
O-quinone methide (Scheme 4.4) (Miroshnikova et al., 2006). The studies in this 
chapter show implicitly this not to be the case and that isomerisation of AQ to ISQ 
has in fact resulted in the successful elimination of bioactivation, in the rat to any 
form of toxic quinone imine metabolite. This was notable by the lack of glutathione 
conjugates in the bile and urine of rats treated with [3H]-ISQ, thus proving that this 
route of bioisosterism has provided a route of metabolic escape.
By making further structural changes by incorporating a tert butyl group in 
place of the diethyl group of ISQ, we have not only successfully blocked 
bioactivation, but also produced a molecule with a simple metabolic route by virtue 
of the enhanced stability of the N-tert butyl side-chain. Importantly, no P450 
hydroxylation of the aromatic ring was observed. Indeed, NTBISQ was found to 
mainly undergo direct glucuronidation in vivo in rats.
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Amodiaquine (AQ) Amodiquine Quinone Imine
Schem e 4.4 Oxidation o f  AQ  to a the toxic quinone im ine m etabolite and  
potential pathway o f  isoquine 0 -q u in on e m ethide form ation according to Lin  
and co-w orkers (M iroshnikova et a l , 2006).
Toxicological studies of NTBISQ have revealed that the compound can affect 
the heart, liver and skeletal muscle of rats at high doses. Toxicity of this kind with 
the 4-aminoquinoline class of antimalarials is not unknown. Cardiotoxicity has 
previously been reported with the use of CQ and hydroxylCQ in patients undergoing 
treatment for connective tissue disorders or lupus. Chronic dosing of these drugs has 
led to instances of heart conduction disorders and also retinopathy (Roos et a l, 2002; 
Tanaka et al., 2004).
The toxic effects observed with NTBISQ were also seen with CQ and AQ in 
an identical study. Importantly, the effects were only observed at very high 
concentrations and with repeated dosage. The adverse effects were deemed to be 
reversible and also species specific as they were not seen in the monkey or mouse, 
therefore they are unlikely to occur at therapeutic doses in clinic.
147
Dispositional studies after a single dose of NTBISQ showed accumulation in 
the liver. However, this was seen to diminish over time and did not lead to concerns 
over direct toxicity due to retention. No such accumulation was seen in the heart or 
muscle in these studies.
The data in this chapter reports the initial findings of an extremely promising 
novel compound. We have clearly demonstrated that NTBISQ has a desirable 
ADME profile, with no bioactivation observed in rats in vivo or in vitro and a simple 
metabolic profile. This, coupled with its excellent antimalarial and pharmacokinetic 
properties gives rise to a novel 4-aminoquinoline with great potential for use in the 
battle against malaria.
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5.1 INTRODUCTION
The haemoglobin degradation pathway in Plasmodium falciparum has been 
successfully exploited as the therapeutic target of chloroquine (CQ) (la) and other 4- 
aminoquinolines. As the parasite catabolizes human haemoglobin, the haematin bi­
product (lc) is detoxified by crystallisation to haemazoin (Francis et al., 1997). CQ 
interacts with the porphyrin ring of haematin by a 7t-7i stacking interaction of the 
quinoline ring. Accumulation of the haemidrug complex within the erythrocyte 
ultimately poisons the parasite. Resistance to this mechanism of action has proven 
difficult to induce and has developed relatively slowly and only after considerable 
human exposure. CQ resistance is the result of point mutations in a parasite 
transporter known as PfCRT (Bray et al., 2005).
Amodiaquine (AQ) (lb) is active against CQ-resistant strains of P. 
falciparum. However, its use has been severely restricted by hepatotoxicity and 
agranulocytosis in humans (Hatton et al., 1986; Neftel et al., 1986). This appears to 
be the result of bioactivation to form a reactive quinone imine metabolite that can 
bind irreversibly to cellular macromolecules and may lead to direct toxicity as well 
as immune-mediated hypersensitivity reactions. IgG antibodies have been detected 
in patients with adverse reactions to AQ (Christie et al., 1989; Rouveix et al., 1989).
In order to enhance the metabolic stability of AQ we demonstrated that 
introduction of fluorine into the 4-hydroxyanilino nucleus increases the oxidation 
potential of the molecule and reduces the in vivo oxidation of the molecule to a 
cytotoxic quinone imine. From this earlier work, we demonstrated that the 4’- 
hydroxyl group could be replaced with a 4’-fluorine atom to produce an AQ 
analogue, fluoro-AQ (2d), with antimalarial activity in the low nanomolar range.
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Figure 5.1 Structures of CQ (la), AQ (lb) and Drug Target Haematin (lc)
Amodiaquine Amodiaquine Quinone Imine (AQQI)
Binding to cellular 
proteins
Hepatoxicity and 
Agranulocytosis
Scheme 5.1 Oxidation of AQ to a reactive quinone imine metabolite
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An alternative approach to circumvent the facile oxidation of AQ involves 
isomerisation of the 3’ and 4’ groups. It was proposed that interchange of the 3’- 
hydroxyl and the 4’- Mannich side-chain function of AQ would provide a new series 
of analogues that cannot form toxic quinone imine metabolites via cytochrome P450- 
mediated metabolism. Isomeric AQ analogues were prepared using a simple two- 
step procedure, and then tested against K1 (CQ-resistant) and HB3 (CQ-sensitive) 
strains of P. falciparum in vitro. While several analogues displayed potent 
antimalarial activity against both strains, isoquine (ISQ) (Id), the direct isomer of 
AQ, was selected for in vivo antimalarial assessment. The potent in vitro 
antimalarial activity of ISQ was translated into excellent oral in vivo ED50 activity of
1.6 and 3.7 mg/kg against the P. yoelii NS strain compared to 7.9 and 7.4 mg/kg for 
AQ. Subsequent metabolism studies in the rat model demonstrated that ISQ does not 
undergo in vivo bioactivation, as evidenced by the complete lack of glutathione 
metabolites in bile. A drawback with Id is the low oral bioavailability in animal 
models and this was demonstrated to be on account of extensive metabolism of the 
A-diethylamino Mannich side-chain. Further studies in this area have revealed that 
the N-tert butyl analogue (le) (Figure 5.2) has superior pharmacokinetic and 
pharmacodynamic profiles to ISQ in four animal species, including primates. This 
compound is undergoing further advanced pre-clinical evaluation with 
GlaxoSmithKline pharmaceuticals.
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AQ (lb)
Oxidation to a
M-tert butyl
NTBISQ(le)
Figure 5.2 Rational drug-design of AQ analogues based on 
metabolism/toxicity considerations. The N-tert butyl analogue le has an 
exceptional pharmacodynamic and pharmacokinetic profile.
Recent independent studies by the Sergheraert and the Lin groups have 
utilized the aryl anilino quinoline core as a template for the design of additional 
isomers of AQ and tebuquine (TBQ) (Delarue et al., 2001; Miroshnikova et al., 
2006). The latter 4-aminoquinoline is a biaryl analogue of AQ with potent 
antimalarial activity but was not developed further due to toxicity. Our own studies 
with TBQ and other 4-hydroxyanilino containing antimalarials such as cycloquine 
and pyronaridine have confirmed that these molecules readily produce metabolism 
dependent neutrophil toxicity. For TBQ, we obtained evidence for the formation of 
a glutathione adduct derived by a novel chemical mechanism where the Mannich 
side-chain is replaced with glutathione.
The aim of this research was to investigate two series of AQ analogues where 
the 4’-hydroxyl function of AQ is replaced by either fluorine or chlorine; the 
intention, as in previous work, was to produce analogues incapable of producing 
quinone imine metabolites by P450 oxidation. The array of target molecules is 
highlighted in Figure 5.3. For comparison purposes, we have also examined the
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antimalarial profile of two 4’-dehydroxy analogues of AQ. Following completion of 
the syntheses, appropriate antimalarial assessment and pre-clinical pharmacological 
assessment, we aimed to select suitable back-up compounds to (Id) with appropriate 
properties suitable for drug development.
2d: R ,,R 2 = Et
2e: R|, R2 = (CH2)4
2f: R „R 2 = (CH2)5
2g: R], R2 = (CH2)2N(Me)(CH2)2
2h: R], R2 = nPr
2i: R,, R2 = nBu
2j:R „R 2 = (CH2)20(CH2)2
2k:R ,, = H, R2 = tBu
3d: R = Cl, Rt, R2 = 
3e: R — Cl, R], R2 = 
3f: R = Cl, R , ,R 2 = 
3g: R=C1,Ri,R2 = 
3h: R = Cl, Rj, R2 = 
3i: R = Cl, R , ,R 2 = 
3j: R = Cl, R], R? = 
3k: R = C1,Ri,R"2 = 
3I:R = C 1,R ,,R 2 = 
pyridyl)(CH2)2 
3m: R = Cl, R), R2 :
3n:R = C l,R ,,R 2 = (CH2)6
Et
(CH2)4
(CH2)5
( CH 2)2N (Me)( CH2)2
nPr
nBu
(CH2)2N(Et)(CH2)2
(CH2)2N(iPr)(CH2)2
(CH2)N(2-
3o: R = Cl, R, = H, R2 = tBu 
4d: R = H, R, = H ,R 2 = 'Bu
21: R = F 
3p: R = Cl 
4e: R = H
Figure 5.3 Structures of 4’chloro and 4’ fluoro analogues of AQ
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5.2 RESULTS AND DISCUSSION
5.2.1 Chemistry
Although the original reported route to fluoro-AQ was relatively efficient we 
reasoned that shortening the number of synthetic steps and developing a route where 
a point of diversity appears in the penultimate step of the synthesis could achieve a 
significant improvement to the synthesis of target molecules in Figure 5.3. The 
alternative route adopted for the synthesis of 4’-chloro and 4’-fluoro analogues is 
shown in Scheme 5.2.
R  R
2 a : R  = F  2 b : R  =  F  2 c : R  = F
3 a : R  =  Cl 3 b : R  =  Cl 3 c : R  =  Cl
2 d - 2 j:  R  = F 
3 d - 3 p :  R  = C l
Reagents and conditions (i) Fe/HCI/H20 ,  reflux; (ii) 4,7-dichloro 
quinoline, EtOH, reflux, (iii) DIEA, CH2C12, DMF, M n02;
(iv) amine then NaHB(OAc)3
Scheme 5.2 Synthesis of 4’fluoro and 4’chloro analogues by reductive 
amination of aldehydes, 2c and 3c.
For the synthesis of 4’-chloro analogues nitro reduction of 3a was easily 
achieved using iron powder and HC1 in reluxing aqueous ethanol. The resulting 
amine 3b was then allowed to react with 4, 7-dichloroquinoline to provide 3c in 
excellent yield as a yellow powder following standard work-up. Quinoline 3c proved
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to be quite insoluble in dichloromethane, so a combination of dichloromethane, DMF 
and a small amount of diisopropylethyl amine were used as solvents to dissolve the 
alcohol for Mn02-mediated oxidation. After 18h reflux, precipitates derived from 
the oxidant Mn02 were filtered off with celite. In many runs, significant losses 
occurred at this stage and a more satisfactory work-up procedure involved the use of 
a pre-column with ethyl acetate prior to flash column chromatography using 
methanol/dichloromethane as eluent. The key aldehyde was obtained in moderate to 
good yields following flash column chromatography. The final step involved 
reductive amination of the aldehyde 3c with a variety of different amines to produce 
a small array of target molecules depicted in Figure 5.3. In all cases the reductive 
amination procedure worked well and flash column chromatography gave the 
products 3d-3p in good yields. (Table 5.1)
Scheme 5.2 also depicts the synthesis of the fluorinated series of analogues 
and the approach used is essentially the same as that discussed. The only exception 
to this was alternative conditions were explored for the reduction of the nitro group 
of 2a and the oxidation of the benzylic alcohol 2c to the corresponding aldehyde. 
Disappointingly, the use of powdered iron/ HC1 gave the desired amine 2b in low 
yields following basification and work-up. Alternative reducing conditions using 
methanol, ammonium chloride and zinc dust or granulated tin and concentrated 
hydrochloric acid provided the product 2b in good yield, following addition of 
sodium hydroxide solution to the amine in the work-up phase of the reaction. The 
synthesis of 2c from 2b proceeded in high yields without event. In contrast to the 4’- 
chloro series, oxidation of 2c with Mn02 gave the desired aldehyde in poor yields, 
possibly due to the insolubility of the quinoline aldehyde. An alternative method 
based on chromium (VI) was explored which provided the aldehyde in moderate
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yield. Reductive amination and work-up provided the desired compound as a dark 
brown solid. NMR analysis of the products prior to chromatography indicated 
complex formation (very broad peaks in the aromatic and aliphatic region); the 
nature of this complexation remains undefined. Acidification using HC1 and 
basification using sodium bicarbonate provided the free bases which were pure by 
NMR and microanalysis following flash column chromatography. Although the new 
route provided target molecules in acceptable yields for the 4’-chloro series, the final 
reductive amination step in the 4’-fluoro series requires optimisation (Tables 5.1 A 
and B). For this reason, the previously used linear approach was employed for 
selected analogues as shown Scheme 5.3. The first step in the sequence involved free 
radical bromination of 2-fluoro-5-nitrotoluene (or 2-chloro-5-nitrotoluene) using 
NBS/AIBN to give the benzylic bromide as a crystalline solid in good yield.
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A Fluoro Series
Aldehyde Amine Product
Yield
(%)
2c diethylamine 2d 24
2c pyrrolidine 2e 20
2c piperidine 2f 31
2c N-methylpiperazine 2g 31
2c dipropylamine 2h 27
2c dibutylamine 2i 42
2c morpholine 2j 23
B Chloro Series
Aldehyde Amine Product
Yield
(%)
3c diethylamine 3d 74
3c pyrrolidine 3e 61
3c piperidine 3f 92
3c N-methylpiperazine 3g 89
3c dipropylamine 3h 85
3c dibutylamine 3i 24
3c N-ethyl piperazine 3j 63
3c N-isopropylpiperazine 3k 62
3c 1 -(2-pyridy l)-piperazine 31 98
3c 4-(-pyrrolidinyl)-piperazine 3m 56
3c hexamethylene imine 3n 35
Tables 5.1A and B Yields for reductive amination of aldehydes 2c and 3c
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RN02
4a: R = F 
5a: R = Cl
4b: R = F 4c: R = F, R1 = H, R2 = tert-butyl;
5bR = CI 4d: R = F, R1, R2 = N1-imidazoyl
6aR = H 5c-5f: R = Cl, R1,R2 = alkyl,
cycloalkyl, N1-imldazoyl 
5g, R = f-Bu 
5h, R = N'-imidazoyl
iv
R
NR1R2 v 2k, 2I, 3e, 3k, 
3o, 3p, 4d
NH2
7a: R = F, R1, R2 = f-Bu; 7b: R = F, R1, R2 = N1-imidazoyl 
8a-8d: R = Cl, R1, R2 = alkyl, cycloalkyl, N1-imidazoyl 
8e: R = H, R1 = H, R2 = tBu 
8f: R = H, R1, R2 = N1-imidazoyl
Reagents and conditions: (i) NBS, AIBN, reflux; (ii) amine, K2C 0 3, CH3CN, reflux; (iii) MeOH, RT then 
0°C, NaHB(OAc)3; (iv) Sn/HCl, H20 , reflux; (v) 4,7-dichloroquinoline, EtOH, HCl, reflux
Scheme 5.3 Synthesis of 4-dehydroxy, 4’chloro and 4’fluoro analogues of AQ.
The resulting benzyl bromide 4b was then allowed to react with the 
appropriate amine to provide intermediates (4c, 4d, and 5c-5f) that were reduced and 
coupled with 4, 7-dichloroquinoline as shown. Benzyl bromides 4b, 5b and 6a were 
also allowed to react with imidazole and this enabled the synthesis of novel weak 
base imidazole derivatives 7b, 8d and 8f. For intermediates 5c-5e 2-chloro 5-nitro 
benzaldehyde was also used as starting material in a reductive amination approach as 
shown (Scheme 5.3).
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5.2.2 Biology
5.2.2.1 In Vitro Antimalarial Activity versus Plasmodium falciparum
Initial testing was carried out using a CQ-sensitive strain of P. falciparum 
(Table 5.2). In the 4’-fluoro series, the weak base morpholine analogue 2j and 
analogues 2h and 2i expressed relatively poor antimalarial activity versus the 3D7 
strain. The N-tert butyl analogue 2k was the most potent in this series with activity 
equivalent to CQ (la) and ISQ (Id). The 4’-chloro analogues tested were all active 
around 30 nM with the exception of 3h and in line with the 4’-fluoro series, the 4 - 
chloro N-tert butyl analogue 3o expressed the highest antimalarial activity. 
Interestingly, within these two templates, the side-chain alkyl amine or cyclic amine 
groups can be replaced with imidazole to produce analogues 21 and 3p which both 
showed antimalarial activity in the low nanomolar region.
Table 5.3 lists activity for the 4’-chloro series versus a CQ-resistant TM6 and 
sensitive HB3 strain. The IC50s were lower against these two strains and the most 
potent analogue was the N-tert butyl analogue 3o. Analogues 3e, 3f, 3j and 3k also 
expressed excellent activities against these two strains. For the 4’-chloro series as a 
whole, there is a clear lack of cross-resistance.
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Compound IC50 (nM) 3D7 Compound IC50 (nM) 3D7
2d 27.3 (3) ± 11.5 3d 30.4 (3) ± 15.2
2e 29.7 (3) ± 11.1 3f 25.7 (3) ± 10.6
2f 33.2 (3) ± 15.2 3g 86.8 (3) ±43.1
2g 35.1 (3) ±8.7 3h 277.3 (3) ±34.6
2h 85.2 (3) ±18.1 3j 39.7 (3) ±9.3
2i 95.2 (3) ±30.2 31 27.2 (3) ± 18.1
2j 550.7 (3) ±90.4 3n 14.5 (3) ±2.2
2k 12.1 (3) ±5.3 3o 7.8 (6) ±3.2
21 27.2 (3) ±3.4
CQ (la) 9.1 (3) ±4.9 AQ (lb) 4.7 (3) ±2.9
ISQ (Id) 7.8 (6) ±2.2 NTBISQ (le) 6.0 (6) ± 4.0
Table 5.2 In vitro antimalarial activities of the chloro and fluoro series 
versus CQ-sensitive 3D7 strain of Plasmodium falciparum. aAQ and NTBISQ 
(le) were tested as the hydrochloride salt. CQ was tested as the diphosphate. All 
other compounds were all tested as free bases.
Compound
3d
3e
3f
3g
3i
3j
3k
31
3m
3n
3o
4d
CQ
AQ
IC50 (nM) 
TM6
10.2 ±5.3
4.2 ± 1.3
9.4 ±6.7
24.4 ±4.8
66.3 ± 11.3
10.3 ±4.3
6.4 ±2.3 
500 ±22.4
360.3 ± 13.3
7.0 ± 1.2
4.5 ±3.2
5.0 ±2.2 
75 ±22.1
7.2 ±3.3
IC50 (nM) 
HB3
12.3 ±5.1
15.2 ±3.7
12.3 ±3.2
54.5 ±8.3 
144.3 ±12.8
9.6 ±3.4
9.1 ±2.1 
485 ± 14.1 
760 ±23.3
16.1 ±7.2
8.1 ±3.2
10.1 ±3.2
20.2 ± 10.1
5.5 ±3.2
Table 5.3 In vitro antimalarial activities of 4-chloro series versus CQ- 
sensitive HB3 Strain and TM6 CQ-Resistant of Plasmodium falciparum. TM6 is
a CQ-resistant strain of P. falciparum, HB3 and 3D7 are CQ-sensitive strains of P. 
falciparum.
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As this project progressed, the excellent profiles displayed by the ISQ 
analogue Id, and in particular the metabolic advantages provided by the N-tert butyl 
side-chain led to the selection of 2k for further biological assessment against eight 
additional strains of P. falciparum. In the expanded testing contained in Table 5.3, 
data is also included for the pyrrolidino analogue 2e.
Strain CQ AQ 2k 2e
TM6 212.0 ± 30.1 6.9 ±3.2 21.9 ±5.4 60.8 ± 8.9
Kl 170.6 ±22.3 20.0 ±2.3 22.0 ±3.4 45.9 ± 12.2
HB3 16.0 ±3.4 8.5 ±3.4 14.6 ±5.4 63.7 ± 11.2
PH3 30.8 ± 12.3 15.2 ±4.4 25.8 ±6.7 25.0 ± 8.2
TM4 112.8 ±22.2 15.1 ±3.3 17.3 ±4.9 46.9 ± 18.1
DD2 59.3 ± 11.1 9.5 ± 1.4 22.4 ± 1.6 36.9 ±4.9
VIS 154.0 ± 17.3 8.9 ±4.6 26.1 ±7.6 52.5 ±9.5
J164 133.5 ± 14.5 18.5 ±4.2 29.2 ±4.5 34.7 ±8.3
Table 5.4 Expanded in vitro antimalarial activities of 2k and 2e versus a 
panel of P. falciparum Isolates. aTM6, Kl, TM4, VIS, J164 are all CQ- resistant 
strains of P. falciparum. The strains HB3, PH3, DD2 are CQ-sensitive.
The data indicates that 2k is superior to the pyrrolidino analogue 2e against 
all of the strains examined. It is also clear that N-tert butyl analogue 2k is potent 
against CQ-resistant strains, though it is not quite as active as AQ against both CQ- 
sensitive and resistant parasites. Based on the activity presented in Table 5.4, the 2k 
was selected for further studies in the mouse model of malaria.
5.2.2.2 In Vivo Antimalarial Activity Against Plasmodium Berghei ANKA
The therapeutic efficacy of 2k and selected 4-aminoquinolines was evaluated 
in a standard ‘4-day test’ in CD1 mice infected intravenously with the murine 
pathogen P berghei ANKA at GlaxoSmithKline, Tres Cantos, Spain.
165
Compound
ED50
(mg/kg)
95 %
Confidence
Interval
ED90
(mg/kg)
95 %
Confidence
Interval
AQ 2.1 2.0 to 2.2 3.2 2.0 to 2.2
ISQ 3.7 3.4 to 3.9 5.3 3.4 to 3.9
desISQ 5.3 4.1 to 6.8 7.3 4.1 to 6.8
NTBISQ (le) 2.8 3.3 to 4.3 4.7 4.8 to 6.1
(2k) 5.3 4.1 to 6.8 12.4 4.1 to 6.8
Table 5.5 Therapeutic efficacy of 2k, NTBISQ (le) and the ISQ series 
against P. berghei ANKA infection in mice. Standard 4-day Test assay3.
Groups of five mice were inoculated i.v. with 107 infected erythrocytes/mice. The compound 
was administered orally once a day for four days starting one hour after infection. Seven 
drug doses were used ranging from 40 to 0.31 mg/kg to determine ED50 and ED90 values. 
Parasitaemia after treatment was measured in peripheral blood by flow cytometry 24 hours 
after the administration of the 4th dose. The results obtained are shown in Table 5.4.
ISQ showed in vivo therapeutic efficacy against P. berghei ANKA with ED50 
and ED90 in the same range as that of AQ. Analogue 2k was also potent in this in 
vivo assay with an ED50 value of 5.3 mg/kg. In conclusion, both 2k and NTBISQ 
showed good therapeutic efficacy against murine parasites (P. berghei), in the same 
range as AQ and other ISQ series compounds.
The therapeutic efficacy of 2k, ISQ, desISQ and the two control compounds, 
AQ and CQ were also evaluated in the standard '4-day test' against the murine 
pathogen P. yoelii 17X. Mice were infected with 6.4 x 106 parasitized 
erythrocytes/mouse i.v. and treatments were started 1 hour after infection. The 
products were administered once a day p.o. in saline. Parasitaemia in peripheral 
blood were measured 96 hours after infection (day 4) and then, every 2-3 days until 
day 23 in order to assess recrudescence after treatment. The results (ED50, ED90, and 
non-recrudescence level) are shown in Table 5.6.
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Compound Test Parameter Mean
(mg/kg)
IC 95 % (1) 
(mg/kg)
CQ 4-day e d 50(2) 3.3 2.8 to 3.7
ED90 4.4 4.0 to 4.9
NRL(3) >40(4) n a (5)
AQ 4-day ED50 2.6 2.1 to 3.2
ED90 3.7 3.3 to 4.1
NRL
rfOA NA
ISQ 4-day ED50 5.2 4.6 to 5.8
ED90 7.6 6.9 to 8.3
NRL >40(4) NA
DesISQ 4-day ED50 5.5 5.1 to 5.9
ED90 8 7.6 to 8.5
NRL
OA NA
2k 4-day ED50 7.7 6.7 to 8.9
ED90 10.6 9.4 to 11.8
NRL
OA NA
Table 5.6 Therapeutic efficacy of 2k and ISQ derivatives against P. yoelii 
17X infection in mice. Standard 4-day Test assay. CQ and AQ were included as 
control compounds.
(1) Interval of confidence of the mean
(2) Dose at which a 50 % of reduction of parasitaemia in peripheral blood is achieved at day 
4 after infection
(3) Non recrudescence level (NRL) is defined as the minimum dose at which no 
recrudescence is observed. Highest dose deployed in this study was 40 mg/kg.
(4) NRL level is only defined for treatments which make parasitaemia undetectable by flow 
cytometry at day 4 in the '4-day test'. At the highest dose deployed CQ, AQ, ISQ, 
desethyllSQ and 2k (40 mg/kg) were unable to render parasitaemia undetectable, therefore it 
is not possible to evaluate NRL level for these compounds properly, although actually it is 
higher than 40 mg/kg
(5) Not applicable
5.2.3 Mechanism of Action - Hematin Binding Studies
Recent efforts have centred on developing titration methods to determine 
accurate equilibrium constants and binding stoichiometries for the most widely used 
quinoline antimalarials. We have applied a UV-Visible spectroscopic method for 
determining accurate binding equilibrium constants for several clinically used 
antimalarials and compared the results with fluoro analogue 2k. Initially, the 
titrations were carried out in a mixed aqueous/organic solvent to minimize porphyrin
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aggregation effects and m-oxo dimer formation. Buffered 40% DMSO was used to 
provide a strictly monomeric haem species in solution.
The mode of action for haem binding was investigated. The potential binding 
processes one and two (Scheme 5.4) were mathematically modelled and examined as 
possible best fits for the titrations. In model one there is a step-wise bonding of two 
equivalents of drug to one molecule of haem. In model two there is a step-wise 
addition of two additions of haem to one equivalent of drug.
The UV-Visible spectra obtained after each titrated addition was analyzed 
and stacked against the corresponding absorbances. The data was transferred for 
analysis using the Pro-Fit non-linear curve fitting program licensed from Quansoft. 
The data was fitted to achieve chi2 at minima to produce Ki and K2 fitted parameters 
for both models. This was initially done at one wavelength and then simultaneously 
at 10-15 wavelengths to give a more unbiased approach to fitting and more accurate 
values in comparison to fitting at just a single wavelength. Table 5.7 below shows 
the Ki and K2 values obtained from this method for CQ, AQ, quinine, 2k and 
mefloquine, with the best fitted model shown.
L ^  PLL Model 1
PLP Model 2
Scheme 5.4 Potential binding interactions for drug (L) with haem (P). After 
the first association of porphyrin with drug, there are two distinct binding events in 
which either another drug or porphyrin molecule coordinate to the intermediate 
adduct.
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An important observation indicated from the resulting fits is that the binding 
stoichiometries for the quinoline-methanol antimalarials, quinine and mefloquine are 
different from the 4-aminoquinolines included in this work. The second binding 
event in the CQ titrations involves the addition of another molecule of haem whereas 
the second binding to the quinine-haem adduct involves a second molecule of ligand. 
This is in line with earlier studies derived from NMR experiments suggesting that the 
binding modes of 4-aminoquinoline antimalarials, such as CQ and AQ and 
quinoline-methanol antimalarials, such as quinine and mefloquine, are different.
Compound Solvent Log K] Log K2
Best
fit
Model
CQ 40% DMSO 4.60(±0.1) 6.70(±0.1) 2
AQ 40% DMSO 4.40(±0.1) 6.20(±0.1) 2
Quinine 40% DMSO 4.40(±0.1) 4.10(±0.1) 1
Mefloquine 40% DMSO 3.84(±0.1) 3.17(±0.1) 1
2k 40% DMSO 5.45(±0.1) 5.68(±0.1) 2
Table 5.7 Equilibrium constants for the binding of antimalarials with haem 
in DMSO solutions
The data measured are in quite good agreement with the literature and 
demonstrate that the fluoro analogue 2k can form a 2:1 complex in solution with 
clearly defined association constants. Selected analogues from the new series of 4- 
aminoquinolines were also examined for their ability to inhibit p-haematin formation.
All of the compounds tested had excellent activity in this assay including the 
imidazole containing analogues 2p, 3p and 4e. These molecules are interesting in 
the sense that in addition to n-n stacking over the porphyrin ring system of haematin, 
these agents may also have the capacity to interfere with haematin dimérisation or
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crystallisation by binding to iron by axial ligation. Both the 2k and chloro variant 3o 
had super-imposable activity in the assay.
In an assay to determine the concentration of drug to inhibit P-haematin 
formation all compounds tested were shown to be equally as potent as CQ with the 
exception of 4e (Table 5.8). This compound was a deshydroxyl analogue of AQ 
indicating the importance of the hydroxyl group in binding to the porphyrin nucleus.
Compounds
IC50
Drug: haemin 
molar ratio'
2k 1.66
21 1.78
3pa 1.58
3j 1.66
4d 1.65
4e 2.65
AQb 0.85
CQ 1.78
Table 5.8 Results of the BHIA assay (inhibition of p-haematin formation).
’The drug concentration required to inhibit P-haematin formation by 50% (IC50) was 
determined for each compound. The results are the mean IC50 of two different 
experiments performed in duplicate. a Compounds not completely dissolved. 
(Parapini etal ,  2000)
5.2.4 Conclusion
The aim of this study was to investigate the antimalarial activity of two series 
of AQ analogues where the 4’-hydroxyl function of AQ was replaced by either 
fluorine or chlorine. The intention of this was to block formation of a toxic quinone 
imine metabolite in vivo whilst retaining an electronegative function capable of 
intramolecular hydrogen bonding. In addition to this, interest was paid to the 
interaction of target compounds with haem.
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The study introduced a divergent synthesis which proved successful for the 
preparation of the chloro series, producing a number of analogues in high yield. The 
linear approach was preferred for the synthesis of the fluoro series due to low yields 
obtained following the divergent route.
Fluoro analogues were tested against the CQ-sensitive 3D7 strain of P. 
falciparum malaria whilst chloro analogues were tested against three falciparum 
strains, the CQ-sensitive 3D7 and HB3 strains and the CQ-resistant TM6 strain. A 
significant conclusion derived from these studies has been that the majority of the 
fluoro analogues were active around 30 nM. The exceptions to this were the 
dipropyl, dibutyl and morpholine side-chain analogues. After calculating the 
lipophilicity of these compounds using computational prediction software 
(VCCLAB, 2005) it was observed that molecules with very high lipophilicity tend to 
be less potent as antimalarials (Table 5.9).
Previous studies in the group have reported the importance of a tert butyl 
function for optimal activity (O'Neill et al., 1997). This was mirrored in the results 
of this chapter as the highest activities were observed with molecules containing a 
tert butylamino group in the side-chain (2k and 3o).
Further screenings of molecule 2k (known as FAQ-4) against a number of 
CQ-sensitive and CQ-resistant strains of P. falciparum malaria showed there was no 
evidence of cross resistance with this drug.
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Table 5.9 Comparison of the in vitro activity and lipophilicity of the most 
and least potent chloro and fluoro analogues (against the 3D7 strain ofP. 
fa lciparu m ).
Studies have shown that the mechanism of action of quinoline antimalarial 
drugs such as CQ relies strongly on the inhibition of the crystallisation process of 
haem to P-haematin (Chou et al., 1980; Slater et al., 1992; Sullivan et al., 1996). 
The mode of bonding between the drug and haem is believed to be by a 7t-7r stacking 
interaction between aromatic groups in the drug and haem (Constantinidis et al., 
1988). Egan and co-workers have described the binding of quinoline antimalarial
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drugs to haem in a 40 % DMSO solution (Egan et al, 1997). According to Egan, the 
best-fit model for the binding of CQ to haem gives a stoichiometry of 1:1. Our study 
contradicts this result in that we found we could model a 2:1 interaction of CQ:haem. 
This model predicts a two-stage interaction between the drug and haem, whereby the 
drug can bind to haem with binding constant Ki before a second equivalent binds 
with binding constant K.2. These results are significant since mefloquine and quinine 
do not form a 2:1 complex with haem but form a 1:1 complex.
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CHAPTER 6
THE EFFECT OF HALOGEN SUBSTITUTION ON THE METABOLISM 
AND DISTRIBUTION OF TWO NOVEL 4-AMINOQUINOLINES
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6.1 INTRODUCTION
This chapter explores a second route of potential metabolic escape by the 
substitution of the 4’-hydroxyl group of amodiaquine (AQ) with a halogen atom.
In 1993 Barnard et al. investigated the effects of the introduction of fluorine 
to the aromatic nucleus of paracetamol (Barnard et al., 1993). They found that 
substitution of fluorine led to an increase in oxidation potential of the drug, thereby 
blocking the in vivo formation of a cytotoxic quinone imine (discussed in Chapter 1, 
Section 1.3.1.1). In a further study, undertaken at The University of Liverpool, this 
was effect was also noted with AQ. The systematic fluorine substitution of the 
aminophenol ring was investigated in order to try and increase the oxidative stability 
of the ring system and also to reduce the in vivo oxidation to amodiaquine quinone 
imine (AQQI) (O'Neill et al., 1994) (Chapter 1, Section 1.4.5). Isosteric replacement 
of the hydroxyl group provided an analogue with significantly raised oxidation 
potential and reduced bioactivation in vivo. In contrast to the reduction in biological 
activity observed in the fluorinated paracetamol series, fluorinated analogues of AQ 
retained pharmacological activity, which suggested that oxidation to quinone imine 
metabolites is not required for antimalarial activity.
These studies present a strong case for the use of fluorine as a means to 
prevent the oxidation of AQ to AQQI. In addition to this, it is thought that chlorine 
substitution may also have a similar effect. Combining this with a tert butylamino 
side-chain in place of the diethylamino side-chain of AQ to increase metabolic 
stability, two back-up compounds have been rationally designed and synthesized. 
These compounds are N-tert butyl fluoro amodiaquine (FAQ-4) and N-tert butyl 
chloro amodiaquine (C1AQ-4) (Figure 6.1). The chemical and radiochemical 
syntheses of these compounds were described in Chapter 2.
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Target Bioactivation - 
Prevent oxidation to 
toxic quinoneimine 
metabolite
Target Metabolic Stability - 
Prevent dealkylation in vivo
AQ
FAQ-4 C1AQ-4
Figure 6.1 Structures of two novel 4-aminoquinolines, FAQ-4 and C1AQ-4 to 
be used as back-up candidates.
These particular compounds were chosen to go forward as candidates in this 
study due their exceptional antimalarial properties in vitro (Table 6.1). Each 
compound was active against both chloroquine-sensitive and -resistant strains of 
parasite in the nanomolar range. In addition to this, FAQ-4 was observed to be 
almost as active as AQ in vivo in mice against the P. berghei rodent strain of malaria 
(see comprehensive SAR in Chapter 5).
Preliminary pharmacokinetic studies have been initiated with FAQ-4. 
Results to date show that whilst the oral bioavailability could not match N-tert butyl 
isoquine (NTBISQ) (Chapter 4) across all species, it was shown to be 100 % in the 
rat and better than that of isoquine (ISQ) in other species (Table 6.1). Data for 
C1AQ-4 has not yet been generated.
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Species ISQ F% desISQ F % NTBISQ F % ■ FAQ-4 F %.
Mouse 21 100 100
Rat 17.0 ±4.0 60 ±26 89 ± 12
OO
Dog NQ NE 92 ± 13
fC V „ ' -H '.,',a  i,- ' 4
Monkey ND 40 ± 14 100
Table 6.1 Oral bioavailability of FAQ-4 in animals compared to other 
compounds of the same class. Data obtained from a pre-clinical, pharmacokinetics 
study at GlaxoSmithKline, Tres Cantos, Spain. Data are expressed as mean ± SD 
(n=3). NE = Not estimated (emesis observed in oral leg may have resulted in 
decreased oral exposure). NQ = Not quantifiable. ND = no data.
The aim of this chapter was to investigate the metabolism and distribution of 
two new series of AQ analogues where the 4’-hydroxyl function of AQ is replaced 
by either a 4’-fluorine or 4’-chlorine atom. This approach provides analogues that 
are resistant to aromatic hydroxylation whilst retaining full activity against malaria 
parasites. In addition, these halogenated ring systems cannot form potentially toxic 
electrophilic quinone imine metabolites (c.f. AQ).
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6.2 MATERIALS AND METHODS
6.2.1 Materials
[3H]-FAQ-4 (24.08 Ci/mmol; radiochemical purity by HPLC greater than 97 
%) and [3H]-ClAQ-4 (46.50 Ci/mmol; radiochemical purity by HPLC greater than 98 
%) were prepared via a 1-step synthesis described previously, (Chapter 2, Sections 
2.2.2.12 and 2.2.2.14). Tissue solubilizer-450 (0.5 N quaternary ammonium 
hydroxide in toluene) was purchased from Beckmann Chemicals, (Bremen, 
Germany). Ultima Flo and Ultima Gold scintillant were from Packard Bioscience 
BV, (Groningen, Netherlands). HPLC grade solvents were products of Fisher 
Scientific, (Loughborough, Leicestershire, UK).
Adult male Wistar rats (200-400 g) were obtained from Charles River 
(Margate, U.K.). The protocols described were undertaken in accordance with 
criteria outlined in a licence granted under the Animals (Scientific Procedures) Act 
1986 and approved by the University of Liverpool Animal Ethics Committee.
5.2.2 Methods
6.2.2.1 In Vivo Metabolism o f [3H]-FAQ-4 and[3H]-ClAQ-4 in the Rat (5 h)
Adult male Wistar rats (250 - 400 g n = 4) were anaesthetised with urethane 
(1.4 g/mL in isotonic saline; 1 mL/kg, i.p.). Polyethylene cannulae were inserted 
into the trachea, femoral vein and common bile duct and the penis was ligated. 
Drug-blank bile was collected for approximately 20 minutes before treatment. [3H]- 
FAQ-4 or [3H]-ClAQ-4 (54 pmol/kg; 20 pCi/rat) was dissolved in saline (0.5-1 mL 
depending on animal weight) and was injected over 10 min (z'.v.). Bile was collected 
hourly for a time period of 5 h into pre-weighed eppendorf tubes. Samples were
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weighed after collection to determine the extent of biliary secretion and stored at -30 
°C until analysis by LC-MS.
After 5 h, urine was aspirated from the bladder and transferred to a pre­
weighed Eppendorf tube and a cardiac puncture was performed. The blood was 
centrifuged (1000 g, 6 min) and the plasma transferred to a separate tube. The 
plasma from each experiment was pooled together and then blood proteins were 
removed by the exhaustive addition of MeOH (5 eq vv) followed by centrifugation 
(1200 g, 10 min). The supernatant was removed and concentrated by evaporation 
before re-dissolving it in MeOH (200 pL). The plasma and urine samples were 
stored at -30 °C until analysis by LC-MS.
Aliquots of bile and urine (30 pL) were mixed with scintillant (4 mL) for 
determination of radioactivity.
6.2.2.2 LC-MS Analysis o f Bile, Urine and Plasma Samples
Aliquots of bile, urine and plasma (100 pL) were analysed at room 
temperature on a Hypersil 5-pm HyPurity Elite C-18 column (150 x 4.6 mm; 
Thermo Hypersil-Keystone, Runcorn, Cheshire, UK) with a gradient of acetonitrile 
(10-50 % over 30 min (FAQ-4), 20-50 % over 30 min (C1AQ-4)) in trifluoroacetic 
acid (0.1 %, v/v). The LC system consisted of two Jasco PU980 pumps (Jasco UK, 
Great Dunmow, Essex, UK) and a Jasco HG-980-30 mixing module. The flow rate 
was 0.9 mL/min. Eluate split-flow to the LC-MS interface was ca. 40 pL/min. A 
Quattro II mass spectrometer (Micromass MS Technologies, Manchester, UK) fitted 
with the standard co-axial electrospray source was used in the positive-ion mode. 
Nitrogen was used as the nebulizing and drying gas. The interface temperature was 
80 °C; the capillary voltage, 3.9 kV. Spectra were acquired between m/z 100 - 1050
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over a scan duration of 5 s. Fragmentation of analyte ions was achieved at a cone 
voltage of 50-70 V. Data were processed with MassLynx 3.5 software (Micromass). 
Radiolabelled analytes in the remainder of the eluate were detected with a 
Radiomatic A250 flow detector (Packard, Pangbourne, Berkshire, UK). Eluate was 
mixed with Ultima-Flo AP scintillant (Packard Bioscience BV, Groningen, 
Netherlands) at 1 mL/min.
6.2.2.3 In Vivo Retention Studies o f [3HJ-FAQ-4 and f3HJ-CIAQ-4 in the Rat 
Adult male Wistar rats (200 - 400 g, n = 4) were administered a solution of
[3H]-FAQ-4 or [3H]-ClAQ-4 (54 pmol/kg; 20 pCi/rat) dissolved in saline (0.5 -  1 
mL; i.p.). The animals were then transferred to individual metabolism cages 
equipped with a well for collecting urine and faeces. The rats were allowed food and 
drink ad libitum for a 24 h period before administration of a lethal dose of 
pentabarbitone.
Aliquots of urine (30 pL) were collected and mixed with scintillant for 
determination of radioactivity. The collected faeces were weighed and dissolved in 
distilled water for a period of 16 h before determination of radioactivity using the 
method described (Section 6.2.2.6). The major organs were then removed and 
assessed for radioactivity.
6.2.2.4 In Vivo Retention Studies o f [3HJ-FAQ-4 and -ClAQ-4 in the Rat (48 h) 
Adult male Wistar rats (n = 4) were administered a solution of either [3H]-
FAQ-4 or [3H]-ClAQ-4 (54 pmol/kg; 20 pCi/rat) dissolved in saline (0.5 -  1 mL; 
i.p.). The animals were kept in a normal animal cage for a period of 24 h before they 
were transferred to individual metabolism cages equipped with a well for collecting
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urine and faeces. The rats remained in the metabolism cages for a further 24 h, with 
full access to food and drink, before overdose using pentabarbitone.
Aliquots of urine (30 pL) were collected and mixed with scintillant for 
determination of radioactivity. The collected faeces were weighed and dissolved in 
distilled water for a period of 16 h before determination of radioactivity using the 
same method as described earlier (Chapter 6, Section 6.2.2.4). The major organs 
were then removed and assessed for radioactivity.
6.2.2.5 In Vivo Retention Studies o f [3H]- FAQ-4 and [3H]-ClAQ-4 in the Rat 
(168-240 h)
Adult male Wistar rats (n = 4) were administered a solution of [3H]-FAQ-4 
or [3H]-ClAQ-4 (54 pmol/kg; 20 pCi/rat) dissolved in saline (0.5 -  1 mL; i.p.). The 
animals were kept in a normal animal cage for a period of 168 h or 240 h with full 
access to food and drink before administration of a lethal dose of pentabarbitone. 
The major organs were then removed and assessed for radioactivity.
6.2.2.6 Tissue Distribution o f [3H]-FAQ-4 and[3HJ-CIAQ-4 in the Rat
At the end of the relevant time-point (5 h, 24 h, 48 h, 168 h or 240 h) the 
animals were killed by a lethal dose of pentabarbitone and the major organs were 
excised (brain, eyes, heart, lungs, liver, kidneys, spleen, testes and skin) and stored at 
-30 °C.
Duplicate portions (50 -  100 mg) of the tissues were weighed and solubilized 
in tissue solubilizer (0.75 mL) at 50 °C for 16 h. The solutions were decolourised 
with hydrogen peroxide (200 pL) over 1 h and then neutralised using glacial acetic 
acid (30 pL) before leaving in the darkness for 16 h to prevent chemoluminescence.
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Ultima Gold scintillant (10 mL) was added before the radioactivity was determined 
by scintillation counting.
6.2.2.7 Cytotoxicity ofFAQ-4 and CIAQ-4 in Isolated Rat Hepatocytes
Male Wistar rats (200 - 250g) (n = 3) were terminally anaesthetised with 
pentobarbitone sodium (90mg/kg in isotonic saline i.p.). Hepatocytes were isolated 
using a two-step collagenase perfusion method adapted from that of Guguen- 
Guillouzo et al (Guguen-Guillouzo et al., 1986). The abdomen was opened and the 
liver cannulated through the portal vein using a gauge catheter. Before perfusion, the 
heart was removed to allow free loss of perfusion buffers. The liver was washed 
with calcium-free HEPES buffer for 10 mins at a flow rate of 40ml/min. The liver 
was then perfused with digestion buffer, a mixture of wash buffer with 5 % CaCl2 
solution, for 6 -  10 mins. The digested tissue was then excised and placed in a Petri 
dish containing wash buffer and DNAase (0.1 % w/v). The tissue was anchored and 
the Glison’s capsule was disrupted and disturbed to release the cells. The cell 
suspension was filtered through gauze to eliminate cell debris, blood and sinusoidal 
cells. The cells were washed three times in DNAase wash buffer before re­
suspending in incubation buffer (HEPES buffer and MgSO4.7H20 (0.25 % w/v)). 
Cell viability was then assessed microscopically using the trypan blue exclusion test.
The cells were then incubated with various concentrations of the relevant 
compound for a period of 6 hours before determining cell viability in the presence of 
test compound using the trypan blue exclusion test.
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6.2.2.8 Statistical A nalysis
All results are expressed as mean ± standard error of the mean (SEM). 
Values to be compared were analysed for non-normality using a Shapiro-Wilk test. 
Student t-tests were used when normality was indicated. A Mann-Whitney U test 
was used for non-parametric data. For analysis of sets of data with variance, a 1-way 
analysis of variance (ANOVA) test was used for parametric data and a Kruskell- 
Wallis test was used for non-parametric data. All calculations were performed using 
StatsDirect statistical software, results were considered to be significant when P < 
0.05.
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6.3 RESULTS AND DISCUSSION
6.3.1 LC-MS Analysis of In Vivo Metabolites of [3H]-FAQ-4 in the Rat
Following administration of [3H]-FAQ-4 (54 pmol/kg, 20 pCi) to male, 
Wistar rats, the total recovery of radioactivity in the bile was 9.76 ± 2.34 % of the 
given dose. This was in the form of six different metabolites (Figure 6.2). 
Metabolites I, II and III were very minor, comprising less than 11 % of the total 
metabolites present, and could not be identified. Metabolite IV, retention time (Rt) 
8.36 min, was found to be the most abundant radioactive component in bile and 
comprised 62.50 ± 9.37 % of the total metabolites present. LC-MS analysis 
identified the characteristic eluting pairs of chlorine isotopes in the positive-ion mass 
chromatogram for m/z 469 (Figure 6.3B). This molecular weight could not be 
attributed to any known simple metabolite and the addition of 111 amu to the parent 
compound did not correspond to any recognised conjugate. The absence of IV in 
drug-blank bile proved the unknown compound to be a product of metabolism and 
not an endogenous component of bile (Figure 6.5). This was further proved by 
comparison of the mass spectrum of m/z 469 with that of the parent compound {m/z 
358) which showed many of the same molecular fragmentation (Figure 6.4). 
Metabolite IV appeared to show the diagnostic loss of 129 amu on the mass 
spectrum to a peak of m/z 340. This also was unassigned. In an attempt to try and 
ascertain the identity of IV and other unknown metabolites, pooled bile was 
concentrated via the exhaustive addition of water and methanol using a Sep-Pak® 
cartridge. This served only to concentrate the endogenous components of bile at the 
expense of the drug metabolites. In addition to this, pooled bile samples were 
fractionated using HPLC in order to isolate the unknown metabolite IV. The isolated 
fractions were then analysed using LC-MS, however resolution could not be
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improved and no further information on the unknown metabolites could be 
determined. It is possible that the unknown metabolite of m/z 469 could be a result 
of multiple transformations in vivo, or that [3H]-FAQ-4 has formed some type of 
complex from interaction with endogenous bile acids.
The parent compound V eluted at Rt = 12.36 (Figure 6.2, represented by the 
shaded area). Only 5.35 ± 2.22 % of the radioactive dose was parent compound. 
Again, LC-MS analysis detected co-eluting pairs of chlorine isotopes for m/z 358 
([M+l]+) and the familiar fragmentation pattern of loss of the tert butyl side-chain (- 
56 amu) could be clearly seen (Figures 6.3 and 6.4A). A sixth metabolite VI (Rt =
17.02 min) was also shown on the HPLC trace; however this too could not be 
identified using LC-MS.
Figure 6.2 HPLC radiochromatogram of the biliary metabolites of [3H]- 
FAQ-4 (54 pmol/kg, 20 pCi; 1 h collection). I, II and III represent unknown minor 
metabolites, IV represents a major metabolite of m/z 469, V represents the parent 
compound [3H]-FAQ-4, VI represents a fourth unidentifiable metabolite.
1 8 8
[3H)-FAQ-4 Rat B, 1 h bile
Figure 6.3 Positive-ion electrospray mass chromatograms corresponding to
(A) m/z 358, [3H]-FAQ-4 and (B) m/z 469, an unknown metabolite excreted in the 
bile of male Wistar rats 5 h after dosing i.v. with [3H]-FAQ-4 (54 pmol/kg, 20 pCi).
(3HJ-FAQ-4 Rat B, 1 b Bile
Hyparify Elite ACN [10-50 % , 30 min), TFA (0.1 %)
Figure 6.4 Positive-ion electrospray mass spectrum showing the 
fragmentation of an unknown metabolite of [3H]-FAQ-4, with m/z 469, excreted 
in the bile of male, Wistar rats dosed Lv. with [3H]-FAQ-4 (54 pmol/kg, 20 pCi, 
l h ) .
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[3H]-FAQ-4
HvPurltv Elite, ACN [10-50 *o, 30 min) TFA (0.1 «20)
A. Bile 1 h, Rat B
B. Drug-blank bile, Rat B
Figure 6.5 Positive-ion electrospray mass chromatograms corresponding to
(A) m/z 469, the unknown, major metabolite excreted in rat bile after dosing i.v. with 
and [3H]-FAQ-4 (54 pmol/kg, 20 pCi); (B) Drug-blank bile indicating the absence of 
the unknown prior to dosing in male, Wistar rats and (C) Total-ion current for drug- 
blank bile.
The metabolic profile of [3H]-FAQ-4 in the urine of male, Wistar rats proved 
to be more straightforward to deduce than that in bile. Following administration of 
the drug, 7.69 ±1.14 % was recovered in urine. The HPLC radio-chromatogram 
showed six metabolites (Figure 6.6). Metabolites I and III were also seen in bile and 
were present only in minor quantities, too low to be identified by LC-MS. 
Metabolites VII, V, VIII and IX were determined by LC-MS which identified pairs 
of chlorine isotopes in the positive-ion mass chromatogram for m/z 388, 358, 374 and 
564 (Figure 6.7). Metabolite VII (m/z 388) eluted at Rt = 10.91 min, comprising 
14.22 ± 2.21 % of the total radioactive metabolites and was identified as the side- 
chain carboxylic acid (Scheme 6.1). The corresponding glucuronide (m/z 564, IX) 
was observed at Rt =15.75 min (9.95 ±3.11 %), the identity of which was confirmed
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by the diagnostic elimination of dehydroglucuronic acid (-176 amu). Metabolite V 
(m/z 358, [M+l]+) was quite clearly the parent compound. It eluted at Rt = 12.36 
min and was the major metabolite found in urine (67.53 ± 9.22 %). Metabolite VIII 
(m/z 374) was identified as the A-oxide of [3H]-FAQ-4 ([M+l+16]+). Analysis of the 
fragmentation pattern of m/z 374 showed the diagnostic loss of 56 amu to m/z 318, 
indicating that the oxygen was most certainly not part of the amino side-chain and 
was instead part of the quinoline ring system (A-oxide) (Figure 6.8).
Figure 6.6 HPLC radiochromatogram of the urinary metabolites of [3H]- 
FAQ-4 (54 jumol/kg, 20 pCi). I and in  represent unknown metabolites, V 
represents the parent compound, [3H]-FAQ-4, VII represents a derivative of [3H]- 
FAQ-4 with a carboxylic acid within the tert butyl side-chain, VIII represents a 
mono-oxygenated species -  likely to be [3H]-FAQ-4-A-oxide and IX represents a 
glucuronide of metabolite VII.
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[3H)-FAQ-4 l ’rioe R at B
Figure 6.7 Positive-ion electrospray mass chromatograms corresponding to
(A) m/z 564 (IX), the glucuronide of metabolite VII; (B) m/z 374, (VIII) [3H]-FAQ- 
4-A-oxide; (C) m/z 358 (V), parent compound - [3H]-FAQ-4; (D) m/z 302, the 
characteristic loss of side-chain observed with [3H]-FAQ-4; (E) m/z 388 (VII), [ H]- 
FAQ-4 with a carboxylic acid incorporated into the amino side-chain excreted in the 
urine of male Wistar rats, 5 h after dosing i.v. with [3H]-FAQ-4 (54 pmol/kg, 20 
pCi).
(3HJ-FAQ-4 Rat B Urine
Hypnrity Elite, ACN (10-50 %, 30 min| TFA (0.1 %)
[M+l+30]+
100
M f 1 
300
m/Z
S00 1000
Figure 6.8 Positive-ion electrospray mass spectrum showing the 
fragmentation of (A) m/z 374, [3H]-FAQ-4-jV-oxide VIII; (B) m/z 358, parent 
compound, [3H]-FAQ-4 V; (C) m/z 388, carboxylic acid side-chain derivative of 
[3H]-FAQ-4 VII, excreted in the urine of male, Wistar rats dosed i.v. with [3H]-FAQ- 
4 (54 pmol/kg, 20 pCi).
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6 .3 .1 .1  C o n c lu sio n
[3H]-FAQ-4 has been shown to undergo metabolism to a total of nine 
metabolites in rats, in vivo (Table 6.2). Of these, four have been identified and the 
structures elucidated (Scheme 6.1). The major biliary metabolite of [3H]-FAQ-4 was 
thought to be m/z 469; however, a corresponding structure could not be assigned. In 
urine [3H]-FAQ-4 was excreted mainly as the parent compound. Importantly, no 
glutathione conjugates were identified indicating that the incorporation of fluorine 
into the AQ backbone has eliminated the possibility of the formation of a toxic 
quinone imine metabolite.
IV Structure unknown (major metabolite) 
MW = 469 
R t= 8.36 
Bile
VII MW 388 
Rt = 10.91 
Urine
IX MW 564 
Rt= 15.75 
Urine
-OH
-OH
Scheme 6.1 Structures of the metabolites identified in the bile and urine of 
male, Wistar rats dosed Lv. with [3H]-FAQ-4 (54 pmol/kg, 20 pCi).
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Peak
Retention
Time
(min) m/z Metabolite Identity
Metabolite 
proportion 
(% of
radiolabeled 
metabolites, 
0-5 h)
Present in 
Bile/Urine
I - III
3.60, 3.80, 
6.26 ND ND
2.43 ±0.21, 
0.47 ±0.03, 
3.57 ±2.31
Bile and 
Urine
IV 8.36 469 ND 62.5 ±9.37 Bile
V 12.36 358 FAQ-4
5.35 ±2.22, 
67.53 ±9.22
Bile and 
Urine
VI 16.26 ND ND 19.0 ±3.49 Bile
VII 10.91 388
Carboxylic acid in 
side-chain of FAQ-4 14.22 ±2.21 Urine
VIII 13.8 374 FAQ-4-W-oxide 3.55 ±0.21 Urine
IX 15.75 564
Glucuronide of 
carboxylic acid side- 
chain derivative 9.95 ±3.11 Urine
Table 6.2 A summary of the metabolites produced in the bile and urine of 
male, Wistar rats after dosing with [3H]-FAQ-4 (54 pmol/kg, 20 pCi).
Metabolites were characterised by LC-MS. ND = No data.
6.3.2 LC-MS Analysis o f/«  Vivo Metabolites of [3H]-ClAQ-4 in the Rat
Administration of the novel 4-aminoquinoline, [3H]-ClAQ-4 to male, Wistar 
rats (54 pmol/kg, 20 pCi, i.v.) led to the formation of a total of six metabolites in bile 
(Figure 6.9). Metabolites I and II were very minor and comprised less than 3 % of 
the total metabolites excreted. Metabolite III eluted at Rt = 13.29 min (4.52 ± 0.03 
%) and was characterized using LC-MS which identified co-eluting pairs of chlorine 
isotopes in the positive-ion electrospray mass chromatogram for m/z 390 (Figure 
5.10). This corresponded to a mono-oxygenated species, the fragmentation pattern 
of which indicated that the oxygen atom was located within the quinoline ring system 
and not the amine side-chain (Figure 6.11). This led us to deduce that the TV-oxide
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had been formed. The major metabolite produced in bile was a side-chain carboxylic 
acid derivative of [3H]-ClAQ-4 IV (Figure 6.9 and Scheme 6.2). IV eluted at Rt — 
14.74 min and represented 60.76 ± 2.34 % of the metabolites present in bile. LC-MS 
analysis located co-eluting pairs of chlorine isotopes for m/z 404 in the positive-ion 
mass spectrum. The acyl glucuronide of this metabolite was not located in the bile. 
Metabolites V and VI could not be assigned. The eluted at 16.09 and 18.09 min and 
represented 12.48 ± 2.94% and 19.53 ± 6.82 % of the biliary metabolites 
respectively.
Figure 6.9 HPLC radiochromatogram of the biliary metabolites of [3H]- 
C1AQ-4 (54 pmol/kg, 20 fiCi; 3 h collection). I, II represent unknown minor 
metabolites; III represents [3H]-ClAQ-4-V-oxide (m/z 390); IV represents a [ H]- 
C1AQ-4 derivative with a carboxylic acid group situated within the amino side-chain 
(m/z 404); V and VI represent further unidentified metabolites.
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Scan ES+ 
404 
l.34e4
[3H]-CLAQ-4 Rat D, Bile 3 h
Hypuritv Elite, ACN |10-50 «4, 30 min), TEA (0.1 %)
Figure 6.10 Positive-ion electrospray mass chromatograms corresponding to
(A) m/z 404 (IV) a carboxylic acid-derivative of [3H]-ClAQ-4 and (B) m/z 390 (III) 
[3H]-ClAQ-4-V-oxide found in the bile of male, Wistar rats, dosed i.v. with [ H]- 
C1AQ-4 (54 pmol/kg, 20 pCi, 3 hour collection).
(3H]-CIAQ-4 Bile Rat B 
Hypurity Elite, ACN [10-50 % , 30 min) TFA (0.1 % ) 
■AES117 170(14 475)
404 [M+l+30]4
Scan ES+ 
I . i3 e 4
Figure 6.11 Positive-ion electrospray mass spectrum showing the 
fragmentation of (A) m/z 404 carboxylic acid side-chain derivative of [ H]-ClAQ-4 
IV and (B) m/z 390, [3H]-ClAQ-4-V-oxide III excreted in the bile of male, Wistar 
rats dosed ¿v. with [3H]-ClAQ-4 (54 pmol/kg, 20 pCi, Rat B 3 h collection).
As with [3H]-FAQ-4, the metabolic profile of [3H]-ClAQ-4 in urine proved to 
be much clearer and easier to deduce than in bile. Four metabolites were shown in 
the radio-chromatogram (Figure 6.12). LC-MS analysis located co-eluting pairs of 
chlorine isotopes for m/z 404, 374, 390 and 333 (Figure 6.13). The first metabolite to 
be resolved eluted at Rt = 11.93 min and represented 28.48 ± 3.33 % of the total 
metabolites observed (IV). This metabolite was common to both bile and urine and 
was found to be the side-chain carboxylic acid derivative, m/z 404 (Figure 6.13,
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Scheme 6.2). Figure 6.14 shows the characteristic loss of the amine side-chain and a 
similar fragmentation pattern to that of the parent compound. The major component 
of urine was shown to be the parent compound, [3H]-ClAQ-4 VII (Figure 6.12, 
shaded peak Rt = 13.46 min; 55.70 ± 6.31 %). The V-oxide of [3H]-ClAQ-4 (m/z 
390, HI), observed in bile was also found in urine to a much greater extent (34.73 ± 
1.67 %). This again was characterized using LC-MS and a similar fragmentation 
pattern was observed (Figure 6.14). The final metabolite to be found in urine was 
m/z 333. This corresponded to the benzyl acid derivative of [3H]-ClAQ-4 (Scheme 
6.2) and eluted at Rt = 16.52 min and was 11.39 ± 2.99 % of the metabolites present 
in urine.
Figure 6.12 HPLC radiochromatogram of the urinary metabolites of [3H]- 
C1AQ-4 (54 pmol/kg, 20 ju.Ci; 3 h collection). IV represents a metabolite of m/z 
404, the carboxylic acid (situated within the tert butyl side-chain), the shaded peak, 
VI, represents the parent compound, [3H]-CLAQ-4, III represents [3H]-ClAQ-4-V- 
oxide and VIII represents a benzoic acid derivative of [3H]-ClAQ-4.
197
16.52
Scan ES+ 
333 
1,32e4
(3HJ-CIAQ-4 Urine Rat D
Hypuritv Elite, ACN (10-50 %, 30 tuin] TFA (0.1 %)
AESI10
A 100'
® AES! 
100- 14.99
Scan ES+ 
390 
1.28e3
%
0-1 I
q  AES110 
100-1
Scan ES+ 
374 
2.74e4
o-U-
AES116
D 100-,
Scan ES+ 
404
8.00e3
0- -*=(- f n - H  f Time
Figure 6.13 Positive-ion electrospray mass chromatograms corresponding^
(A) m/z 333 (VIII) a benzoic acid-derivative of [3H]-ClAQ-4; (B) m/z 390 (III) [ H]- 
ClAQ-4-iV-oxide; (C) m/z 374 (VII) parent compound; (D) m/z 404 (IV),derivative 
of [3H]-ClAQ-4 with carboxylic acid group found in amino side-chain. Metabolites 
were found in the urine of male, Wistar rats, dosed i.v. with [ H]-ClAQ-4 (54 
pmol/kg, 20 pCi).
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Figure 6.14 Positive-ion electrospray mass spectrum showing the 
fragmentation of (A) m/z 333, benzoic acid derivative of [ HJ-C1AQ-4 VIII, (B) m/z 
390, [3H]-ClAQ-4-V-oxide III; (C) m/z 374, parent compound (VII) and (D) m/z 
404’ carboxylic acid side-chain derivative of [3H]-ClAQ-4 excreted in the urine of 
male, Wistar rats dosed i.v. with [3H]-ClAQ-4 (54 pmol/kg, 20 pCi, h).
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6 .3 .2 .1  C on clu sion
The metabolic profile of [3H]-ClAQ-4 in rats has been deduced. All major 
metabolites were structurally assigned (Scheme 6.2, Table 6.3). The major route of 
metabolism appeared to be oxidation to the side-chain carboxylic acid IV (Scheme 
6.2). Oxygenation of the nitrogen of the quinoline ring to form the A-oxide III was 
also observed. No evidence of bioactivation of [3H]-ClAQ-4 was observed, as 
indicated by the lack of glutathione conjugate formation.
Rt = 13.29 min and 14.99 
Bile and Urine (respectively)
VII MW 374 
Rt= 13.46 
Urine
------Cl
IV MW 404
R t= 14.73 and 11.93
Bile and Urine (respectively)
VIII MW 333 
R t= 16.52 
Urine
Scheme 6.2 Structures of the metabolites identified in the bile and urine of 
male, Wistar rats dosed Lv. with [3H]-ClAQ-4 (54 pmol/kg, 20 ftCi).
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Peak
Retention
Time
(min) m/z Metabolite Identity
Metabolite 
proportion 
(% of
radiolabeled 
metabolites, 
0-5 h)
Present in 
Bile/Urine
i , i i , v
and VI
7.30,
8.02,
16.09,
18.09 ND ND
1.08 ±0.21, 
1.63 ±0.26, 
12.48 ±2.94, 
19.53 ±6.82
Bile
III
13.29,
14.99 390 ClAQ-4-iV-oxide
4.52 ±0.03, 
34.43 ± 1.67
Bile and 
Urine
IV
14.73,
11.93 404
Carboxylic acid side- 
chain derivative of 
C1AQ-4
60.76 ±2.34 
28.48 ±3.33
Bile and 
Urine
VII 13.46 374 C1AQ-4 55.70 ±6. 31 Urine
VIII 16.52 333
Benzoic acid 
derivative of C1AQ-4 11.39 ±2. 99 Urine
Table 6.3 A summary of the metabolites produced in the bile and urine of 
male, Wistar rats after dosing with [3H]-ClAQ-4 (54 pmol/kg, 20 pCi).
Metabolites were characterised by LC-MS. ND =No data.
6.3.3 Tissue Distribution of [3H]-FAQ-4 and [3H]-ClAQ-4 in the Rat
Five hours after administration of a single dose of [3H]-FAQ-4 to cannulated 
rats 55.94 ± 5.82 % of the dose could be accounted for in the organs, bile and urine 
(Figure 6.15). The pattern of distribution followed that seen previously with CQ, 
AQ, NTBISQ and ISQ with the majority of the dose being retained in the liver (17.49 
± 0.82 %) and skin 12.44 ± 1.76 %). Elimination of the drug seemed to be favoured 
neither by biliary or urinary excretion systems with 9.16 ± 1.29 % of the dose being 
excreted in bile and 8.06 ± 1.12 % being excreted in the urine.
As might be expected, the pattern of distribution of [3H]-ClAQ-4 in the 
tissues of male, Wistar rats followed the same pattern as the other 4-aminoquinoline 
compounds tested. Slightly less radioactivity than [3H]-FAQ-4 was recovered in the 
tissues, bile and urine, 47.35 ± 4.77 %, the majority of which being found in the liver 
(12.41 ± 0.29 %). Significant differences in areas of accumulation were seen with
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the kidneys, liver and biliary and urinary output. Five hours after dosing with [3H]- 
C1AQ-4 there was significantly more radioactivity found in the kidneys than 
observed with [3H]-FAQ-4, 5.43 ± 0.28 % versus 3.97 ± 0.13 % (p = 0.0054). In the 
liver, there was significantly less [3H]-ClAQ-4 than [3H]-FAQ-4 (p = 0.0209). This 
was followed by a significant increase in biliary excretion after dosing with [3H]- 
C1AQ-4 (14.88 ± 0.83 %, p = 0.0052). The increased biliary excretion of [3H]- 
C1AQ-4 could be attributed to increased lipophi 1 ic ity.
Figure 6.15 Percentage of radioactive dose recovered in tissues 5 h, after 
administration of [3H]-FAQ-4 and [3H]-ClAQ-4 (54 pmol/kg, 20 pCi/rat) to male 
Wistar rats (n = 4). Results are expressed as mean percentage of dose ± SEM. 
Statistics were performed using a one way ANOVA test for parametric data and 
Kruskal Wallis test for non-parametric data. *P<0.05, **P<0.01, ***P<0.001
On comparison of the tissue distribution of the two novel compounds with 
AQ, 5 h after administration it can be observed that at an equivalent dose, the 
halogenated analogues appear to accumulate in the major organs to a much lesser 
extent than AQ (Figure 6.16). In the brain, kidneys, liver and skin it can be seen that 
there was significantly less retention with the halogenated analogues of AQ.
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Figure 6.16 Percentage of radioactive dose recovered in tissues 5 h, after 
administration of [3H]-AQ, [3H]-FAQ-4 and [3H]-ClAQ-4 (54 ¿imol/kg, 20 
fiCi/rat) to male Wistar rats (n = 4). Results are expressed as mean percentage of 
dose ± SEM. Statistics were performed using a one way ANOVA test for parametric 
data and Kruskal Wallis test for non-parametric data. *P<0.05, **P<0.01,
***P<0.001
Animals were dosed with either [3H]-FAQ or [3H]-ClAQ-4 and kept in 
metabolism cages for a period of 24 hours in order to see if the drugs were 
effectively eliminated or if they would accumulate in the tissues over time (Figure 
6.17). Results showed that both drugs were effectively eliminated after 24 hours 
with the total amount of radioactivity recovered with [3H]-FAQ-4 and [3H]-ClAQ-4 
being 51.36 ± 8.68 % and 61.00 ±.93 % respectively. In the kidneys, almost 2-fold 
more drug was found in rats dosed with [3H]-FAQ-4 than those dosed with [3H]- 
C1AQ-41.48 ± 0.11 % versus 0.31 ± 0.07 %, this was found to be highly significant 
(p < 0.0001). The same was seen on comparison of the radioactivity retained in the 
liver 24 hours after dosing. After dosing with [3H]-FAQ-4 6.57 ± 0.27 % of the dose 
remained in the liver, whilst after dosing with the chloro analogue only 1.87 ± 0.21 
% remained (3.5 fold less). This showed great mathematical significance with p < 
0.0001. The lungs were another example where the choice of halogen substitute 
appeared to make a great difference to the retention of the drug. After dosing with
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[3H]-FAQ-4 1.17 ± 0.06 % of the dose remained, in comparison, after dosing with 
[3H]-ClAQ-4 only 0.25 ± 0.08 % remained, a decrease of almost 5-fold (p < 0.0001).
Figure 6.17 Percentage of radioactive dose recovered in tissues 24 h, after 
administration of [3H]-FAQ-4 and [3H]-ClAQ-4 (54 pmol/kg, 20 (iCi/rat) to male 
Wistar rats (n = 4). Results are expressed as mean percentage of dose ± SEM. 
Statistics were performed using a one way ANOVA test for parametric data and 
Kruskal Wallis test for non-parametric data. *P<0.05, **P<0.01, ***P<0.001.
Although the amount of [3H]-FAQ-4 remaining in the rat after 24 hours was 
relatively low (14.76 ± 2.47) (as compared to 38.54 ± 3.41% after 5 h), and 
significantly lower in the liver and skin (p = 0.0286 and p = 0.0011 respectively), it 
was deemed appropriate to investigate to further time-points (Figure 6.18). After 48 
hours 72.79 ± 2.56 % of the dose could be accounted for in tissues, faeces and urine. 
O f this, less than 8 % remained in the tissues; the remainder had been excreted, 
mainly by biliary excretion. After one week (168 h) very little radioactivity 
remained inside the rat (1.22 ± 0.24 %). After 10 days (240 h) radioactivity was 
negligible in the tissues of the rat indicating a lack of accumulation and the effective 
clearance of [3H]-FAQ-4 after a single dose of 54 pmol/kg.
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Figure 6.18 Percentage of radioactive dose recovered in tissues 5 h, 24 h, 48 h, 
168 h and 240 h after administration of [3H]-FAQ-4 (54 pmol/kg, 20 fiCi/rat) to 
male Wistar rats (n = 4). Results are expressed as mean percentage of dose ± SEM. 
Statistics were performed using a one way ANOVA test for parametric data and 
Kruskal Wallis test for non-parametric data. *P<0.05, **P<0.01, ***P<0.001
6.3.3.1 Conclusion
In vivo studies in rats to assess the distribution and potential 
accumulation/retention of two novel compounds have been carried out. The results 
show that both drugs show a similar pattern of distribution to other 4- 
aminoquinolines of the same class, with the majority of the dose being found in the 
liver and skin. Incorporation of a halogen appears to reduce the retention within the 
tissues as compared to AQ, however the choice halogen is important as the chloro 
analogue appears to have significantly less retention and was cleared much more 
effectively by biliary excretion. After carrying out studies for up to 10 days it has 
been shown that [3H]-FAQ-4 was effectively cleared from the rat and there were no 
issues of retention.
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6.3.4 In Vitro Cytotoxicity of FAQ-4 and C1AQ-4 in Rat Hepatocytes
Rat hepatocytes, isolated using a two-step collagen digestion method (Section 
3.2.2.8) were incubated with AQ, FAQ-4 or C1AQ-4 at concentrations of 0, 20, 50, 
100, 200 and 500 pM (Figure 6.19) Results were expressed as the percentage of 
viable cells, measured microscopically, using a trypan blue exclusion test (as a 
percentage of the control). The results from this study show that the most profound 
difference in toxicity of rat hepatocytes was observed with FAQ-4 (Figure 6.19). By 
replacing the hydroxyl group of AQ with fluorine and incorporating a tert butyl 
group into the amine side-chain the T0X50 increases from 78 pM to 385 pM, a 5-fold 
difference. C1AQ-4 also showed less toxicity than AQ after incubation with rat 
hepatocytes, although to a lesser extent than FAQ-4 (Tox5o 120 pM). The in vitro 
therapeutic index of both FAQ-4 and C1AQ-4 was observed to be very high at 29167 
and 11881 respectively showing that the amount of compound required to kill the 
parasite is much lower than that that will cause toxicity to hepatocytes.
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Figure 6.19 V iability o f  m ale, W istar rat hepatocytes, incubated for 6 h w ith  
various concentrations o f  FA Q -4 or C1AQ-4, and stained w ith Trypan blue dye 
as an indicator for cell death. Results are expressed as mean percentage of dose ± 
SEM. Statistics were performed using a one way ANOVA test for parametric data 
and Kruskal Wallis test for non-parametric data. *P<0.05, **P<0.01, ***P<0.001
Compound
IC50 HB3 
Strain 
(nM)
Tox5o Rat 
Hepatocytes 
(pM)
In Vitro 
Therapeutic 
Index
AQ 9.6 ±3.7 78 ±2.35 8125
FAQ-4 13.2 ±3.4 385 ±25.66 29167
C1AQ-4 10.1 ±3.2 120 ± 14.56 11881
T able 6.6 The in vitro therapeutic index o f  AQ , FA Q -4 and C1AQ-4 as a 
m easure o f  the cytotoxicity in m ale, W istar rat hepatocytes
6.3.6 Conclusion
The metabolism and distribution of two novel 4-aminoquinolines antimalarial 
compounds, FAQ-4 and C1AQ-4 has been investigated. Both compounds were 
shown to follow a similar pattern of distribution, typical of that seen with other 
members of the 4-aminoquinoline class investigated. Accumulation occurred mainly 
in the liver and skin of rats. This was observed more so with the fluoro analogue but 
diminished with time, ruling out any concerns of retention.
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The metabolic profile of FAQ-4 was partially determined; however one major 
metabolite remained unidentified. It was thought that this metabolite was of 
molecular weight 468 but the structure could not be assigned and the possibility 
remains that there was an undefined complex with endogenous biliary components. 
Further analysis employing the use of more sensitive LC-MS equipment is 
imperative.
The metabolic profile of C1AQ-4 was more easily defined and all major 
metabolites were characterized, with the main pathway of metabolism being 
formation of the side-chain carboxylic acid analogue (also observed in the metabolic 
profile of FAQ-4). C1AQ-4 underwent more extensive metabolism by this route than 
FAQ-4. It is possible that the increased lipophilicity of C1AQ-4 (logP = 5.50) may 
have an impact on bioavailability as the drug may undergo extensive first-pass 
metabolism.
OO
4 % (urine)
34 % (bile) 
4 %  (urine)
a
t Cl
'OH
14 % (urine) 5 % (bile) 
68 % (urine)
56 % (urine) 61 % (bile) 
28 % (urine)
MW 468 
63 % (bile)
Scheme 6.3 M etabolic profiles o f FAQ-4 and C1AQ-4 compared.
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Importantly, no glutathione conjugation was observed with either halogenated 
compound.
In addition to the metabolism studies of these compounds, research into the 
potential toxicity was also carried out. Cytotoxicity studies revealed that 
incorporation of a halogen in place of the hydroxyl group of amodiaquine greatly 
decreased the toxicity of these compounds in rat hepatocytes. The choice of halogen 
atom appeared to be important as the fluoro analogue proved to be much less toxic 
than the chloro analogue.
Combined with the excellent antiparasitic properties of FAQ-4 and C1AQ-4, 
the results of this study reveal two candidates worthy of being considered back-up 
compounds to N-tert butyl isoquine (NTBISQ) in the search for a novel 4- 
aminoquinoline antimalarial.
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7.1 DISCUSSION
The necessity for a new 4-aminoquinoline antimalarial to supersede 
chloroquine (CQ) and amodiaquine (AQ) is apparent. The PfCRT-mediated 
resistance to CQ and the toxicity of AQ have prompted a re-examination of the 
pharmacology of new and existing antimalarials. Novel antimalarials are required 
that are both safe and effective. It is therefore important to produce new compounds 
which are active against CQ-resistant strains of malaria and do not undergo 
metabolic activation in vivo.
Piperaquine (PQ), a bisquinoline compound (Figure 7.1) is currently 
undergoing phase III trials in combination with dihydroartemisinin (DHA) (Davis et 
al., 2005; Myint et al., 2007). PQ was introduced as a monotherapy for the treatment 
of malaria in the 1960s. It was considered at least as effective as CQ against P. 
falciparum and vivax malaria and better tolerated. Its use declined in the 1980s due 
to the emergence of PQ-resistant strains of P falciparum and the appearance of 
artemisinin derivatives. In the 1990s, a group of Chinese scientists re-discovered PQ 
as one of the components of short-course artemisinin-based combination therapies to 
achieve a high cure-rate without significant adverse effects (Hien et al., 2004). A 
number of clinical trials carried out by White et al. describe DHA-PQ as a highly 
efficacious and well tolerated combination therapy for the treatment of malaria 
(Myint et al., 2007). Concerns with this combination lie in the fact that the 
calculated terminal half-life for PQ is around 543 hours (Chen et al., 1979). 
Compared to that of DHA (approximately 0.5 hours), the development of resistance 
could be a possibility due to prolonged exposure of PQ at sub-therapeutic levels. Of 
equal concern is that the long half-life of PQ may lead to toxicity through 
accumulation as has been observed for CQ. PQ does not, however, contain any
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obvious structural alert for metabolic activation. It is therefore of great importance 
to design a drug that has a half-life shorter than that of both CQ and PQ.
In terms of research of AQ analogues, a number of different groups have 
developed routes to potent 4-aminoquinoline AQ derivatives. For example, 
Sergheraert and co-workers in France have synthesised a series of novel 4- 
aminoquinolines whose design retains the aromatic ring of AQ but lacks the 4’- 
hydroxyl group responsible for the transformation to the toxic quinone imine 
formation in vivo (Figure 7.1) (Delarue et al., 2001). The strategy of the Sergheraert 
group involved the incorporation of a basic side-chain in both the 3’ and 4’ positions 
of the aromatic nucleus to prevent nucleophilic addition of proteins during 
metabolism. The results of this work revealed several compounds with high 
antimalarial activity, with no cross-resistance in vitro and low cytotoxicity in tests 
using a human lung cell line (Delarue et al., 2001).
More recently, studies utilising structural changes to tebuquine have been 
reported. These investigations described a series of isotebuquine analogues with a 
hydroxy group meta rather than para position to the amino group of the aniline 
moiety (Figure 7.1). These structural alterations meant the analogues would be 
unable to produce the toxic quinone imine metabolite in vivo. In vitro testing of 
these novel isotebuquine analogues against CQ-sensitive and CQ-resistant parasites 
showed them to exhibit activity similar to that of tebuquine (Miroshnikova et al., 
2006). However, during in vivo analysis the new isotebuquine analogues showed 
only marginal antimalarial activity, possibly due to poor solubility in vehicle and 
water.
Pyronaridine, an acridine-type Mannich base was first synthesised in the early 
1970s by members of the Zheng laboratory and has been used for nearly twenty
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years as a monotherapy to treat malaria in China (Figure 7.1). In line with the World 
Health Organisation initiative regarding artemisinin-based combination therapies 
(ACTs), MMV are funding a project to develop a low-cost, fixed-ratio combination 
of pyronaridine and artesunate for the treatment of acute uncomplicated malaria. The 
ACT is currently undergoing phase III clinical trials (Shao, 1990). Concerns have 
been raised in regard to pyronaridine having a similar structural alert to AQ and 
paracetamol for hepatoxicity (Lee et ah, 2004; Naisbitt et al., 1998). However, in 
contrast to AQ, which contains a single Mannich amino side-chain at the 3’ position, 
pyronaridine contains amino side-chains at both the 3’ and 5’ positions of the 
aminophenol ring system. Thus, although metabolic oxidation to a quinone imine 
can occur with this drug (Lee et ah, 2004), the presence of the additional substituent 
at the 5’ position might prevent electrophilic attack of the quinone imine with sulfur- 
containing proteins. Like tebuquine however, the quinone imine metabolite of 
pyronaridine has potential to recycle intracellular glutathione leading to its depletion 
which in turn can lead to oxidative stress (Scheme 7.1) (Naisbitt et ah, 1998).
214
Cl
Sergheraert's 4-anilinoquinoline 49 Isotebuquine analogue la
Figure 7.1 4-Aminoquinoline derivatives: piperaquine, pyronaridine, a novel 
4-aminoquinoline from the Sergheraert group and an isotebuquine analogue 
synthesised by Lin et al (Miroshnikova et al., 2006).
Glutathione Depletion
Tebuquine R3 =pCl-Ph 
R! =H  
R2 = ‘B u
Pyronaridine R3 -  H2C
Ri> R2 _ (CH2)4
Scheme 7.1 Redox depletion of glutathione by tebuquine and pyronaridine
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Our studies have shown the development of two distinct routes in the 
production of a novel 4-aminoquinoline antimalarial.
The first strategy involved the interchange of the hydroxyl group of AQ with 
the amino side-chain thus preventing the quinone imine metabolite from being able 
to form. This led initially to isoquine (ISQ), a candidate with unacceptably poor oral 
bioavailability due to multiple routes of metabolism for the A-diethylamino side- 
chain. Replacement of the diethylamino side chain with the more stable tert 
butylamino moiety led to N-tert butyl isoquine [(NTBISQ) Chapter 4] a drug 
candidate with almost 100 % oral bioavailability across four animal species.
The second strategy involves the introduction of a halogen atom in place of 
the hydroxyl group of AQ. Substitution of AQ with fluorine has been shown to 
completely abolish the intracellular depletion of glutathione associated with 
formation of the toxic quinone imine metabolite of AQ and also prevents activation 
within granulocytes (O'Neill et al., 1994; Tingle et al., 1995). Combining this line of 
reasoning with the increased metabolic stability of a tert butylamino side-chain led 
us to the compounds N-tert butyl fluoro amodiaquine and N-tert butyl chloro 
amodiaquine [(FAQ-4 and C1AQ-4) Chapter 5], Figure 7.2 highlights the pathway of 
development of the lead compound, NTBISQ and the back-up compounds, FAQ-4 
and C1AQ-4 from CQ.
We have presented extensive metabolic and dispositional studies on 
NTBISQ, FAQ-4, and C1AQ-4, making direct comparisons to CQ, AQ and ISQ. 
Each compound was synthesised via highly efficient and inexpensive routes, 
allowing for in depth in vitro and in vivo pharmacological testing to be performed. 
This chapter presents an overview of all the major findings of this thesis and will 
directly compare the results generated by each of the three novel compounds.
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CQ - Resistance AQ - Toxic Metabolite
NTBISQ - Lead Compound
No toxic metabolite formation 
100 % Oral bioavailabilily 
Excellent in vitro and in vivo 
antimalarial activity
NTBFA - Back-up Compound 1.
Reduced oxidation potential due 
to incorporation of F 
Excellent in vitro and in vivo 
antimalarial activity
NTBC1A- Back-up Compound 2.
Reduced oxidation potential due 
to incorporation of Cl 
Excellent in vitro antimalarial 
activity
Figure 7.2 Rational re-design of old drugs for new. A summary highlighting 
the problems associated with current therapies and the structural changes from CQ to 
NTBISQ, NTBFA and NTBC1A.
7.1.1 In  Vitro Activities of NTBISQ, FAQ and C1AQ-4
A number of different analogues of ISQ and AQ have been synthesized and 
their antimalarial activity tested. The results of these tests saw NTBISQ, FAQ-4 and 
C1AQ-4 to have excellent in vitro activity against a number of different strains of P. 
falciparum malaria, including two CQ-resistant strains (K1 and TM6) (Table 7.1). 
The activities of NTBISQ, C1AQ-4 and FAQ-4 were highly comparable with that of
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Quinone imine-type métabolite
Scheme 7.5 Possible P450-mediated hydroxylation of XAQ-4 analogues, 
leading to a quinone imine-type métabolite (X = Cl or F).
7.1.3.2 Distribution
The dispositional fate of each novel compound in vivo in rats was 
investigated. The importance of these studies lay in the fact that adverse effects may 
occur with drug accumulation due to direct toxicity. In a study by McChesney and 
co-workers in 1967 CQ was shown to accumulate in the tissues of rhesus monkeys 
(McChesney et al., 1967). The study showed that after 96 hours, 35 % of the dose 
was present in the tissues. The liver was one of the main organs of accumulation. In 
our studies tissues with major affinity for radioactivity included the liver and skin. 
The pattern of distribution of [3H]-NTBISQ, [3H]-FAQ-4 and [3H]-ClAQ-4 was 
remarkably similar, despite the differences in structure and radically different routes 
of metabolism (Figure 7.3). Significantly less [3H]-ClAQ-4 was retained in the liver 
and skin as compared to [3H]-NTBISQ (p = 0.0310 and 0.0396). The amount of 
radioactivity in the bile after dosing with [3H]-FAQ-4 and [3H]-CLAQ-4 was much
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AQ and no evidence of cross-resistance between strains of P. falciparum was 
observed with any of the drugs investigated, aside that of CQ.
IC50 nM
Drug K1 HB3 3D7 TM6
CQ 183.2 ± 11.1 14.9 ±3.9 19.4 ± 1.9 75 ±22.1
AQ 15.1 ±9.4 9.6 ± 3.7 11.2 ± 1.4 7.2 ±3.3
NTBISQ 13.2 ± 3.2 12.6 ±5.3 11.2 ± 2.2 ND
FAQ-4 20.2 ±4.6 13.2 ±3.4 11.2 ± 2.5 ND
C1AQ-4 ND 10.1 ±3.2 ND 3.0 ±2.2
Table 7.1 In vitro antimalarial activities of CQ, AQ, NTBISQ, FAQ-4 and 
C1AQ-4. Data obtained from The School of Tropical Medicine, Liverpool. Values 
expressed as mean IC50 (nM) ± the standard deviation against four strains of the 
malaria parasite, P. falciparum: the CQ-resistant strains K1 and TM6 and the CQ- 
sensitive strains HB3 and 3D7. ND = No data.
7.1.2 In Vivo Activities of NTBISQ, FAQ-4 and C1AQ-4
Following evaluation of the therapeutic efficacy of NTBISQ, FAQ-4 and 
q AQ-4 against P. berghei in mice the in vivo activity of NTBISQ was comparable 
with that of AQ (Table 7.2). FAQ-4 was observed to be less active and C1AQ-4 was 
considerably less potent than AQ (ED50 approximately 19 mg/kg). It was postulated 
that the reduced activity observed with C1AQ-4 could be a consequence of its 
increased lipid solubility (Table 7.3), implying that the compound may have 
undergone rapid first-pass metabolism in the liver resulting in less compound 
reaching the bloodstream. The results of these analyses showed NTBISQ to be the 
most potent of the three novel compounds at killing malaria parasites in vivo.
2 1 8
Compound
ED50
(mg/kg)
95%
Confidence
Interval
(mg/kg)
ED90
(mg/kg)
95 %
Confidence
Interval
(mg/kg)
CQ 3.3 •
0001 4.4 4.0 -4.9
AQ 2.6 2.1 -3.2 3.7 3.3 -4.1
NTBISQ 2.8 3.3-4.3 4.7 4.8-6.1
FAQ-4 5.3
OOSO1 12.4 10.7 -14.4
C1AQ-4 18.9a
Table 7.2 The therapeutic efficacy of CQ, AQ, NTBISQ, FAQ-4 and C1AQ- 
4 against the P. berghei ANKA infection in mice. Data was taken froni a study at 
GlaxoSmithKline, Tres Cantos, Spain using a standard 4-day test assay. Preliminary 
data, confidence interval could not be set due to irregularities in data.
7.1.3 Metabolism and Distribution of NTBISQ, FAQ-4 and C1AQ-4
7.1.3.1 Metabolism
The mass fate and tissue distribution of each drug was investigated in rats. 
Each compound was labelled with a tritium atom incorporated into the quinoline ring 
system in order to enable analysis by radiometric HPLC and scintillation counting. 
Compounds were given i.v. at a dose of 54 pmol/kg, 20 pCi and bile, urine and 
plasma were analysed using LC-MS.
Administration of [3H]-NTBISQ gave rise to the simplest metabolic profile of 
the three compounds (Scheme 7.2). In bile, [3H]-NTBISQ was observed to undergo 
direct glucuronidation to form solely, its phenolic O-glucuronide. In urine, [ H]- 
NTBISQ was excreted entirely as the parent compound. No other metabolites were 
observed in the HPLC trace. In a parallel in vitro study undertaken recently at 
GlaxoSmithKline, using human hepatocytes, similar results were observed. The 
main metabolites were the phenolic O-glucuronide and a quinolinone (which was not 
observed in out studies) (Scheme 7.2). The ultimate model for the metabolism of 
drugs in man is, of course, man. However the in vitro studies carried out by
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GlaxoSmithKline showed all routes observed in vivo in rats were also observed in 
human, thus validating the use of the rat model in these studies.
NTBISQ quinolinone NTBISQ NTBISQ-O-glucuronide
Scheme 7.2 In vitro metabolic profile of NTBISQ in human hepatocytes. The
quinolinone was not observed in vivo in the rat.
Administration of [3H]-FAQ-4 to rats led to a more complex metabolic 
profile. In bile, one major metabolite was detected by HPLC the molecular weight of 
which was thought to be 468. After numerous attempts, the putative metabolite 
could not be structurally assigned without the use of more sensitive equipment.
In urine, [3H]-FAQ-4 was mainly present as the parent compound. Three 
other metabolites were excreted by this route also and these were the side-chain 
carboxylic acid, the N-oxide and a glucuronide of the carboxylic acid derivative 
(Scheme 7.3).
2 2 0
FAQ-4 W-Oxide FAQ_4 Side-Chain Carboxylic Acid
(main component of urine)
Unassigned Structure
MW = 468
(main biliary metabolite) OH
HOOC-
0-glucuronide
-O H
Scheme 7.3 Metabolic profile of [3H]-FAQ-4, 5 hours after Lv administration 
to male, W istar rats.
Following the administration of [3H]-ClAQ-4 to rats (54 pmol/kg, 20 pCi) 
four major metabolites were found in bile and urine. LC-MS analysis revealed the 
presence of co-eluting pairs of chlorine isotopes which ultimately led to the 
assignment of metabolite structures (Scheme 7.4). As with [3H]-NTBISQ and [3H]- 
FAQ-4 the major component in urine was the parent compound. Similarly to [3H]- 
FAQ-4 the side-chain carboxylic acid was formed, however conversion to this 
metabolite was much greater with [3H]-ClAQ-4. There lies the possibility that this 
transformation may offer a significant route of clearance and could also explain the 
lower in vivo activity observed with [ Hj-ClAQ-4.
2 2 1
Cl N Cl
'OH
O
ClAQ-4 A-Oxide ClAQ-4
(main product urine)
Side-Chain Carboxylic Acid
(main biliry metabolite)
Cl
.0
Benzoic Acid Derivative
Scheme 7.4 Metabolic profile of [3H]-ClAQ-4, 5 hours after i.v administration 
of male, Wistar rats.
P450 hydroxylation could potentially occur at any position of the aromatic 
ring of NTBISQ, FAQ-4 and ClAQ-4. This could ultimately lead to the formation of 
quinone imine-type metabolites (Scheme 7.5). The studies in this thesis have shown 
definitively that this was not the case. In addition, no glutathione conjugation was 
observed in vivo or in vitro with any of the compounds studied.
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Quinone imine-type métabolite
Scheme 7.5 Possible P450-mediated hydroxylation of XAQ-4 analogues, 
leading to a quinone imine-type métabolite (X = Cl or F).
7.1.3.2 Distribution
The dispositional fate of each novel compound in vivo in rats was 
investigated. The importance of these studies lay in the fact that adverse effects may 
occur with drug accumulation due to direct toxicity. In a study by McChesney and 
co-workers in 1967 CQ was shown to accumulate in the tissues of rhesus monkeys 
(McChesney et al., 1967). The study showed that after 96 hours, 35 % of the dose 
was present in the tissues. The liver was one of the main organs of accumulation. In 
our studies tissues with major affinity for radioactivity included the liver and skin. 
The pattern of distribution of [3H]-NTBISQ, [3H]-FAQ-4 and [3H]-ClAQ-4 was 
remarkably similar, despite the differences in structure and radically different routes 
of metabolism (Figure 7.3). Significantly less [3H]-ClAQ-4 was retained in the liver 
and skin as compared to [3H]-NTBISQ (p = 0.0310 and 0.0396). The amount of 
radioactivity in the bile after dosing with [3H]-FAQ-4 and [3H]-CLAQ-4 was much
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greater than after dosing with [3H]-NTBISQ which could be attributed to the 
increased lipophilic nature of these compounds (Table 7.3).
At the time of measurement all radiolabelled drug had been cleared from the 
blood making it impossible to work out the relative plasmartissue ratios.
■ NTBISQ
Figure 7.3 Percentage of radioactive dose recovered in tissues 5 h, after 
administration of [3H]-NTBISQ, [3H]-FAQ-4 and [3H]-ClAQ-4 (54 pmol/kg, 20 
pCi/rat) to male Wistar rats (n = 4). Results are expressed as mean percentage of 
dose ± SEM. Statistics were performed using a one way ANOVA test for parametric 
data and Kruskal Wallis test for non-parametric data. *P<0.05, **P<0.01, 
***P<0.001
Compound LogP LogS
PKa
(acid)
PKa
(side-chain
amine)
CQ 5.03 ±0.88 -4.04 ± 0.68 NA 10
AQ 4.79 ± 0.67 -3.81 ± 1.25 10.4 9.1
ISQ 4.84 ±0.86 -4.33 ±0.33 7.7 9.1
NTBISQ 4.41 ±0.83 -4.68 ± 0.68 7.7 9.1
FAQ-4 5.11 ±0.48 -4.02 ± 1.42 NA 9.1
C1AQ-4 5.50 ±0.59 -5.28 ±0.93 NA 9.1
Table 7.3 In silico prediction of lipophilicity (logP), solubility (logS) and 
PKa of CQ, AQ, ISQ, NTBISQ, FAQ-4 and C1AQ-4 using computational 
software (VCCLAB, 2005). NA = Not applicable.
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Investigation into the possible retention of these compounds in the organs of 
the rat saw that after 24 hours the majority of the radioactive dose of each compound 
was excreted in bile and urine (Figure 7.4). In particular, despite its increased 
lipophilicity C1AQ-4 displayed the least retention in all of the tissues tested.
The compounds investigated all had similar whole body disposition in the rat, 
despite radically different routes of metabolism. It is possible that this was due to the 
molecules having similar physiochemical properties as indicated in table 7.3.
Figure 7.4 Percentage of radioactive dose recovered in tissues 24 h, after 
administration of [3H]-NTBISQ, [3H]-FAQ-4 and [3H]-ClAQ-4 (54 pmol/kg, 20 
jiCi/rat) to male W istar rats (n = 4). Results are expressed as mean percentage of 
dose ± SEM. Statistics were performed using a one way ANOVA test for parametric 
data and Kruskal Wallis test for non-parametric data. *P<0.05, **P<0.01, 
***P<0.001
7.1.4 Toxicity
The cytotoxicity of NTBISQ, FAQ-4 and C1AQ-4 was investigated using 
isolated rat hepatocytes (Figure 7.5). Primary hepatocytes are only viable for a short 
number of hours, therefore the longevity of these preparations is too short to 
investigate time-dependant metabolism. However, the relative toxicities of these 
compounds could be compared after 6 hour incubations.
■ NTBISQ 
|^ 4  ■ FAQ-4
I ■ C1AQ-4
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All compounds were shown to be less toxic to the rat liver cells in 
comparison to AQ. NTBISQ was shown to be the most cytotoxic of the three 
analogues tested with a Tox50 value of 40 pM. In comparison to the antimalarial 
activity of NTBISQ the in vitro therapeutic window remained above 3000 indicating 
that the compound is selective for the malaria parasite. FAQ-4 was shown to cause 
little damage to hepatocytes with Tox5o greater than 150 pM.
The results of this work show that NTBISQ may not be without its limitations 
clinically and it is possible it may cause some level of toxicity in humans. The cause 
of this toxicity may be due to the ability of the 4-aminoquinoline compounds to 
induce phospholipidosis in the liver.
Figure 7.5 V iability o f  m ale, W istar rat hepatocytes, incubated for 6 h w ith  
various concentrations o f  N T BISQ , FA Q -4 or C1AQ-4, and stained with Trypan
blue dye as an indicator for cell death. Results are expressed as mean percentage 
of dose ± SEM. Statistics were performed using a one way ANOVA test for 
parametric data and Kruskal Wallis test for non-parametric data. *P<0.05, **P<0.01, 
***P<0.001
2 2 6
7.1.5 Conclusion
This thesis has described the complete pathway of development of three 
novel 4-aminoquinoline compounds. Starting with the chemical synthesis, each 
compound has been prepared in good yield, using efficient and inexpensive routes. It 
is estimated that NTBISQ will cost less than $3 for a course of treatment - for a 
disease that is prevalent mainly in poverty-stricken areas this is essential.
The in vitro antimalarial activity of each novel compound has been shown to 
be comparable to that of AQ and NTBISQ has shown excellent in vivo activity. 
Extensive metabolism and dispositional work has been carried out resulting in 
complete metabolic profiles for NTBISQ and C1AQ-4. Most importantly, we have 
demonstrated with two chemical series that it is possible to dissociate metabolic 
activation from the efficacy of the 4-aminoquinolin antimalarials.
The main pathway of metabolism of NTBISQ is glucuronidation. In the 
absence of any bioactivation in vivo it is clear that by the implementation of 
structure-activity-design, we have successfully presented a means of metabolic 
escape in each compound. One major metabolite of [ HJ-FAQ-4 remained 
unresolved. It was possible that the parent ion was not identified in the spectra 
obtained. Further studies implementing the use of LC-NMR are required in order to 
elucidate the putative ion before it can be held unequivocally that FAQ-4 does not 
form a quinone imine metabolite in vivo.
At present the clinical situation, in terms of 4-aminoquinoline treatment of 
malaria, stands with the use of CQ being very limited due to the related resistance 
and AQ may only be used for acute treatment of malaria, rather than prophylaxis due 
to issues of toxicity. In addition, two drugs, PQ and pyronaridine are being 
developed as artemisinin-based combination therapies (ACTs). Whilst the
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advantages of NTBISQ over AQ have been made clear, the benefits over PQ and 
pyronaridine still remain to be discussed. Table 7.4 shows a summary of some of the 
main parameters of interest of these CQ alternatives. From these data it can be seen 
that NTBISQ holds a clear advantage over PQ in the sense it is almost four-times 
more active against the K1 CQ-resistant strain of P. falciparum.
The use of NTBISQ in clinic is most likely to be in the form of an ACT and 
the preferred partner drug to be combined with NTBISQ is one with similar 
pharmacokinetics. The shorter half-life of NTBISQ in comparison with PQ offers a 
further advantage. Combination of an artemisinin-based compound with a very low 
half-life to a 4-aminoquinoline with a very long half-life c.f. PQ may result in the 
parasite being exposed to sub-lethal concentrations of one drug, resulting in the 
emergence of drug-resistance.
Quinoline antimalarials are potentially cardiotoxic, as observed in the rat at 
high doses of NTBISQ and in man after chronic dosing of CQ. Although, no 
clinically significant cardiovascular effects have been observed with PQ, 
gastrointestinal disturbances have been reported in China as a dose-limiting adverse 
effect (Karunajeewa et al., 2004). In addition to this, resistance has developed in 
China before and prospective monitoring of PQ in combination with DHA will be 
required. Few toxicological concerns have been raised with pyronaridine except for 
transient electrocardiographic changes in man. This is in contrast to data reported for 
NTBISQ where initial findings suggest the dose-related toxicity to cardiac tissue, 
skeletal muscle and liver in rats. It is thought that this toxicity is due to 
phospholipidosis, a class effect of the 4-aminoquinolines also seen with CQ (Reasor 
et al., 2006).
2 2 8
Although pyronaridine has better in vitro activity against the K1 strain of 
malaria than NTBISQ (Table 7.4), NTBISQ holds an advantage in that it has a 
simpler chemical synthesis and will also cost less to prepare.
The overall results of this thesis show that out of the three novel compounds 
tested, NTBISQ is a clear lead candidate for further development, with FAQ-4 and 
C1AQ-4 worthy back-ups. NTBISQ has been shown to be comparable, if not 
superior to two compounds currently entering phase III clinical trials as combination 
chemotherapy. Indeed, NTBISQ is now due to enter phase I clinical trials in man. It 
is only when clinical data has been obtained that we will be able to fully define the 
relationship between drug metabolism, drug disposition and drug safety for the novel 
4-aminoquinoline antimalarials.
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